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“Absorb what is useful, discard what is not, and add what is uniquely your own.” 
– Bruce Lee 
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During the first half of the twentieth century the significance of the phosphate esters in biochemistry was 
established. In 1910, Levene made the major discovery that deoxyribonucleic acids (DNA) consist of 
nucleosides linked together by phosphodiesters.1 His research set a scientific foundation, that proved 
crucial in the elucidation of the three-dimensional structure and function of DNA in the 1950s. In the same 
era it was also discovered that the conversion of adenosine diphosphate to adenosine triphosphate, 
facilitated by pyrophosphate co-enzyme A, forms the cornerstone of cellular respiration, thereby further 
signifying the importance of phosphorylation in biological processes.2 In the following decades, the 
number of known biochemical processes involving phosphorylation reactions rapidly expanded. For 
example: protein phosphorylation, a regulatory mechanism that activates or deactivates proteins, became 
known as the most widespread type of post-translational modification (PTM) and recognized as a key 
reaction in cellular signal transduction. It is now clear that phosphorylation affects all four major 
biomolecules – proteins, lipids, carbohydrates and nucleic acids – and plays a pivotal role in the most basic 
cellular functions, such as cellular energy transfer, signal transduction, protein regulation and the 
biosynthesis and maintenance of the genome. Considering both the relevance and vastness of these 
biological processes, it is not surprising that there is a growing demand for well-defined phosphorylated 
molecular tools that facilitate the studying of the corresponding molecular mechanisms. In addition to a 
fundamental understanding of normal cell function, such tools can also be effective at elucidating the 
molecular mechanisms behind various pathologies and help to define potential therapeutics. Synthetic 
organic chemistry has already proven to be invaluable for the preparation of phosphorylated molecular 
tools that were designed to this end. However, most natural phosphates are inherently susceptibility to 
hydrolysis, trans-esterification and enzymatic cleavage. This property limits their use through possible 
premature degradation or restricted synthetic accessibility; the latter especially when considering the 
chemical complexity which biomolecules tend to present. 
The research described in this Thesis focuses on the development of new molecular tools intended to 
facilitate the study of the PTM, adenosine diphosphate ribosylation. In this context new reagents and 





ADP-Ribose Transferases  
Adenosine diphosphate ribosylation (ADP-ribosylation) is a post-translational modification regulated by 
ADP-ribose transferases (ARTs), in which NAD+ is used to transfer ADP-ribose onto a nucleophilic 
heteroatom of an acceptor biomolecule, with simultaneous release of nicotinamide. Mono-ADP-
ribosylation (MARylation) is a highly conserved PTM that is thought to have evolved in primal prokaryotes 
as a cellular-defense mechanism against viruses and antimicrobial biomolecules. Most ARTs expressed by 
these organisms MARylate viral DNA, RNA and proteins in order to disrupt the replication cycle. Over time, 
however, these originally defensive ADP-ribosylating proteins mutated into bacterial toxins, giving rise to 
various species of pathogenic bacteria; including infamous examples such as Bordetella pertussis 
(pertussis toxin)3, Clostridium botulinum (C2-toxin, C3-toxin)4,5, Corynebacterium diphtheria (diphtheria 
toxin)6 and Vibrio cholera (cholera toxin)7. Each ART-toxin MARylates specific key regulatory proteins of 
the eukaryotic host cell; a modification highly detrimental to their function. Interestingly, all ARTs 
expressed in eukaryotes share similar substrates, catalytic triads and a specific structural fold (known as 
the ART-folds) with prototypical bacterial toxins, indicating an evolutionary lineage. Based on the 
homology of the catalytic domain, all eukaryotic ARTs can be categorized as cholera toxin-like or 
diphtheria toxin-like. In humans, 21 ARTs are expressed that can be differentiated into two subfamilies: 
17 poly(ADP-ribose) polymerases (PARPs) and 4 ecto-ADP-ribose transferases (ARCTs). PARPs 1 to 5 are 
diphtheria toxin-like, sharing the highly conserved ART-fold and the histidine-tyrosine-glutamate (HYE) 
motif, which facilitates the binding of NAD+.8 The ARCTs are cell surface enzymes that are excreted in the 
extracellular department.9 They are related to cholera-toxin and make use of an alternative arginine-
serine-glutamate (RSE) motif.10 In this chapter, the discussion will be focused on the HYE-PARPs, as their 
role in DNA damage repair, telomere maintenance and regulation of apoptosis have highlighted these 




Figure 1: The catalytic mechanism of auto-ADP-ribosylation of chicken PARP-1, at the auto-modification domain (AMD). NAD+ is 






PARP Mono- & Poly-ADP-Ribosylation 
Both mono(ADP)ribosylation (MARylation) and the succeeding poly(ADP)ribosylation (PARylation) are 
modifications catalyzed by enzymes belonging to the PARP family. In contrast to their name, most PARPs 
are actually transferases and only capable of transferring a single mono-ADP-ribose onto a nucleophilic 
amino-acid at the auto-modification domain, or that of another target protein. However, at least PARP-1, 
PARP-2, and PARP-5a/b (tankyrases) are capable of catalyzing PARylation.12,13 PARP-1 to 5 catalyzed ADP-
ribosylation starts with the binding of NAD+ in the ART-fold. The histidine imidazole side-chain, belonging 
to the conserved HYE motif (Figure 1; H862-Y896-E988), forms a hydrogen bond with the C2-OH of the NAD+ 
adenosine moiety.11 On the other end of the molecule, the electron-poor nicotinamide undergoes π-π 
stacking with two electron-rich tyrosine residues (Figure 1; Y896-Y907). These binding interactions, among 
various others, force a spatial orientation that instills strain on the pyridinium N-glycosidic bond, lowering 
the activation energy.14 The exact function of HYE-glutamate during the initial ADP-ribosylation reaction 
is different from its role during the PARylating elongation reactions. The inherent nucleophilicity of 
proposed acceptor side chains, primarily those of glutamate and aspartate, is sufficient for the transfer to 
occur without the aid of the HYE-glutamate.13,15,16 This theory is supported by PARP-1 mutant studies, 
where the absence of the Glu988 only gave a 3-fold decrease in auto-MARylation activity.17 However, the 
HYE-glutamate is likely to facilitate the reaction through favorable hydrogen bonding and assisting in 
polarization of the acceptor side chain. 
During PARylation, additional ADP-ribose residues are sequentially transferred onto a previously 
attached acceptor ADP-ribose, to form linear or branched chains of poly-ADP-ribose, consisting of up to 
200 monomeric units. Most elongations proceed via α-ribosylation of NAD+ onto the C2-OH of the terminal 
adenosine moiety, resulting in a linear extension of the ADPR-polymer chain (Figure 2). In this instance, 
the HYE-glutamate residue forms a hydrogen bonding network between the acceptor C2-OH of the 
terminal adenosine and the C2-OH of the bound NAD+ nicotinamide ribose.18 Subsequent basic catalysis 
by the HYE-glutamate enables the SN2-displacement of the nicotinamide. For PARP-1, branching of the 
chain irregularly occurs once every 20 to 50 ADP-ribose units, when a similar NAD+ glycosylation reaction 
takes place at the C2-OH of an internal ribose moiety.19 The branching sites are ribosylated following the 
same linear-branching extension pattern, providing the polymer with a dendritic macrostructure. 
 




Poly-ADP-Ribosylation in DNA Repair 
In eukaryotes, PARP-1, PARP-2 and PARP-3 are involved in the detection and initiation of single- and 
double-strand DNA break repair mechanisms, including base- and nucleotide excision repair.20,21 
Particularly PARP-1 has been subject of extensive studying, as it is the primary target for poly-ADP-
ribosylation through auto-modification in response to DNA damage. The mechanism of PARP-1 activation 
starts by ligation of the zinc finger domains to the disconnected nucleobases at the DNA break.22 The 
enforced proximity caused by this interaction allows PARP-1’s Trp-Gly-Arg (WGR) domain to bind DNA, 
triggering a cascade of conformational changes that initiate its catalytic activity.23 The auto-PARylation of 
PARP-1 promotes the recruitment of co-enzyme Histone PARylation factor 1 (HPF1), which is responsible 
for trans-ADP-ribosylation of the histones (H1, H2B and H3).24 It is postulated that the negative charge 
carried by the phosphate rich poly(ADP-ribose) chains relaxes the histone and partially dissociates the 
DNA-bound PARP-1, creating a binding cavity for DNA repair proteins XRCC1, DNA ligase-3 and DNA 
polymerase-β.25,26 After DNA repair, the PARylated proteins are regenerated through hydrolysis of the 
PAR-polymers by hydrolases PAR, MacroD1, MacroD2 and TARG1, completing the ADP-ribosylation cycle.  
The glutamic acid and aspartate have shown to be primarily acceptor amino acids for ADP-ribosylation 
at the histone, and more recently lysine, arginine, cysteine and serine have also been reported.27–30 
However, data regarding the covalent poly-ADP-ribosylation of histone proteins at glutamate or aspartate 
residues is conflicting, and can be viewed as controversial when considering the chemical sensitivity of 
anomeric esters. Furthermore, non-covalent complexes between poly-ADP and the histone have also 
been reported.31–33 Overall the relation between ADP-ribosylation and the target protein’s acceptor amino 
acids and the corresponding biochemical function is poorly understood. Synthetic organic research 
towards well-defined mono- and poly-ADPr fragments and ADPr-functionalized oligopeptides have 
already proven to be incredible useful in advancing our understanding of this complex PTM.16,34–36 The 
chemically diverse nature of these constructs makes them synthetically challenging. The main difficulty 
arises from necessity to combine several specialized subfields of organic chemistry, namely carbohydrate-
, peptide- and nucleic chemistry, each associated with their own unique reactivity, tailor-made protecting 
groups and corresponding orthogonality. This, combined with the various labile bonds within these 
constructs (Figure 3), constrains the synthetic accessibility and biochemical applicability. An organic 
 
Figure 3: The general structure of an ADPr-functionalized oligopeptide, depicting the three most labile 




chemical approach to address such limitations is to introduce chemical modifications that stabilize specific 
labile bonds, while, at the same time, retaining similar overall physical and chemical properties. 
 
Stabilized NAD+ Analogues 
Carbanicotinamide Adenine Dinucleotide. In the 1980s scientific evidence signifying the importance 
of ADP-ribosylation as a regulatory PTM was rapidly being accumulated. As both the exact function and 
mechanism were still barely understood, there was a growing demand for molecular tools that could help 
to elucidate this class of PTMs.37 In 1988, Slama and co-workers were the first to design and synthesize a 
stabilized analogue to this end, which came in the form of carbocyclic-nicotinamide adenine dinucleotide 
(C-NAD+).38 It was reasoned that substituting the ring oxygen of the nicotinamide riboside moiety with a 
methylene would stabilize the adjacent C-N bond, making it resistant to cleavage, while retaining a similar 
structure and polarity profile to that of natural NAD+.  
 
 
Scheme 1: Synthesis overview of C-NAD+ as described by Slama and co-workers. Reagents and conditions: [a] OsO4, MNO, 
tBuOH/H2O,  50 °C. [b] HCl, MeOH. [c] LiEt3BH, THF,  0 °C. [d] 1-(2,4-dinitrophenyl)-3-carbamoylpyridiniumchloride, H2O. [e] 
(CH3O)3PO, POCl3, 0 °C. [f] Ac2O, pyr, 10 °C. [g] 6, DMF/pyr. 
 
Their synthesis started from D/L-ribofuranosylamine 2, which was prepared on multigram-scale by 
adopting three literature procedures. The route commenced with a Diels-Alder reaction between achiral 
cyclopentadiene and tosylcyanide, followed by acidic hydrolysis, to produce 139. After the cis-
dihydoxylation and lactam methanolysis of 1, as described by Cermak et al.40, the sequance is finalized by 
reduction of the methyl ester41, providing racemic ribofuranosylamine 2 in 76% yield over three steps. 
From here, the nicotinamide moiety could be introduced via application of the Zincke reaction, reacting 
the secondary amine in 2 with 1-(2,4-dinitrophenyl)nicotinamide chloride.42 Selective phosphorylation of 
the primary alcohol, by treatment with phosphoryl chloride, lead to produce D/L-4 as a single product. The 
coupling of 4 to adenosine monophosphate (AMP) proved to be the most difficult step during the 
synthesis. Various unsatisfactory coupling conditions were attempted, including Bovine 
adenylyltransferase catalyzed phosphorylation and Michelson activation. The latter involves the 
formation of a reactive mixed anhydride between a donor phosphate monoester (e.g. 4) and diphenyl 
phosphorochloridate. Controlled substitution of the diphenoxyphosphoryloxy-moiety with an acceptor 
phosphate leads to the formation of the desired pyrophosphate. Finally, the authors adopted a more 
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refined iteration of this activation-displacement method, as described by Furusawa et al.43, to successfully 
couple di-n-butylphosphinothioic anhydride 6, under the agency of silver nitrate, with D/L-C-NMN 4, 
providing C-NAD+ and its respective diastereoisomer. A simple but effective optimization was found in the 
acetyl protection of the 2,3-diol in 4. The improved solubility of 5 allowed for the use of more favorable 
solvent mixtures during the subsequent coupling reaction, significantly improving yield and 
reproducibility. After ammonia mediated deacylation during work-up, the two diastereoisomeric C-NAD 
analogues could be separated chromatographically. The structures were assigned by exposing both 
diastereoisomers to yeast and equine liver alcohol dehydrogenases, that naturally use NAD+ as a co-
substrate in the oxidation of alcohols. Both enzymes showed activity with the compound that was 
accordingly assigned as C-NAD+, while no enzymatic activity was observed with L-ribosyl-C-NAD+. Although 
the authors did not evaluate C-NAD+ in context of PARPs, it was demonstrated that the analogue was 
capable of non-covalently inhibiting NAD glycohydrolase from Bungarus Fasciatus venom at micromolar 
concentrations. In 1998, C-NAD+ was used by Ruf and co-workers to obtain the first crystal structure of 
PARP-1 with a NAD+ mimetic bound in the active site.14 
 
Benzamide Adenine Dinucleotide. At the beginning of the 1990s the importance of poly-ADP-
ribosylation in DNA-repair mechanism was well-established, and PARPs were considered as interesting 
therapeutic targets in relation to cancer research. However, at this time, no suitable PARP inhibitors were 
known. In response Krohn et al. proposed benzamide riboside (10) and benzamide mononucleotide (11, 
Scheme 2), which were predicted to be anabolized intracellularly to the actual envisioned PARP inhibitor 
and NAD+ analogue; benzamide adenine dinucleotide (BAD, Scheme 3).44 In this design the riboside ring-
oxygen is retained, instead the labile anomeric C1-N+ bond is removed by substituting the nicotinamide 
moiety with benzamide.  
 
 
Scheme 2: Synthesis of benzamide mononucleotide as described by Krohn and co-workers. Reagents and 
conditions: [a] nBuLi, 12, THF, -85 °C. [b] BF3·Et2O, Et3SiH, DCM, -78 °C. [c] MeI, MeNO3, 100 °C. [d] NaOH, 
MeOH, reflux. [e] i: SOCl2, DMF, reflux. ii: NH4OH. [f] Pt/C, H2, THF. [g] Acetone, H2SO4, 0 °C. [h] POCl3, 




After various investigative reactions and refinements, the final synthesis commenced with the 
nucleophilic addition of lithiated 3-bromophenyl oxazoline 12 onto benzylated D-ribonolactone 7. 
Subsequent silane deoxygenation of the anomeric hydroxyl, in intermediate 8, afforded protected 
riboside 9 in stereoselective fashion. Recovery of the amide from the oxazoline moiety and ensuing 
debenzylation provided benzamide riboside (10). To facilitate the installation of the phosphate the 2,3-
diol was protected as an isopropylidene acetal. Phosphorylation of the primary alcohol and acidic cleavage 
of the isopropylidene were carried out in a single operation, yielding target benzamide mononucleotide 
11. As part of their study, Krohn et al. evaluated 11 for its biological activity. Although no 
poly(ADP)ribosylation inhibition was found, 11 showed up to nanomolar level toxicity towards various 
human tumor cell lines.45 This potent anti-proliferate activity could indeed be contributed to the anabolic 
conversion of 11 to BAD, which acted through the inhibition of inosine-5-monophosphate 
dehydrogenase  (IMPDH).  
Zatorski and co-workers expanded on the synthesis of BAD (Scheme 3) to determine if the analogue 
showed selective inhibition between the two IMPDH isoforms (type I and II).46 Experiencing disappointing 
yields with the PV-phosphorylation method reported by Krohn et al, the authors turned to a 
phosphoramidite approach for the preparation of 15. The reaction of benzamide riboside 13 with 2-
cyanoethyl N,N-diisopropylchlorophosphoramidite, followed by tetrazole mediated installment of the 
second 2-cyanoethanol and oxidation with tert-butyl peroxide, gave the desired dicyanoethyl phosphate. 
The crude intermediate was treated with methanolic ammonia during work-up, providing phosphate 
diester 14. After elimination of the second cyanoethyl, protected benzamide riboside 15 was converted 
to activated imidazolium species 16 followed by reaction with 2,3-O-isopropylidene AMP in a one-pot 
procedure. Final, acidic deprotection of the isopropylidene groups provided the desired NAD+ analogue 
BAD in excellent yield. Unfortunately, BAD did not show selective inhibition between the two isoforms of 
IMPDH. In 2018, however, Langelier and co-workers established that BAD inhibits the DNA-dependent 
PARP-1 automodification activity, starting at 50 micromolar concentration.35 In contrast, C-NAD+ only 
showed similar levels of inhibition at concentrations twelve times higher. Additionally, the authors were 
able to obtain the crystal structure of the PARP-1 catalytic domain bound to BAD.  
 
 
Scheme 3: Synthesis of BAD as described by Zatorski and co-workers. Reagents and conditions: [a] i: 2-cyanoethyl 
N,N-diisopropylchlorophosphoramidite, DIPEA, DCM. ii: β-cyanoethanol, tetrazole, MeCN. iii: tBuOOH. iv: NH3, 
MeOH. [b] NH3, MeOH, 55 °C. [c] i: CDI, DMF. ii: 2,3-O-isopropylidene AMP. [d] Dowex-50·H+, H2O. 
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Fluoro-Nicotinamide Adenine Dinucleotide. In the continuous search for NAD+ analogues Sleath et al 
explored substituting the C2-OH at the nicotinamide riboside.47 Previous research had shown that the 
native NAD+ hydroxyl at the C2-position participates in base-catalyzed nicotinamide-glycosyl bond 
cleavage performed by enzymes such as ADP-ribosyltransferases and NAD+-glycohydrolases. As part of 
their investigation three arabino-NAD+ derivatives were synthesized, including fluoro-nicotinamide 
mononucleotide 25β and fluoro-NAD+ analogue F-NAD+ (Scheme 4).  
 
 
Scheme 4: Synthesis of F-NAD+ as described by Sleath and co-workers. Reagents and conditions: [a] DAST, DCM/pyr, 0 °C. [b] 
H2SO4, dioxane/ethanol. [c] p-nitrobenzoyl chloride, DCM/pyr, -30 °C. [d] Dowex-50·H+, dioxane:water, 80 °C. [e] NaHCO3, NaIO4, 
H2O/MeCN. [f] i: Ac2O, pyr. ii: HBr, AcOH, DCM. [g] i: Nicotinamide, MeCN. ii: NH3, MeOH, 0 °C. [h] POCl3, m-cresol, 5 °C. [i] i: Ac2O, 
pyr. ii: (PhO)2POCl, Bu3N, DMF. iii: AMP, DMF. iv: NH3, MeOH, 0 °C. 
 
Sleath’s synthesis started with DAST mediated fluorination of protected allofuranose 17, showing typical 
SN2-inversion of the stereochemistry. Selective deprotection of the terminal isopropylidene with dilute 
acid, followed by reprotection of primary hydroxyl with p-nitrobenzoyl chloride, provided alloside 20. 
Transformation to the arabino-conformation was carried out via an oxidative cleavage method. After 
removal of the 1,2-O-isopropylidene, the produced diol was cleaved with sodium periodate, effectively 
converting the C2-OH into the (open-chain) anomeric aldehyde, which, upon ring-closure with the original 
C5-OH, generates the desired fluoro-arabinofuranose 22. A one-pot acetylation-bromination procedure 
gave α-bromide 23 in over 95% diastereoisomeric excess. Anomeric displacement of the bromine with 
nicotinamide  and consecutive ammonolysis of the ester-based protecting groups produced primarily 
beta-anomer 24β. Separation of the α/β-mixture was postponed until after formation of F-NAD+. To 
facilitate the solubility of the α/β-nicotinamide nucleotide derivative, the phosphorylation reaction was 
carried out in m-cresol with phosphoryl chloride48, yielding fluorinated NMN analogue 25α and 25β as a 
diastereoisomeric mixture. The coupling reaction was accomplished via a modified version of the earlier 
discussed Michelson method, in which the secondary hydroxyl in 25 is acetylated in situ to accommodate 
14 
 
for the otherwise poor solubility of the NAD+ derivative under the succeeding coupling conditions. 
Activation with diphenyl chlorophosphate and reaction of the activated intermediate with AMP 
successfully gave a mixture of F-NAD+ and the α-nicotinamide diastereoisomer. F-NAD+ was then isolated 
by chromatographic separation. 
Fluoro-nicotinamides have been applied extensively to study ARTs, including a subclass of enzymes 
known as ADP-ribose cyclases (ARCs). The best-known ARCs are CD38 and CD157.49 These transmembrane 
enzymes are employed by mammalian cells to metabolize NAD+, generating ADPR and to a lesser extent 
cyclic ADP-ribose (cADPR).50,51 The latter is a second messenger that regulates intercellular Ca2+ 
concentrations as part of cell signal transductions. CD38 has become known as a powerful marker for 
several human hematological tumor cell lines, and is directly involved in various cellular immune response 
mechanisms.52 The involvement of CD38 in these type of physiological processes has led to a persistent 
scientific interest in its catalytic mechanism. In 2000, Sauve and co-workers established the active site’s 
catalytic residue as the side chain carboxylate of glutamic acid 226.53 This was demonstrated by exposing 
the enzyme to the above described fluorinated NMN analogue 25β (Scheme 4), which reacted with Glu226 
to provide a stable covalent enzyme-inhibitor intermediate, as was determined by mass spectrometry. 
The electronegative fluorine atom at the C2-position significantly increases the dissociation energy of the 
anomeric ester bond towards the oxocarbenium-ion transition state, thereby drastically slowing down the 
succeeding hydrolysis or cyclization step. In 2010, Zhang et al complemented these results by publishing 
the first X-ray crystal structure of CD38, with irreversible covalent inhibitor F-NAD+ bound to Glu226.54 By 
crystalizing F-NAD+ with a Glu146-mutant CD38, it was also discovered that the point removal of this second 
key residue abolishes CD38s hydrolytic activity, while greatly enhancing its cyclization activity.  
 
 
Figure 4: The structure of fluorescent activity-based probe Rh-6-F-NAD+. 
 
To study the CD38-mediated signal processes, Jiang and co-workers sought to develop a labeling 
method for the real-time monitoring of the enzyme. To this end they designed and synthesized a 
fluorescent activity-based probe based on F-NAD+, aiming to take advantage of the covalent nature of the 
inhibitor.55 Installation of a propargyl group onto the N6-position of the adenine moiety enables click-
conjugation with an azido bearing fluorophore (Figure 4). In their study Rhodamine was selected at the 




Stabilized ADP-ribosylated Oligopeptides 
Ever since poly-ADP-ribosylation of chromatin proteins was discovered to be involved in processes such 
as DNA-repair, cell division, inflammatory response and aging, there has been a growing interest in 
understanding these processes at a molecular level. However, the complexity of PARylation has led to 
scientific controversy regarding the target proteins and, most notably, the nature of the acceptor amino-
acid(s). Structurally well-defined ADP-ribosylated oligopeptides were conceived as tools to help elucidate 
the biochemistry of PARylation. The first chemical synthesis of such constructs was described by van der 
Heden van Noort et al in 2011.56 They recognized that the main difficulty in constructing the native mono- 
and poly-ADP-ribosylated peptides would be the chemical compatibility between the anomeric linkage (at 
the ribosylated amino acid), the pyrophosphate bridge and solid-phase peptide chemistry. The 
MARylation sites of a mammalian RhoA protein and a heptapeptide, based on the natural occurring N-
terminus of the human histone, were selected as target molecules for their chemical endeavor. Although 
the latter is naturally PARylated at the glutamic acid residue, the presence of an anomeric ester bond was 
considered to be not feasible in the synthesis of the construct. Instead glutamine was incorporated as a 




Scheme 5: Synthesis of ADP-ribosylated oligopeptides as described by van der Heden van Noort et al. Reagents and conditions: 
[a] PtO2, H2, EtOAc, 10 °C. [b] Z-Asp-OBn or Z-Glu-OBn, EDC·HCl, DCM. [c] i: 10% Pd/C, H2, MeOH. ii: FmocOSu, NaHCO3, H2O 




A key step in the synthesis entailed the careful hydrogenation of β-azido-riboside 26, to provide the 
unstable intermediate hemiaminal ether 27 (Scheme 5). Immediate in situ condensation with the 
corresponding Asn and Gln building blocks gave ribosylated amino acids 28 and 29, respectively, as α/β-
anomeric mixtures. After chromatographically separation, followed by protecting group manipulations, 
the acquired α-derivatives 30 and 31 were applied as building blocks in a standard solid-phase peptide 
synthesis. Phosphorylation of the immobilized ribosylated peptides was carried out with di(p-
methoxybenzyl)-N,N-diisopropyl phosphoramidite (36), using dicyanoimidazole (DCI) as an activator. 
Constructing the ADPR pyrophosphate bridge for both peptides comprised the same methodology, using 
a different sequence of event. For ribosylated peptide 32, iodine mediated oxidation of the installed di-p-
methoxybenzyl phosphite led to the formation of an phosphorimidazolidate. This immobilized activated 
phosphate species was then coupled to adenosine monophosphate 37. Alternatively, for peptide 33, the 
introduced phosphite moiety was oxidized with tert-butyl hydroperoxide. Cleavage of the p-
methoxybenzyl groups yielded the terminal phosphate, that was subsequently condensed with adenosine 
phosphorimidazolidate 38. The latter approach turned out advantageous as an excess of the activated 
species could be applied. Global deprotection and release from solid support provided the desired ADP-
ribosylated peptides 34 and 35.  
This line of research was continued by Kistemaker et al, who refined the strategy by preparing pre-
phosphorylated amino acid-riboside building blocks (Scheme 6, 39-41) and applying these in an improved 
methodology for the on-resin installment of the pyrophosphate.34 The ribosylated amino-acid building 
blocks were incorporated into peptide fragments via a standard SPPS protocol to give immobilized 
ribosylated oligopeptide 42. Using finely-tuned conditions, the tert-butyl groups could be eliminated, 
leaving the anomeric configuration intact. Next, the pyrophosphate was assembled by adapting the 
phosphoramidite–phosphonate methodology, as described by Gold and van Delft et al,57 to the synthesis 
on solid-phase. The immobilized phosphate species 43 was condensed with adenosine phosphoramidite 
45 in presence of 5-ethylthiotetrazole as an activator. Oxidation of the phosphite–phosphate intermediate 
by CSO, followed by global deprotection and concomitant release from solid support, yielded the 
respective ADP-ribosylated peptide 44. In this way a multitude of biologically relevant MARylated peptides 
 
Scheme 6: Synthesis of ADP-ribosylated oligopeptides as described by Kistemaker et al. Reagents and conditions: [a] i: HCl:HFIP 
ii: Pyridine [b] i: ETT, MeCN ii: CSO, iii: DBU, iv: NH3, TFE v: NH4OH. 
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were synthesized and successfully used to study the substrate specificity of human MacroD2 and TARG1 
macro-domains. Chapter 4 of this thesis describes the synthesis of a mono-ADP-ribosylated H2B conjugate 
bioisostere wherein a carba-riboside is synthetically incorporated to stabilized the peptide-ribose 
glycosidic bond. 
Although the synthesis strategies discussed above were successful in providing several MARylated 
peptides, each required distinct chemical modifications and highly tailored reaction conditions, and thus 
are not generally applicable. A practical approach which addressed this limitation was presented by Liu et 
al (Scheme 7).58 By implementing click-chemistry, they enabled the post-synthetic introduction of the 
ADPr-moiety onto oligopeptides. First an azide functionalized amino acid is incorporated into the target 
peptide (47) through standard solid phase peptide synthesis. After release from solid support, an α-
propargyl configured ADP-ribose building block is installed via the copper catalyzed azide-alkyne 
cycloaddition (CuAAC), resulting in a triazole-based linkage (48). Several derivatives of biologically relevant 
ADP-ribosylated proteins were prepared this way, including an ADPr-ubiquitin analogue that was 
phosphorylated naturally during biological evaluation, even though it contained an artificial triazole 
linkage.   
 




Molecular tools are commonly designed on the basis of functionally relevant natural substrates, 
intermediates or metabolites. However, care should be taken when reactive or (enzymatically) degradable  
functionalities are involved in biological process of interest. This also holds true for pyrophosphates.  A 
pyrophosphate moiety within a molecular tool can be considered a labile functionality for both synthesis 
and biological application, as it is susceptible to hydrolytic or enzymatic degradation. Methylene 
bisphosphonate are considered stable analogues of pyrophosphates and several common methods for 
installing these are discussed in the following section. 
Terminal Methylene Bisphosphonates. Between 1963 and 1965, Meyers and co-workers published a 
series of articles on the preparation and implementation of methylene bisphosphates as stabilized 
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bioisosteres for pyrophosphates (Scheme 8).59–61 In methylene bisphosphates the oxygen atom conjoining 
the two phosphates in the original pyrophosphate is replaced by a methylene, providing resistance to 
cleavage. The synthesis of adenosine methylene diphosphate (me-ADP, 42)  was accomplished by 
activation of methylenediphosphonic acid with N,N-dicyclohexylcarbodiimide (DCC), followed by coupling 
onto adenosine. A similar approach was applied in the synthesis of 2-me-ATP 43. Here AMP  was 
preactivated with DCC and subsequent condensation with methylenediphosphonic acid gave 2-me-ATP 
43.  An alternative method entailing the reaction of adenosine 5-monophosphoramidate with 
methylenediphosphonic acid  also led to the isolation of methylene triphosphate 43. 
 
 
Scheme 8: Exemplified common methods for installing methylene bisphosphates. Reagents and conditions: [a] i: 2,3-isopropyl 
adenosine, DCC, pyr, 60 °C. ii: AcOH/H2O, 100 °C. [b] i: Bu4NOH, H2O. ii: 5-tosyl-adenosine, MeCN. [c] AMP, DCC, pyr/H2O. [d] 
Adenosine 5-monophosphoramidate, o-chlorophenol, pyr. [e] i: Bu4NOH, H2O. ii: 1-geranyl chloride, MeCN. [f] i: Alco-OH, 
(EtO)3PO. ii TEAB, H2O. [g] PPh3, DEAD, THF, 60 °C.  
 
Carbodiimide activation of methylenediphosphonic acid became a well-known strategy for the installation 
of methylene bisphosphonates. Another procedure to methylenediphosphates include the conversion of 
a specific alcohol into a leaving group through alkylsulfonation or halogenation and subsequent 
nucleophilic substitution by anionic methylene diphosphonate (Scheme 8, conditions b and e).62,63 
Alternatively, Lesiak et al make use of methylene bisphosphonic(dichloride) to directly phosphorylate 
alcohol 45 under basic conditions.64 Upon quenching with water, the trichloromethylene diphosphonate 
ester intermediate is converted into respective methylenediphosphonic acid 46. The small discrepancy in 
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reactivity between formed trichloromethylene diphosphonate ester and unreacted methylene 
bisphophonic(dichloride) results in the formation of minor amounts of symmetric diester 47.65 Hence, 
symmetric methylene bisphosphonates diesters can be accessed conveniently and in high yields by 
applying two equivalents of the alcohol instead.66,67 Each of the discussed strategies install the 
bisphosphonate moiety in an unprotected fashion, which can be disadvantageous in terms of the solubility 
degree in common reaction solvents and the ease of purification. In 1998, Vincent and co-workers 
adopted a reported method for preparing phosphonate mono-esters, using modified Mitsunobu 
conditions, to the synthesis of guanosine methylene diphosphonate (me-GDP).68,69 The tribenzylester of 
methylenediphosphonic acid (48) was coupled to the C5-OH of protected guanosine 49  to give fully 
protected  50 that after silica column purification, reductive global debenzylation provided me-GDP in 
near quantitative yield.  
Unsymmetric Methylene Bisphosphonates. Numerous biologically relevant pyrophosphates are 
unsymmetric diesters with two different alcohols incorporated; for example NAD+ and ADPr. In 1986, 
Meyer and co-workers were the first to synthesize an unsymmetric methylene bisphosphonate 
bioisostere, based on NAD+, with the objective to raise antibodies for the detection of ADP-ribose 
conjugates.70 me-NAD+ (Figure 5) was prepared by coupling me-ADP 51 with 2,3-O-isopropylidene 
nicotinamide riboside using the earlier described DCC coupling conditions, followed by acidic 
deprotection. At the same time, Marquez et al implemented the methylene bisphosphonate moiety in an 
effort to further enhance the effectiveness of known antitumor agent thiazole-4-carboximade adenine 
dinucleotide (TAD), using identical coupling conditions.71 In both cases the yields were relatively low; 20% 
and 36% respectively. Mechanistic study of the DCC-coupling reaction by Pankiewicz and co-workers 
Figure 5: Outlined in grey: The mechanism behind the formation of unsymmetric methylene bisphosphonate nucleotides via 
carbodiimide activation. Below: An overview of unsymmetric methylene bisphosphonate bioisosteres prepared via DCC coupling. 
With the exception of me-NAD+, each of these were prepared by Pankiewicz et al using the appropriate acceptor building blocks, 
in order: 2,3-O-isopropyl thiazofurin, 2,3-O-isopropyl D-ribose, riboflavin, 1,3-dipalmitoyl glycol, N-acetylethanolamine. 
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revealed that me-ADP dimerizes rapidly upon activation with stoichiometric DCC, forming the 
corresponding tetraphosphonate analogue (i.e. 53). The dimer was isolated and proved to be unreactive 
towards alcohols. This guided them to investigate alternative reaction pathways towards the formation 
of unsymmetric diesters. 31P NMR spectroscopy revealed that tetraphosphonate 53 could undergo a 
second and third DCC-activation, followed by two respective intramolecular condensation reactions, 
giving rise to bicyclic intermediate 55. Addition of an acceptor alcohol to 55 at 60 °C allows for nucleophilic 
attack on either bispyrophosphonic position (56). Iteration of this reaction on the remaining 
bispyrophosphonate leads to tetraester 57, which is effectively the pyrophosphoric dimer of the desired 
(un)symmetric methylene bisphosphonate. Hence, final hydrolysis of 57 by the addition of water produces 
two equivalents of methylene bisphosphonate 58. By implementing these findings into an improved 
procedure, five unsymmetric methylene bisphosphonates were prepared; me-TAD, me-ADPr, me-FAD, 
me-CDP-DAG and me-CDP-N-acetylethanolamine. In 1999, Ikeda reported an adaptation of Vincent’s 
Mitsunobu methodology for the synthesis of phosphor-protected unsymmetric methylene 
bisphosphonates.72 After coupling tribenzyl methylene phosphonate ester 48, the acquired thiazofurin 
tetraester could selectively be mono-debenzylated at the terminal phosphonate using stoichiometric 
amounts of DABCO in refluxing toluene. This set the stage for the installment of an adenosine building 
block, using the same Mitsunobu conditions, yielding fully protected me-TAD in 72% yield. The 
carbodiimide and Mitsunobu activations have become established coupling methods for the synthesis of 
both terminal and unsymmetric methylene bisphosphonates. However, the conditions these methods 
impose were considered too constraining when it came to the synthesis of methylene bisphosphonate 
analogues of complex biomolecules such as poly-ADP-ribose fragments. Therefore, an improved 
methodology for the synthesis of terminal-, symmetric- and unsymmetric methylene bisphosphonates 
could facilitate PARylation related research. New reagents and complimentary methodology to this end 
are described in detail in Chapter 2 and Chapter 3 of this thesis. 
 
NAD+ Analogues in PARylation Target Labeling 
NAD+ analogues functionalized with a ligation handle have been developed and employed in the mapping 
of ADP-ribosylation activity. The analogues that are accepted as cofactors by a PARP will be metabolically 
incorporated, carrying over the ligation handles to the produced ADPr-polymer, thereby enabling the 
visualization of the ADP-ribosylated protein via bioorthogonal labeling. This was first demonstrated by the 
group of Lin, who used 6- or 8-N-propargyl-NAD+ to study PARP-1 activity in vitro (Figure 6).73 Thirty minute 
incubation of ssDNA with either N-propargyl-NAD+ was followed by click-chemistry conjugation of an 
azido-bearing Rhodamine label. After SDS-PAGE, this allowed for Western blot analysis of tagged auto-
ADP-ribosylated PARP-1. In a similar manner, the more efficient 6-N-propargyl-NAD+ was employed to 
label over 70 PARP-1 PARylation substrate proteins. Complimentary results were found by the group of 
Marx using a 2-alkyne-NAD+ analogue to visualize the PARylation of PARP-1 and Histone H1.2.74 Complete 
removal of the modified adenosine C2-OH resulted, as expected, in total loss of poly-ADP-ribose assembly, 
while deletion of the C3-OH only leads to diminished PAR formation. Small handle modifications were 
tolerated at the 6-position of adenine, but most optimal were modifications at the 2-position, at which 
even bulky substituents are accepted.75 Two accordingly fitted NAD+ analogues, using a cyclooctyne for 
strain-promoted azide-alkyne cycloaddition ligation and a cyclopropene for the inverse-electron-demand 





Figure 6: The labeling of PARylated proteins exemplified with 6-N-propagyl-NAD+ as reported by the team of Lin. The propargyl 
bearing NAD+ analogue is metabolically incorporated into the ADPr-polymer. A rhodamine reporter-group is then linked using 
click chemistry, allowing for Western Blot analysis.  
 
Although global identification of PARylation targets had been achieved through use of handle fitted 
NAD+ analogues, identifying specific PARylation targets for each of the 17 PARP members remained 
complicated due to their unanimous use of NAD+ as a cofactor. Cohen and co-workers presented an 
elegant solution by engineering individual PARP binding pockets to match an orthogonally attuned NAD+ 
analogue.76 Based on the crystal structure  of substrate-bound PARP-1, it was established that mutating 
Lys903 to an alanine would create a unique hydrophobic pocket. A complementary ethyl substituent at the 
C5-position on the nicotinamide moiety was installed to achieve specific pairing with the engineered PARP. 
Using this analogue-sensitive strategy, 42 PARylation targets were identified for PARP-1 and 301 for PARP-
2, with a 52% and 7% respective target overlap. The group of Kraus reported a similar analogue-sensitive 
approach.77 The 8-position of the adenine moiety was instead selected as the modification site, as 
substituents at this position are poorly tolerated by wild-type PARPs. A library of 11 NAD+ analogues were 
synthesized bearing various R-groups at the 8-position and screened against 20 PARP-1 mutants. From 
the data it was deduced that mutating Leu877 to alanine would result in the desired analogue-sensitivity. 
Modifying the 8-position of the adenine had the additional advantage that the introduced R-group could 
simultaneously bear function as a ligation handle. With this in mind, clickable 8-Bu(3-yne)T-NAD+ was 
designed as the complementary analogue for asPARP-1. Moreover, this particular analogue also 
demonstrated activity with similarly engineered asPARP-2 and asPARP-3 mutants. Interestingly, 167 
protein targets were found for PARP-1, 87 for PARP-2 and 401 for PARP-3, which differs significantly from 
the findings of Cohen. A reason for this discrepancy was not discussed in the article, but a possible 





The field of bioorthogonal chemistry aims to develop chemical reactions that are applicable in vivo without 
affecting natural occurring biochemical processes. In order to do so effectively, the artificially introduced 
reactive moieties have to be inert to the diverse spectrum of functional groups that reside in a biological 
system, while still demonstrating specific reactivity towards each other. In addition, a bioorthogonal 
reaction must be tolerable to aqueous conditions and physiological pH, while displaying sufficiently fast 
kinetics for the reaction to proceeds rapidly at sub-micromolar concentrations, as this is desired for most 
biological labeling experiments. Bioorthogonal reactions have made a significant impact to the field of 
molecular biology, granting tools to study glycosylation chemistry in living cells and animals78, enable the 
conjugation of functional moieties to therapeutically relevant proteins79, and facilitate the in vivo 
assembly of imaging agents. 
 
 
Figure 7: Examples of bioorthogonal reactions used as labeling and conjugation strategies and their relative approximate rates. 
 
Several (pseudo) bioorthogonal two-step labeling techniques have been developed, the most 
established methods of which are (Figure 7); Staudinger–Bertozzi ligation80, CuI-catalyzed alkyne–azide 
cycloaddition (CuAAC)81,82, Huisgen strain-promoted alkyne–azide cycloadditions (SPAAC)83,84 and inverse-
electron-demand Diels–Alder reaction (IEDDA).85 Except for the last, each of these methods utilizes the 
azide functionality. Azides have virtually no precedence among biomolecules and show exceptional 
biocompatibility. The groups isoelectric nature allows it to act as both an electrophile and a nucleophile, 
which enables participation in a wide variety of reactions, often thermodynamically driven by the 
expulsion of nitrogen. Staudinger–Bertozzi ligation applies an o-triarylphosphine benzoate handle to react 
with an azide functionalized (bio)molecule. After nucleophilic attack of the phosphine onto the azide, the 
intermediate aza-ylide cyclizes onto the adjacent ester to covalently link the azide substituent in the form 
of an amide bond. The reaction has been used to label biomolecules in cells and living animals.86,87 The 
primary disadvantage of the Staudinger–Bertozzi ligation are the relative slow reaction kinetics, with a 
second order rate constant of approximately 10-3 M-1 s-1.88 Secondly, the o-triarylphosphine benzoate 
moiety is susceptibility to oxidation and enzymatic cleavage.  
Ligation strategies based on alkyne-azide [3 + 2] cycloadditions comes in two variation; CuAAC and 
SPAAC. The reactions are similar in that they conjoin the two reaction partners by producing a triazole 
linkage. The first entails the reaction of an azide with a terminal alkyne, catalyzed by CuI salts. The reaction 
displays considerably faster kinetics than the Staudinger–Bertozzi ligation (± 10 – 200 M-1 s-1)89, but cannot 
be considered fully bioorthogonal because of the reliance on a cytotoxic copper catalyst. The SPAAC 
variant utilizes ring strained cyclooctynes to accelerate the alkyne-azide reaction into a bioorthogonally 
acceptable range without depending on a copper catalyst, demonstrating rate constants of 10-2 to 1 M-1 
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s-1.90 The hydrophobic nature of the cyclooctyne moiety can, however, negatively affect water solubility 
of the often already lipophilic reporter groups.  Both CuAAC and SPAAC have been used to label 
biomolecules within complex biological systems, including living mammalian cells and animals.91–93 
The IEDDA reaction is the most recent addition to bioorthogonal reactions. It involves a Diels–Alder 
reaction between an electron deficient tetrazine (diene) and strained alkene or alkyne. The initial [4+2]-
cycloaddition results in a highly strained bicyclic intermediate, consisting of two fused six-membered 
rings. Driven by the elevation of ring strain, the adduct undergoes a retro-Diels–Alder reaction to expulse 
nitrogen. Alkene dienophiles afford the corresponding 4,5-dihydropyridazine, while alkynes yield the 




Figure 8: Top: The mechanism of the IEDDA reaction. Bottom: In order of increasing reactivity, five strained 
alkenes that have been applied as tetrazine reaction partners for the IEDDA-based ligation strategy. 
 
The IEDDA reaction rates are affected by electronic effects of the substituents in the reaction partners, 
dienophile ring strain and steric effects. For the tetrazine reactant, electron withdrawing substituents 
lower the LUMO energy and thereby accelerate the reaction rate, whereas electron donating substituents 
adjacent to the dienophile act conversely by raising the respective HOMO energy.94–96 Ring strain plays an 
even more profound role in determining the reaction rate constants. The increase in reactivity caused by 
this phenomena is two-sided. Firstly, strain heightens the dienophiles HOMO energy and as a result the 
reaction rate constant. This was empirically substantiated by Saur et al who demonstrated that the rate 
constant correlated with ring strain in the following order: cyclopropene › cyclobutene › cyclopentene › 
cyclohexene › cyclooctene.97 The most highly reactive dienophiles were found to be trans-cyclooctenes 
(TCO), however, which have a lower degree of ring strain than for example the less reactive 
cyclopropenes. A computational study by Houk et al endorsed these findings, and additionally exposed 
that the structural distortion, caused by the adopted TCO crown conformation, mimics the transition state 
geometry.98 Consequently, significantly less distortion energy is required for the dienophile to enter a 
productive transition state, increasing the rate constant. Installing an opposing cyclopropane in TCO forces 
the ring from a crown conformation to a half-chair conformation, further lowering the distortion energy 
required, thereby enhancing the reaction rate 160-fold.99  
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Steric effects induced by substituents on either tetrazine or dienophile side have similar dampening 
effect on reactivity, which can be contributed to both steric repulsion and raised distortion energies. 
Overall, the IEDDA reaction exhibiting the fastest reaction kinetics among bioorthogonal reactions, with 
reported rate constants of up to 106 M-1 s-1. The main drawback of the IEDDA ligation strategy is that both 
the tetrazine and most reactive dienephiles are relative lipophilic and sterically encumbered. These 
properties may influence the water solubility and biological response of the functionalized molecules. 
Chapter 5 describes the synthesis, reaction kinetics and biochemical implementation of N-acylazetines as 
compact hydrophilic ligation handles for the IEDDA-based bioorthogonal strategy. While Chapter 6 delves 
further into the reaction kinetics, isolating the effects of electron induction and ring strain on the 
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Pyrophosphates are present in numerous natural products that are involved in a wide variety of 
fundamental physiological processes, including cell metabolism, immunity and genome maintenance.1–5 
Consequently, pyrophosphates are important components of molecular tools or probes that aim to study 
and influence these processes.6–8 Pyrophosphates are inherently susceptible to hydrolysis, trans-
esterification and enzymatic cleavage.9,10 If a higher stability is desired, methylene bisphosphonates are 
attractive pyrophosphate bioisosteres that are less prone to undergo hydrolysis both during synthesis and 
in physiological surroundings.11 Methylene bisphosphonate isosteres of sugar nucleotides and nucleoside 
di- and triphoshates have been applied in studies that aim to elucidate the function of various 
enzymes.8,12,13 Terminal methylene bisphosphonates monoesters have been synthesized in the past using 
either methylene bisphosphonic dichloride or partially protected monochloridite derivatives as the 
phosphonylating agent14,15. (Un)symmetric methylene bisphosphonates diesters can be accessed using 
Mitsunobu chemistry or by condensing a hydroxyl of a target (bio)molecule with an independently 
prepared terminal methylene bisphosphonate.16,17 The published methods use unselective reagents and 
limit the regioselectivity of substitution reactions at the bisphosphonate core. Moreover, no generic 
strategy exists that readily allows for the introduction of methylene bisphosphonate moieties in 
structurally diverse pyrophosphate-containing (bio)molecules. This chapter describes the development of 
such a strategy and its application in the synthesis of terminal methylene bisphosphates. 
 
 
Figure 1: Methodology for the synthesis of terminal or unsymmetric methylene bisphosphates. Reagent 3 features orthogonal removable 
protecting groups PG and PG* and can be prepared from methylphosphonate 1 and chlorophosphoramidite 2. The reagent is coupled to an 
alcohol containing substrate (R1OH) via a (PIII) phosphoramidite coupling-oxidation sequence (PCO), to give protected intermediate 4, a precursor 
for terminal methylene bisphosphonates. Alternatively, after selective PG*-deprotection (5), a second alcohol (R2OH) can be introduced through 
phosphordiester condensation (PDC), leading to protected intermediate 6, precursor of unsymmetric methylene bisphosphates. 
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Results and Discussion 
It was envisioned that universal reagents capable of providing access to both terminal and unsymmetric 
methylene bisphosphonates had to be orthogonally protected to allow two sequential condensations 
under conditions compatible with common biomolecules. These requirements could be met through the 
application of phosphanylmethylphosphonate reagents (3, Figure 1). Azole-mediated condensation 
between an alcohol and 3, followed by in situ oxidation, would give fully protected methylene 
bisphosphonate tetraester 4. Global deprotection of 4 would provide terminal methylene bisphosphonate 
functionalized molecules. Alternatively, selective deprotection of 4 to bisphosphonotriester 5, 
consecutive PV-condensation with a second alcohol would give bisphosphonotetraester 6 and removal of 
the protecting groups in 6 would provide unsymmetric methylene bisphosphonates. This chapter 
describes the development and optimization of the syntheses of several phosphanylmethylphosphonate 
reagents and their application in the preparation of terminal methylene bisphosphonates, both in solution 
and on solid-support. 
 
 
Scheme 1: Exploratory study towards the synthetic accessibility and application of phosphanylmethylphosphonates. 
Reagents and conditions: [a] n-BuLi, THF, -78 ˚C, 0.5h » add 16, 15 min. [b] i: N6-Benzoyl-2,3-O-di-iso-butyryladenosine (9), 
tetrazole, MeCN, 10 min. ii: tBuOOH, 15 min. [c] 10% TFA in DCM, 0.5h. [d] PhSH/Et3N/dioxane (1:2:2), 48h. [e] 
PhSH/Et3N/dioxane (1:2:2), 16h. [f] i: 10% TFA in DCM, 0.5h. ii: NH4OH, 16h. [*] Yields based on 31P NMR and LCMS analysis. 
 
To evaluate the proposed methodology, phosphanylmethylphosphonate 9 was chosen as a reagent 
suitable for the introduction of terminal methylene bisphosphonate monoesters (Scheme 1). Lithiation of 
di-tert-butyl methylphosphonate (7) with 1 equivalent of n-BuLi, followed by the addition of 
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phosphoramidite 8, provided the desired phosphanylmethylphosphonate 9 in 39% yield.18 The 
phosphorylating properties of reagent 9 were investigated by exploring the synthesis of known adenosine- 
5’-methylene bisphosphonates (13, Scheme 1).19 Condensation of phosphoramidite 9 with partially 
protected adenosine 1020 was accomplished using 1H-tetrazole as activator. Subsequent in situ tBuOOH-
mediated oxidation of the phosphonite-phosphonate intermediate afforded methylene bisphosphonates 
of adenosine 11 in 37% yield. Next, the deprotection of the tert-butyl groups was investigated. 31P-NMR 
spectroscopy was used to screen the reaction progression at varying concentrations of trifluoroacetic acid 
(TFA) in DCM. Optimal conditions were found at 10% TFA; providing clean conversion within 30 minutes. 
Successive demethylation of 12 with thiophenol in the presence of TEA proceeded sluggishly, taking 48 
 
 
Figure 2: Exploratory sequential deprotection of compound 11, monitored by 31P NMR spectrometry (162 MHz). A NMR tube was 
charged with an aliquot of the reaction mixture and fitted with an acetone-d6 capillary (required for locking). A: Fully protected 
11, before addition of PhSH:TEA. B: The reaction mixture after 16h treatment with PhSH:TEA:dioxane (1:2:2); showing complete 
conversion into demethylated intermediate 14. C: After extractive work-up (removal of PhSH and TEA) and concentration, the 
residue was treated with 10% TFA in DCM for 30 minutes, resulting in cleavage of the tert-butyl groups (intermediate 13). 
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hours to complete. It was reasoned that the terminal phosphate becomes deprotonated under basic 
demethylation conditions. The resulting increased electron density surrounding the phosphor lowers the 
leaving group capacity of the methyl phosphate. Indeed, demethylation proceeded significantly smoother 
after reversing the order of deprotection (Figure 2, 11 » 14). ). 31P-NMR spectrometry and LCMS analysis 
showed clean peak-to-peak conversion of 11 (Figure 2, A) to 14 (Figure 2, B) within 16 hours. After 
extractive work-up, crude methylene diphosphate 14 was deprotected using the previously determined 
TFA conditions, providing protonated bisphosphonate monoester 13 (Figure 2). Finally, ammonia 
mediated deacylation provided me-ADP (Scheme 1, 15) in quantitative yield (based on 31P-NMR 
spectrometry and LCMS).  
With the proposed methodology validated, efforts were directed towards the preparation of protected 
phosphanyl methylphosphonates 17 and 20. Reagent 17 is orthogonally protected with a tert-butyl group 
at the terminal phosphate. After the coupling-oxidation sequence of reagent 17 with a specific alcohol, 
selective deprotection of the tert-butyl group in the acquired intermediate would allow for a PV-
condensation with second relevant alcohol, leading to unsymmetric methylene bisphosphonate diesters. 
The application of reagent 17 will be discussed in Chapter 3. Reagent 20 contains the base labile 2-
cyanoethanol protecting group to accommodate the synthesis of terminal methylene bisphosphonates 
monoesters both in solution and on solid-support.  
 
 
Scheme 2: Synthesis of phosphanyl methylphosphonate 17 and 20. Reagents and 
conditions: [a] i: n-BuLi, THF, -78 oC, 0.5 h. ii: 8, -78 oC, 15 min [b] i: LDA, THF, -78 ˚C, 0.5h. 
ii: 18, -78 ˚C » RT, 16h. [c] DCI, 2-cyanoethanol, DCM, 3.5h. 
 
Phosphanylmethylphosphonate reagent 17 is prepared according to a similar procedure as described for 
the synthesis of otherwise protected reagent 9 (Scheme 2). Lithiation of methylphosphonate 16 with 1 
equivalent of n-BuLi was followed by the addition of chlorophosphine 8, providing target phosphoramidite 
17 in 32% yield. During refinement of this reaction, it was found that the relatively low yield could be 
attributed to two unwanted modes of quenching and partial PIII-oxidation during column purification. First 
of all, the diminished yield was partially caused by proton-exchange between emerging bisphosphonate 
17 and lithiated methylphosphonate 16, neutralizing the reactant. This problem was circumvented by 
switching to 2.1 equivalents LDA, increasing the yield to 45%. In addition, it was found that commercially 
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available 8 was contaminated with diisopropylamine hydrochloride (DIPA·HCl), another species capable 
of quenching the lithiated methylphosphonate 16. Removal of DIPA·HCl, by precipitation in n-hexane prior 
to addition and applying the solution through a filter, further increased the yield of the reaction. During 
the purification of 17, partial oxidation of the PIII (up to 30%) would sporadically occur during column 
purification. It was empirically determined that this could be attributed to silica gel impurities (potentially 
trace metals). The oxidation was prevented when high-purity grade silica was used to purify 17. After 
these refinements were implemented the synthesis of 17 proceeded cleanly, as determined by 31P NMR 
spectroscopy (Figure 3), increasing product yield to 70%. The monitoring of the synthesis of 17 is shown 
in Figure 3. Addition of lithiated 16 onto chlorophosphoramidite 8 gave rise to wide variety of phosphor 
species. The lithiation of formed 17 by excess LDA introduces an additional stereocenter, providing four 
additional (distinguishable) diastereoisomers (Figure 3, A). Subsequent quenching with aqueous sodium 
 
 
Figure 3: Synthesis of phosphanyl methylphosphonate reagent 17, monitored by 31P NMR spectrometry (162 MHz). A NMR 
tube was charged with an aliquot of the reaction mixture and fitted with an acetone-d6 capillary (required for locking). A: The 
reaction mixture after complete addition of the chlorophosphoramidite. B: The crude reaction mixture after quenching with 




bicarbonate protonates the lithium species, converting it into the desired bisphosphonate (Figure 3, B) 
which was isolated cleanly using high-purity grade silica (Figure 3, C). 
Reagent 20, fitted with the more labile cyanoethyl protecting group, was prepared via adjustment of 
the above described protocol (Scheme 2). tert-Butyl methylphosphonate 7 was deprotonated  by LDA and 
subsequent reaction with bis(diisopropylamino)chlorophosphoramidite 18 afforded bis-amidite 19 in 76% 
yield. Selective substitution of one of the diisopropylamine groups with 2-cyanoethanol, under the agency 
of 0.6 eq. 4,5-dicyanoimidazole (DCI), provided reagent 20 in 82% yield. 
 
 
Scheme 3: Solution-phase synthesis of me-ADP 15 and methylene analogue of ATP 23 Reagents and conditions: [a] 
i: 20, DCI, MeCN, 15 min. ii: tBuOOH, 15 min. [b] HCl (1.2 eq, 0.5M), HFIP, 4h. [c] Ammonia, 16h. [d] i: 23, ETT, MeCN, 
15 min. ii: tBuOOH, 15 min. iii: DBU, 0.5h. iv: ammonia, 16h. 
 
Having the reagents in hand, the synthesis of the methylene bisphosphonate analogues of adenosine di- 
and triphosphate21 (me-ADP 15 and me-ATP 23, Scheme 3) with reagent 20 was undertaken. Coupling of 
20 with adenosine derivative 10 under the influence of DCI and subsequent oxidation of the PIII-PV 
intermediate gave protected me-ADP 21 in 93% isolated yield. Removal of the terminal tert-butyl 
protecting groups was carried out with HCl in hexafluoroisopropanol (HFIP), to obtain partially protected 
ADP analogue 22 in 97% yield. Global deprotection of 22 by treatment with aqueous ammonia provided 
adenosine methylene bisphosphonate (15) in 73% yield. The syntheses of adenosine methylene 
triphosphate 23 was effectuated in a one-pot procedure. Methylene diphosphate 22 was first 
phosphorylated with bis(methylsulfonyl)ethyl) diisopropylphosphoramidite (24)22 in the presence of 5-
ethylthiotetrazole (ETT). Ensuing in situ oxidation of the phosphite-phosphate anhydride intermediate by 
tBuOOH gave the desired methylene triphosphate intermediate, as was determined by 31P-NMR 
spectroscopy. The cyanoethyl and methylsulfonyl)ethyl  protective groups were simultaneously cleaved 
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by DBU, followed by global deacylation with ammonia. Crude me-ATP 23 was purified by size-exclusion 
and anion-exchange chromatography. 
Next, the applicability of newly developed methodology for automated solid-phase synthesis was 
investigated. For this purpose, the methylene bisphosphonates analogues of all nucleosides (me-ADP 15, 
me-CDP 28, me-GDP 29 and me-UDP 30, Scheme 4) were selected as target molecules. Commercially 
available controlled pore glass (CPG), pre-loaded with the respective suitably protected nucleoside 
through a succinyl linker (25)23, was loaded into an automated solid-phase oligonucleotide synthesizer. 
The four-step cycle procedure started with coupling of the immobilized nucleoside with phosphanyl 
methylphosphonate reagent 20, using ETT as the activating agent. Subsequent oxidation with (1S)-(+)-(10-
camphorsulfonyl)-oxaziridine (CSO) yielded protected resin-bound methylene bisphosphonate nucleotide 
26. The terminal tert-butyl groups in intermediate 26 were cleaved with HCl in HFIP (27), followed by DBU 
mediated removal of the 2-cyanoethyl group. Final ammonolysis of the acyl protecting groups with 
concomitant release from the solid support was effected by treatment with aqueous ammonia. The crude 
products were purified by gel filtration, providing methylene bisphosphonate nucleotides 15 (39%), 28 
(46%), 29 (44%) and 30 (52%). 
 
 
Scheme 4: Automated solid-phase synthesis of methylene bisphosphonate nucleotides. Reagents and 
conditions: [a] 4 x HCl (50 mM), HFIP, 1 min. [b] i: 2 x ETT and 20, MeCN, 5 min. ii: 2 x CSO, MeCN, 5 min. [c] 






The necessity of strong basic conditions during the preparation of the phosphanylmethylphosphonate 
reagents impedes the use of base-labile protecting groups at the PV-position. The use of 
bis(diisopropylamino)-chlorophosphoramidite circumvents this issue at the PIII-position, as was 
demonstrated for compound 20. The reliance on base-stable protecting groups, such as the tert-butyl, 
limits the scope to acid stable substrates. This restriction became evident while attempting to synthesize 
the acid labile mono-substituted methylene bisphosphonate analogue of farnesyl pyrophosphate24 and 
isopentenyl pyrophosphate25. Although the key phosphoramidite coupling proceeded efficiently (32a in 
71%, 32b in 65%), the acid sensitive aliphatic tails decomposed during tert-butyl removal. It can be 
concluded that the method, in its present form, is limited to substrates stable to at least diluted TFA. In 




Scheme 6: Attempted synthesis of isopentenyl- (a) and farnesyl (b) methylene 
bisphosphonate phosphonate analogues. 
 
Conclusion 
A new class of orthogonally protected phosphanylmethylphosphonate reagents has been developed for 
the synthesis of methylene bisphosphonate esters. Relevant examples are 17, 19 and 20, which are 
provided with selectively removable tert-butyl groups. These reagents are readily accessible through a 
one-pot procedure by reacting a lithiated methylphosphonate diester with the corresponding 
chlorophosphoramidite. Terminal methylene bisphosphonates could be prepared by phosphitylation of 
an alcohol with phosphanyl-methylphosphonate 20, followed by in situ oxidation using tBuOOH, as has 
been demonstrated in the solution-phase synthesis of analogues of adenosine di- and triphosphate (me-
ADP 15 and me-ATP 23). In addition, the method has proven to be suitable for solid-phase synthesis, as 
shown for nucleotides methylene bisphosphonates (15, 28-30). Phosphanylmethyl bis(amidite) 19 
enables potential installation of other relevant protecting groups. Reagent 17 was designed and prepared 
while its application for the synthesis of unsymmetric methylene bisphosphates is described in the next 
Chapter. 
 




General: All solvents used under anhydrous conditions were stored over 4Å molecular sieves except for 
methanol which was stored over 3Å molecular sieves. Solvents used for workup and column 
chromatography were of technical grade from Sigma Aldrich and used directly. Unless stated otherwise, 
solvents were removed by rotary evaporation under reduced pressure at 40 °C. Reactions were monitored 
by TLC‐analysis using Merck aluminum DC Silicagel 60 F254 with detection by spraying with 20% H2SO4 in 
EtOH, (NH4)6Mo7O24·4(H2O) (25 g/L) and (NH4)4Ce(SO4)4·2(H2O) (10 g/L) in 10% sulfuric acid or by spraying 
with a solution of ninhydrin (3 g/L) in EtOH / AcOH (20/1 v/v), followed by charring at approx. 250°C. 
Column chromatography was performed on Fluka silicagel (0.04 – 0.063 mm) or for methylene 
bis(phosphorus) compounds on high-purity grade silica (Sigma-Aldrich, Davisil Grade, 633). 
NMR: 1H‐, 13C‐ and 31P-NMR Experiments were carried out on a Brüker AV-400 (400 MHz) or a Brüker AV-
500 (500 MHz) and AVIII-Brüker DMX‐600 (600 MHz). Chemical shifts are given in ppm (δ) and directly 
referenced to TMS (0.00 ppm) in CDCl3 or D2O via the solvent residual signal. CDCl3 used in the 
characterization of phosphoramidite containing compounds was neutralized before use by filtering over 
aluminum oxide (Type WB-5: Basic). 31P Chemical shifts are indirectly referenced to H3PO4 (0.00 ppm) 
according to the IUPAC method. 31P NMR spectra measured to monitor reactions were made by charging 
a NMR tube with an aliquot of the reaction mixture and fitting the tube with an acetone-d6 capillary. 
LC-MS: Analysis were carried out on a JASCO HPLC system (detection simultaneously at 214 and 254 nm) 
coupled to a PE/SCIEX API 165 single quadruple mass spectrometer (Perkin-Elmer) using an analytical 
Gemini C18 column (Phenomex, 50 x 4.60 mm, 3 micron) in combination eluents A: H2O; B: MeCN and C: 
0.1 M aq. NH4OAc or a Thermo Finnigan LCQ Advantage MAX ion-trap mass spectrometer with an 
electrospray ion source coupled to Surveyor HPLC system (Thermo Finnegan) using an analytical Gemini 
C18 column (Phenomex, 50 x 4.60 mm, 3 micron) in combination with eluents A: H2O; B: MeCN and C: 1% 
aq. TFA as the solvent system. High resolution mass spectra were recorded by direct injection (2 μL of a 2 
μM solution in water/acetonitrile; 50/50; v/v and 0.1% formic acid) on a mass spectrometer (Thermo 
Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, 
sheath gas flow 10, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z 
= 150-2000) and dioctylpthalate (m/z = 391.2842) as a “lock mass”. 
Trace Metal Chelation: High purity grade silica should be used when purifying methylene mono-
phosphonic acids by silica gel column chromatography. Methylene mono-phosphonic acids (8) could be 
purified using silica gel column chromatography. However, it was found that after column purification 
the characteristic 31P NMR peaks showed extreme signal broadening, to such an extent that the signals 
became difficult to detect. This broadening effect could be reversed by passing the purified methylene 
mono-phosphonic acid over an EDTA functionalized resin (a resin used to capture metal ions). This 
indicates that signal broadening resulted from metal ions bound to the phosphate, which could only 




Preparation of Phosphoramidite Reagents: 
 
 
Phosphanylmethylphosphonate 9: Reagent was prepared according to the procedure described for 17, 
using the following amounts: 2.5M solution of n-BuLi in n-hexane (4.2 ml, 10.5 mmol, 2.1 eq), 
diisopropylamine (1.6 ml, 11.2 mmol, 2.2 eq), di-tert-butyl methylphosphonate26 (1.0 g, 5.0 mmol, 1.0 eq) 
in THF (5 mL) and chloro(diisopropylamino) methoxyphosphine (1.17 ml, 6.0 mmol, 1.2 eq) in n-hexane (5 
mL). Purification by silica gel column chromatography (12.5% » 15% EtOAc in PE + 1% TEA) provided the 
product as a colorless oil (1.0 g, 2.7 mmol, 54%). 1H NMR: (400 MHz, CDCl3) δ 3.53 – 3.36 (m, 2H), 3.45 (d, 
J = 14.0, 3H), 2.23 (ddd, J = 18.8, 14.4, 1.5 Hz, 1H), 1.86 (ddd, J = 20.2, 14.5, 1.0 Hz, 1H), 1.51 (s, 18H), 1.20 
(d, J = 6.7 Hz, 6H), 1.13 (d, J = 6.8 Hz, 6H). 13C NMR: (101  MHz, CDCl3) δ 81.62, 81.54, 81.47, 54.18, 53.97, 
44.63, 44.52, 36.55, 36.23, 35.17, 34.85, 30.41, 30.37, 30.30, 24.36, 24.25, 24.17. 31P NMR: (122 MHz, 




Phosphanylmethylphosphonate 17: A 2.5 M solution of n-BuLi in n-hexane (3.4 ml, 8.4 mmol, 2.1 eq) was 
carefully added to a cooled solution of (-78 ˚C) diisopropylamine (1.2 ml, 8.4 mmol, 2.1 eq) in dry THF (4 
mL), under argon atmosphere. The reaction mixture was stirred for 30 minutes. Next, a solution of tert-
butyl methyl methylphosphonate27 (0.63ml, 4.0 mmol, 1 eq) in THF (4 mL) was added dropwise over 5 
minutes, and the reaction was stirred for an additional 30 minutes. Lastly, commercially acquired 
chloro(diisopropylamino)methoxyphosphine (0.93 ml, 4.8 mmol, 1.2 eq) was purified by dissolving in n-
hexane (4 mL), to precipitating DIPA·HCl contaminates. The resulting solution was added dropwise (±5 
minutes) through a syringe fitted with silica filter and small layer of molecular sieves (±1 cm, 4Å). The cold 
reaction mixture was stirred for 30 minutes, before it was quenched with ethanol (2 mL) and poured into 
a two-layer system of DCM and saturated aqueous sodium bicarbonate. After extraction, the organic layer 
was dried over sodium sulfate, filtered and concentrated in vacuo. The concentrate was purified by silica 
gel column chromatography  (30% EtOAc in PE + 1% TEA), providing 17 as a colorless oil (0.91 g, 2.8 mmol, 
70%). 1H NMR: (400 MHz, CDCl3) δ 3.72 (d, J = 11.2 Hz, 3H), 3.44 (dd, J = 14.2, 1.2 Hz, 3H), 2.32 (dddd, J = 
19.8, 14.8, 11.8, 2.9 Hz, 1H), 1.89 (dddd, J = 20.9, 17.5, 14.5, 2.9 Hz, 1H), 1.52 (d, J = 2.2 Hz, 9H), 1.21 (d, J 
= 6.7 Hz, 6H), 1.13 (d, J = 6.8 Hz, 6H). 13C NMR: (101 MHz, CDCl3) δ 82.26, 82.18, 82.13, 82.05, 54.18, 53.97, 
51.73, 44.52, 44.41, 33.32, 33.20, 33.01, 32.89, 31.96, 31.84, 31.65, 31.53, 30.27, 30.23, 30.22, 30.21, 
30.17, 24.32, 24.27, 24.10, 24.02. 31P NMR: (162 MHz, CDCl3) δ = 121.03 (d, J = 56.7 Hz), 120.85 (d, J = 55.1 
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Phosphanylmethylphosphonate 19: A 2.5M solution of n-BuLi in n-hexane (8.4 ml, 21 mmol, 2.1 eq) was 
carefully added to a cooled solution (-78 ˚C) of diisopropylamine (3.14 ml, 21 mmol, 2.1 eq) in dry THF (10 
mL), under argon atmosphere. The reaction mixture was stirred for 30 minutes. Next, a solution of di-tert-
butyl methylphosphonate (2.08 g, 10 mmol) in THF (10 mL) was added dropwise over 5 minutes, and the 
reaction mixture was stirred for an additional 30 minutes. Lastly, a solution of 
bis(diisopropylamino)chlorophosphoamidite (3.2 g, 12 mmol) in n-hexane:THF (2:1 v:v, 15 mL) was 
prepared and added dropwise (±5 minutes) through a syringe fitted with a silica filter. After addition, the 
cooling bath was removed and the solution was stirred overnight at room temperature. The reaction 
mixture was poured into saturated aqueous sodium bicarbonate and was extracted with EtOAc. The 
organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. Purification by silica gel 
column chromatography (5% » 10% EtOAc in PE + 2% TEA) yielded the product as a colorless oil (3.33 g, 
7.6 mmol, 76%), that crystalized to a white solid. 1H NMR: (400 MHz, CDCl3) δ 3.38 (dq, J = 18.0, 6.6 Hz, 
4H), 2.12 (dd, J = 20.7, 1.6 Hz, 2H), 1.52 (s, 18H), 1.19 (t, J = 7.5 Hz, 24H). 13C NMR: (101 MHz, CDCl3) δ 
81.15, 81.06, 46.98, 46.86, 32.31, 32.00, 30.93, 30.63, 30.46, 30.43, 24.16, 24.10, 23.89, 23.81. 31P NMR: 
(162 MHz, CDCl3) δ 39.63 (d, J = 89.1 Hz), 21.78 (d, J = 89.1 Hz). HRMS: Calculated for C21H51NO4P2 
457.33186 [M+H+H2O]+; found 457.33178. 
 
 
Phosphanylmethylphosphonate 20: DCI (0.538 g, 4.56 mmol, 0.6 eq) was added to a dry solution of di-
tert-butyl ((bis(diisopropylamino)phosphaneyl)methyl)phosphonate (3.33 g, 7.59 mmol) and 2-
cyanoethanol (0.519 ml, 7.59 mmol) in DCM (50 mL). The reaction progression was followed by 31P NMR, 
which indicated completion after 3.5 hours. The solution was concentrated in vacuo and purified by silica 
gel column chromatography (30% » 40% EtOAc + 1% TEA), providing phosphanyl methylphosphonate 20 
(2.54 g, 6.22 mmol, 82%) as a colorless oil. 1H NMR: (500 MHz, CDCl3) δ 3.92 – 3.74 (m, 2H), 3.58 – 3.40 
(m, 2H), 2.65 (q, J = 6.3, 5.9 Hz, 2H), 2.30 (ddd, J = 19.0, 14.4, 1.1 Hz, 1H), 1.89 (ddd, J = 20.3, 14.5, 1.5 Hz, 
1H), 1.58 – 1.45 (m, 18H), 1.21 (d, J = 6.7 Hz, 6H), 1.14 (d, J = 6.8 Hz, 6H). 13C NMR: (126 MHz, CDCl3) δ = 
117.57, 81.62, 81.58, 81.55, 81.51, 61.58, 61.38, 44.80, 35.99, 35.74, 34.89, 34.64, 30.22, 30.19, 23.95, 
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20.08, 20.02. 31P NMR: (202 MHz, CDCl3) δ = 117.95 (d, J = 60.6 Hz), 15.25 (d, J = 60.6 Hz). Calculated for 
C18H39N2O4P2 409.23796 [M+H]+; found 409.23792. 
 
 
Bis(methylsulfonylethanol) Phosphoramidite 24: Diisopropylamine (1.63 ml, 11.46 mmol, 2 eq) was 
added to a cooled (0 °C) solution of DIPEA (2,0 ml, 11,46 mmol) and trichlorophosphane (0.50 ml, 5.73 
mmol, 1 eq) in THF (20 mL). After 10 minutes, a solution of methylsulfonylethanol (1.42 g, 11.46 mmol, 2 
eq) in THF (10 mL) was carefully added. The cooling bath was removed and the reaction mixture was 
stirred for 3 hours, after which 31P NMR: indicated completion of the reaction. The mixture was filtered, 
rinsed and diluted with EtOAc. The filtrate was washed with saturated aqueous sodium bicarbonate and 
brine. The organic layer was isolated, dried over magnesium sulfate and concentrated in vacuo. The solid 
residue was recrystallized by cooling a supersaturated solution of the impure product in acetone : n-
hexane (1:2 v:v, 5 mL), affording phosphoramidite 24 (1.15 g, 3.05 mmol, 53%) as a white crystalline 
substance.22 Alternatively, the residue can be purified using silica gel column chromatography (20% » 30% 
acetone in PE + 1% TEA). 1H NMR: (400 MHz, CDCl3) δ = 4.19 – 3.98 (m, 2H), 3.58 (dh, J=10.4, 6.8, 1H), 3.38 
– 3.20 (m, 2H), 3.01 (d, J=0.9, 3H), 1.20 (d, J=6.9, 6H). 13C NMR: (101 MHz, CDCl3) δ = 57.51, 57.31, 56.00, 
55.92, 43.17, 43.04, 42.67, 24.49, 24.42. 31P NMR: (162 MHz, CDCl3) δ = 148.27. 
 
Coupling Reactions in Solution: 
 
Protected me-ADP 11: N6-Benzoyl-2,3-O-di-iso-butyryladenosine (0.213 g, 0.416 mmol) was co-
evaporated with pyridine (10 mL) and MeCN (10 mL) and put under argon atmosphere. Phosphanyl 
methylphosphonate 9 (122 mg, 0.330 mmol) was added as a solution (1 mL; 15% pyridine in MeCN) and 
the mixture was reduced in volume.  The concentrated mixture was co-evaporated once more with MeCN, 
redissolved in MeCN (4 mL) and put under argon atmosphere. Tetrazole (1.1 mL, 0.495 mmol) in MeCN 
(0.45M) was added. 31P NMR indicated full conversion within 10 minutes. tert-butyl hydroperoxide (180 
µl, 0.991 mmol) was added, and the reaction mixture was stirred for an additional 15 minutes. The 
reaction was concentrated in vacuo and redissolved in EtOAc. The solution was washed with aqueous 
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sodium bicarbonate and brine. The organic layer was dried over magnesium sulfate and concentrated in 
vacuo. Purification by silica gel column chromatography (100% EtOAc » 1% MeOH in EtOAc » 3% MeOH) 
yielded methylene bisphosphonate 11 as a colorless oil (86 mg, 0.108 mmol, 33%). 1H NMR: (400 MHz, 
CDCl3) δ 9.48 (d, J = 10.0 Hz, 1H), 8.82 (s, 1H), 8.53 (d, J = 20.4 Hz, 1H), 8.10 – 7.99 (m, 2H), 7.63 – 7.55 (m, 
1H), 7.51 (dd, J = 8.2, 6.7 Hz, 2H), 6.34 (t, J = 6.3 Hz, 1H), 5.89 (dt, J = 18.0, 5.9 Hz, 1H), 5.70 (ddd, J = 15.6, 
5.7, 3.3 Hz, 1H), 4.46 (d, J = 6.4 Hz, 2H), 3.85 – 3.64 (m, 4H), 2.65 (dt, J = 14.0, 6.9 Hz, 1H), 2.58 – 2.31 (m, 
3H), 1.52 (dd, J = 3.7, 1.4 Hz, 18H), 1.23 (d, J = 7.0 Hz, 6H), 1.11 (dd, J = 14.6, 7.0 Hz, 6H). 13C NMR: (101 
MHz, CDCl3) δ 175.61, 175.55, 175.21, 164.72, 152.82, 151.70, 151.66, 149.70, 141.59, 133.55, 132.63, 
128.67, 127.88, 122.96, 85.58, 83.88, 83.82, 83.80, 83.74, 83.71, 81.93, 81.86, 81.79, 81.72, 73.21, 73.11, 
70.54, 70.45, 65.06, 64.99, 64.93, 53.27, 53.21, 53.11, 33.68, 33.49, 30.20, 30.16, 30.13, 18.82, 18.80, 
18.71, 18.64, 18.54. 31P NMR: (162 MHz, CDCl3) δ 23.73, 23.66, 23.32, 23.25, 9.61, 9.54, 9.47. LCMS: 
Calculated for C35H52N5O12P2 796.31 [M+H]+; found 796.00 
 
 
me-ADP 15: Methylene bisphosphonate 11 (37 mg, 46 µmol, 1 eq) was dissolved in a mixture of 
thiophenol:dioxane: TEA 1:2:2 (1.94 M, 0.5 mL) and the reaction was stirred overnight. 31P NMR and LCMS 
analysis indicated complete conversion into intermediate 14 (see page S16). The reaction mixture was 
poured into a separation funnel containing water, acidified with acetic acid and washed with Et2O (3x, to 
remove thiophenol). The water layer was isolated and concentrated in vacuo. The residue was dissolved 
in 10% TFA in DCM (0.5 mL). After 30 minutes, the reaction mixture was analyzed by 31P NMR 
spectrometry, showing complete conversion. The reaction mixture co-evaporated with dioxane and 
chloroform. Ammonia (30%, 1 mL) was added and solution was stirred overnight. The final reaction 
mixture was analyzed by LCMS analysis. This was an exploratory experiment to determine the 





Protected me-ADP 21: Adenosine 10 (0.465 g, 0.909 mmol, 1.1 eq) and phosphanyl methylphosphonate 
20 (0.408 g, 1.00 mmol, 1 eq) were co-evaporated with MeCN (8 mL), redissolved in MeCN (4 mL) and put 
under argon atmosphere. The reaction was stirred until all solids were dissolved and DCI (0.161 g, 1.36 
mmol, 1.5 eq) was added. 31P-NMR indicated full conversion within 15 minutes. Oxidation was initiated 
the addition of tert-butyl hydroperoxide (0.331 ml, 1.82 mmol, 2 eq) in decane (5.5 M). The reaction 
mixture was stirred for an additional 15 minutes. The solution was poured into a separation funnel 
containing water and EtOAc, washed with aqueous sodium bicarbonate (to remove DCI) and brine. The 
organic layer was dried over Na2SO4 and concentrated in vacuo. Purification by silica gel column 
chromatography (25% » 50% acetone in DCM) yielded compound 21 (705 mg, 0.845 mmol, 93%) as white 
foam. 1H NMR: (500 MHz, CDCl3) δ 9.31 (s, 1H), 8.76 (d, J = 2.9 Hz, 1H), 8.40 (d, J = 44.2 Hz, 1H), 8.06 – 
7.93 (m, 2H), 7.60 – 7.52 (m, 1H), 7.47 (dd, J = 8.4, 7.0 Hz, 2H), 6.27 (dd, J = 21.0, 5.9 Hz, 1H), 5.88 (dt, J = 
38.9, 5.8 Hz, 1H), 5.68 (ddd, J = 23.2, 5.6, 3.7 Hz, 1H), 4.51 – 4.38 (m, 3H), 4.35 – 4.23 (m, 2H), 2.74 (dp, J 
= 7.6, 6.2 Hz, 2H), 2.60 (h, J = 7.0 Hz, 1H), 2.55 – 2.39 (m, 3H), 1.53 – 1.42 (m, 18H), 1.19 (d, J = 7.0 Hz, 6H), 
1.12 – 1.03 (m, 7H). 13C NMR: (126 MHz, CDCl3) δ 175.77, 175.66, 175.43, 175.40, 164.86, 152.94, 151.87, 
151.82, 149.85, 133.63, 132.83, 128.86, 128.01, 123.60, 123.48, 116.95, 116.86, 86.24, 85.77, 84.25, 
84.23, 84.18, 84.17, 84.16, 84.09, 84.07, 84.01, 81.88, 81.82, 81.61, 81.55, 73.19, 73.08, 70.48, 70.39, 
65.33, 64.98, 61.28, 61.24, 33.82, 33.63, 30.73, 30.55, 30.37, 30.34, 30.31, 30.28, 29.65, 29.61, 29.48, 
29.43, 28.53, 28.36, 19.90, 19.85, 18.98, 18.96, 18.86, 18.82, 18.81, 18.70. 31P NMR: (202 MHz, CDCl3) δ 
22.86 (d, J = 6.1 Hz), 22.53 (d, J = 6.1 Hz), 8.73, 8.64. HRMS: Calculated for C37H53N6O12P2 835.31912 
[M+H]+; found 835.31958 
 
 
Protected me-ADP 22: A 6M HCl in dioxane : water (1:1 v:v, 84 µl, 0.505 mmol, 1.2 eq) was added to a 
solution of adenosine methylene bisphosphonate 21 (351 mg, 0.420 mmol, 1 eq) in HFIP (1 mL). The 
reaction was shortly sonicated until the HCl solution was dissolved in the HFIP. The reaction was 
monitored by 31P NMR, which indicated full conversion after 4 hours. The reaction was diluted with 
dioxane : toluene (1:1 v:v, 20 mL) and co-evaporated, this was repeated thrice to remove all traces of 
HFIP, providing adenosine methylenephosphonic acid 22 as a colorless oil (295 mg, 0.408 mmol, 97%). 
The product was used without further purification. 31P NMR: (162 MHz, Acetone-D6) δ = 22.08 (d, J = 8.1 





me-ADP 15: A 6M HCl in dioxane : water (1:1 v:v, 39 µL, 0.236 mmol, 1.2 eq) was added to a solution of 
adenosine methylene bisphosphonate 22 (164 mg, 0.196 mmol) in HFIP (1 mL). The reaction was 
monitored by 31P NMR spectrometry, which indicated full conversion after 4 hours. The reaction was 
quenched with ammonium hydroxide (0.1 mL) and concentrated in vacuo. The concentrate was 
redissolved in ammonium hydroxide (1 mL, 17.5 mmol) and the reaction was stirred overnight. The excess 
ammonia was purged by stirring under vacuum. The crude material was purified using size-exclusion 
(HW40-column, 0.15 M aqueous NH4OAc) chromatography. Lyophilization provided me-ADP 15 (61 mg, 
0.143 mmol, 73%) as a white powder. 1H NMR: (600 MHz, D2O) δ 8.25 (s, 1H), 7.87 (s, 1H), 5.87 (d, J = 5.3 
Hz, 1H), 4.57 (t, J = 5.2 Hz, 1H), 4.37 (t, J = 4.7 Hz, 1H), 4.22 (d, J = 3.8 Hz, 1H), 4.03 (m, J = 4.9, 4.3 Hz, 2H), 
2.05 (t, J = 19.9, 2.0 Hz, 2H). 13C NMR: (151 MHz, D2O) δ 155.95, 153.36, 149.39, 140.58, 119.08, 88.00, 
84.58, 75.15, 71.10, 64.47, 29.33, 28.51, 27.68. 31P NMR: (202 MHz, D2O) δ = 18.20 (d, J = 8.1 Hz), 21.68 
(d, J = 8.1 Hz), 16.55 (d, J = 8.1 Hz), 16.46 (d, J = 8.1 Hz).  
 
 
me-ATP 23: Crude adenosine methylene bisphosphonate 22 (295 mg, 0.408 mmol, 1 eq) and bis(2-
(methylsulfonyl)ethyl) diisopropylphosphoramidite 24 (185 mg, 0.490 mmol, 1.2 eq) were co-evaporated 
with MeCN (8 mL),  redissolved in dry MeCN (4 mL) and put under argon atmosphere. The reaction was 
stirred until all solids were dissolved, after which ETT (80 mg, 0.612 mmol, 1.5 eq) was added. 31P-NMR 
indicated full conversion within 15 minutes. Oxidation was initiated by the addition of tert-butyl 
hydroperoxide (111 µl, 0.612 mmol, 1.5 eq) in decane (5.5 M). After 15 minutes, DBU (431 µl, 2.86 mmol, 
7 eq) was added and the reaction mixture was stirred for an additional 30 minutes. Ammonia (30%, 5 mL) 
was added and the reaction mixture was stirred overnight. The excess ammonia was purged by stirring 
under vacuum. The crude material was purified using size-exclusion (HW40-column, 0.15 M aqueous 
NH4OAc) and anion-exchange chromatography (Source 15Q, 10 mM » 1 M, aqueous NH4OAc). 
Lyophilization provided me-ATP 23 (14.4 mg, 0.029 mmol, 14%) as a white powder. 1H NMR: (500 MHz, 
D2O) δ 8.55 (s, 1H), 8.20 (s, 1H), 6.06 (d, J = 5.4 Hz, 1H), 4.96 – 4.92 (m, 1H), 4.72 (t, J = 5.2 Hz, 1H), 4.53 (t, 
J = 4.5 Hz, 1H), 4.36 (t, J = 3.4 Hz, 1H), 4.18 (q, J = 4.2 Hz, 2H), 2.37 (t, J = 20.3 Hz, 2H). 13C NMR: (126 MHz, 
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D2O) δ 153.86, 150.58, 148.66, 118.37, 87.16, 84.03, 83.97, 74.36, 70.16, 63.61, 63.57, 28.63, 27.62, 26.58. 
31P NMR (202 MHz, D2O) δ 18.25 (d, J = 9.9 Hz), 7.72 (dd, J = 25.3, 9.2 Hz), -9.65 (d, J = 24.6 Hz). HRMS: 
Calculated for C11H19N5O12P3 506.02431 [M+H]+; found 506.02347. 
 
 
Protected me-Isopentenyl Diphosphate 32a: Isoprenol (41.8 µL, 0.414 mmol) and di-tert-butyl (((2-
cyanoethoxy) (diisopropylamino) phosphanyl)methyl)phosphonate (203 mg, 0,497 mmol, 1.2 eq) were 
co-evaporated with MeCN (4 mL),  redissolved in MeCN (2 mL) and put under argon atmosphere. The 
reaction was stirred until all solids were dissolved and DCI (73.4 mg, 0.621 mmol, 1.5 eq) was added. 31P-
NMR indicated full conversion within 15 minutes. Oxidation was initiated the addition of tert-butyl 
hydroperoxide (151 µl, 0.828 mmol, 2 eq) in decane (5.5 M). The reaction mixture was stirred for an 
additional 15 minutes. The solution was poured into a separation funnel containing water and EtOAc, 
washed with sodium bicarbonate. The organic layer was dried over Na2SO4 and concentrated in vacuo. 
Purification by silica gel column chromatography (25% » 50% acetone in DCM) yielded the title compound 
(121 mg, 0.296 mmol, 71%) as colorless oil. 1H NMR: (400 MHz, CDCl3) δ 4.81 (d, J = 23.3 Hz, 2H), 4.39 – 
4.28 (m, 2H), 4.24 (q, J = 7.2 Hz, 2H), 2.86 – 2.70 (m, 2H), 2.50 – 2.34 (m, 4H), 1.77 (s, 3H), 1.56 – 1.51 (m, 
18H). 13C NMR: (101 MHz, CDCl3) δ 140.96, 116.69, 112.71, 64.45, 60.75, 38.40, 30.90, 30.28, 29.54, 28.14, 
22.41, 19.90. 31P NMR: (162 MHz, CDCl3) δ 21.00, 8.80. 
 
 
Protected Farnesol me-Diphosphate (32b): Farnesol (125 µL, 0.5 mmol) and (((2-cyanoethoxy) 
(diisopropylamino)phosphanyl)methyl)phosphonate  (245 mg, 0.600 mmol, 1.2 eq) were co-evaporated 
with MeCN (4 mL),  redissolved in MeCN (2 mL), put under argon atmosphere and charged with 2,6-
lutidine (116 µL, 1.00 mmol, 2 eq).  2,6-lutidine·HCl (108 mg, 0.750 mmol, 1.5 eq) was added. 31P-NMR 
indicated full conversion within 15 minutes. Oxidation was initiated the addition of tert-butyl 
hydroperoxide (182 µL, 1.00 mmol, 2 eq) in decane (5.5 M). The reaction mixture was stirred for an 
additional 15 minutes. The solution was poured into a separation funnel containing water and EtOAc, 
washed with sodium bicarbonate (to remove DCI). The organic layer was dried over sodium carbonate 
and concentrated in vacuo. Purification by silica gel column chromatography (10% » 25% acetone in DCM) 
yielded the title compound (176 mg, 0.323 mmol, 65%) as colorless oil. 1H NMR: (400 MHz, CDCl3) δ 5.47 
– 5.35 (t, 1H), 5.16 – 5.03 (m, 2H), 4.65 (t, J = 8.0 Hz, 2H), 4.33 (dtd, J = 7.8, 6.4, 4.3 Hz, 2H), 2.79 (q, J = 6.3 
Hz, 2H), 2.53 – 2.30 (m, 2H), 2.07 (ddd, J = 18.6, 10.6, 4.7 Hz, 7H), 1.97 (dd, J = 9.2, 6.2 Hz, 1H), 1.75 – 1.65 
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(m, 7H), 1.61 (d, J = 4.7 Hz, 5H), 1.54 (d, J = 2.4 Hz, 18H).  31P NMR: (162 MHz, CDCl3) δ 21.20 (d, J = 10.7 
Hz), 8.86 (d, J = 10.5 Hz). HRMS: Calculated for C27H49NO6P2Na 568.29273 [M+Na]+; found 568.29244. 
 
Nucleotide Synthesis on Solid Phase 
Methylene bisphosphonate functionalized nucleotides me-ADP, me-CDP, me-GDP and me-UDP were 
prepared from CPG resin pre-loaded with the respective nucleoside. The nucleosides were attached 
to the resin through a succinyl linker connected at the O3-position. The O5-positions were capped with 
a DMT and the exocyclic amine in A, C and G were protected with the 4-tert-butylphenoxyacetyl (Tac) 
moiety: 
 
Figure S1: Overview of the solid-phase synthesis of the methylene bisphosphonate nucleotides me-ADP, me-CDP, me-GDP 
and me-UDP. 
 
For each experiment 300 mg of pre-loaded GPC resin (±10 µmol loaded nucleoside) was loaded in a 
Mermade 6 oligonucleotide synthesizer. The synthesis was fully carried out under argon atmosphere. 
The nucleotides were purified using size-exclusion (HW40-column, 0.15 M aqueous NH4OAc) 
chromatography. 
I. DMT-Deprotection: The DMT was removed by treatment with HCl in hexafluoroisopropanol (50 
mM, 1 mL) four times for 1 minute. The resin was washed with MeCN (3 x 2 mL). 
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II. Coupling: The reaction vessel was charged with phosphanyl methylphosphonate 20 (0.1 M in 
MeCN, 300 µL) and ETT (0.5 M in MeCN, 600 µL) and left to stand for 5 minutes. This cycle was 
repeated once, before the resin was rinsed with MeCN (3 x 2 mL). 
III. Oxidation: The phosphinite-phosphonate intermediate was oxidized by treatment with (1S)-(+)-
(10-camphorsulfonyl)oxaziridine (0.5 M in MeCN, 2 mL) twice for 5 minutes, and washed with 
MeCN (3 x 2 mL). 
IV. Deprotection: The tert-butyl groups were removed by treating the resin with HCl in 
hexafluoroisopropanol (50 mM, 1 mL) four times for 1 minute. The resin was washed with MeCN 
(3 x 2 mL), before being treated with DBU (1 M in DMF, 1 mL) twice for 2 minutes, to eliminate 
the 2-cyanoethanol (CE). The resin was washed with MeCN (3 x 2 mL). 
V. Cleavage: The resin was treated with NH4OH (35%) for 1 hour, removing the remaining acyl-
based protecting groups (Ac, TAC) and releasing the nucleotide from resin. 
 
Yields and Data28: 
me-ADP (15): 1.66 mg, 3.9 µmol, ±39%. For NMR data see solution phase synthesis for compound 
15. 
me-CDP (28): 1.86 mg, 4.64 µmol, ±46%. 1H NMR: (500 MHz, D2O) δ 8.17 (d, J = 7.8 Hz, 1H), 6.20 (d, 
J = 7.8 Hz, 1H), 5.91 (d, J = 2.9 Hz, 1H), 4.35 – 4.30 (m, 2H), 4.27 – 4.23 (m, 1H), 4.16 (m, J = 43.9, 
11.9, 5.1, 2.4 Hz, 2H), 2.15 (td, J = 19.8, 1.5 Hz, 2H). 31P NMR (202 MHz, D2O) δ 18.92 (d, J = 10.3 Hz), 
15.29 (d, J = 10.1 Hz). 
me-GDP (29): 1.92 mg, 4.35 µmol, ±44%. 1H NMR: (500 MHz, D2O) δ 8.32 (s, 1H), 5.91 (d, J = 5.5 Hz, 
1H), 4.73 (t, J = 5.4 Hz, 1H), 4.48 (t, J = 4.6 Hz, 1H), 4.30 (d, J = 3.8 Hz, 1H), 4.17 – 4.08 (m, 2H), 2.20 
– 2.09 (t, J = 19.9, 2H). 31P NMR: (202 MHz, D2O) δ 18.80, 15.78. 
me-UDP (30): 2.07 mg, 5.25 µmol, ±52%. 1H NMR (500 MHz, D2O) δ 7.87 (dt, J = 8.6, 1.3 Hz, 1H), 
5.87 – 5.78 (m, 2H), 4.29 – 4.21 (m, 2H), 4.13 (d, J = 3.9 Hz, 1H), 4.10 – 3.93 (m, 2H), 2.05 (t, J = 19.7 
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Pyrophosphate monoesters and unsymmetric pyrophosphate diesters are ubiquitous structural elements 
in biomolecules that fulfill essential roles in processes such as: biosynthesis, DNA repair, cellular 
metabolism and cell signaling. For instance, in cellular respiration four unsymmetric pyrophosphates, 
adenosine diphosphate (ADP)1, coenzyme A2, flavin adenine dinucleotide (FAD)3 and nicotinamide 
adenine dinucleotide (NAD+) work in unison to provide the required energy to sustain life.4 Redox cofactor 
FAD not only functions in the electron transport chain, but also acts as a strong oxidizing agent that 
participates in a broad spectrum of oxidative metabolic pathways.5 Another prevalent group of 
unsymmetric pyrophosphates are nucleotide diphosphate sugars. These are utilized by 
glycosyltransferases to transfer monosaccharides onto acceptor molecules, such as saccharides, lipids or 
proteins.6  Both glycosylation and phosphorylation of amino acid side chains within proteins are well-
known post-translational modifications (PTM), that regulate protein intracellular transport and activity.7 
A lesser studied PTM concerns the indirect transfer of pyrophosphates onto peptides. Adenosine 
diphosphate ribosylation (ADP-ribosylation) is a prominent example of indirect (pyro)phosphorylation, 
where a monomer or polymer of ADPr is linked to an amino acid side chain in an acceptor protein.8,9 ADP-
ribosylation plays an important role in DNA repair and the recent synthesis of molecules (or analogues 
thereof) involved in ADP-ribosylation has attracted a lot of scientific interest.10,11 However, existing 
methodologies are considered unsuited for the synthesis of unsymmetric methylene bisphosphonate 
analogues of complex biomolecules, such as poly-ADP-ribose fragments. Therefore, an improved 
methodology to this end could facilitate PARylation related research. Chapter 2 introduces phosphanyl-
methylphosphonate reagents for the synthesis of terminal methylene bisphosphonates as stabilized 
 
 
Figure 1: An overview of the methodology for the synthesis of unsymmetric methylene bisphosphonates. PCO: 
Phosphoramidite coupling-oxidation sequence. PDC: Phosphodiester condensation. 
Combined Phosphoramidite-Phosphodiester Reagents for 
the Synthesis of Unsymmetric Methylene Bisphosphonates 
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analogues of pyrophosphates monoesters. In this chapter the scope of the methodology based on such 
reagents is broadened by the preparation of the more complex unsymmetric methylene bisphosphonates, 
as showcased by the synthesis of adenosine bisphosphate ribose (ADPR) analogue 14 and flavin adenine 
dinucleotide (FAD) analogue 17 (Scheme 3).  As depicted in Figure 1, orthogonal protected 
phosphanylmethylphosphonate 1 reacts with an alcohol of choice using the phosphoramidite coupling-
oxidation sequence to give fully protected methylene bisphosphonate diester 2. Selective removal of the 
tert-butyl group results in the formation of 3 that is amenable for condensation with another alcohol of 
choice using an suitable condensation agent.  
 
Results and Discussion 
 
Figure 2: Phosphorylation of adenosine building block 5 using phosphanyl methylphosphonate reagent 1, monitored by 31P 
NMR spectroscopy (162 MHz). A NMR tube was charged with an aliquot of the reaction mixture and fitted with an acetone-
d6 capillary (required for locking). A: The reagent before addition of the activator (DCI). B: The reaction mixture 10 minutes 
after addition of DCI; shows clean conversion into the phosphonite-phosphonate intermediate (peak II » IV). C: The reaction 
mixture 15 minutes after addition of tBuOOH; oxidation of the phosphonite (peak IV » VI). 
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First, the condensation efficiency of reagent 1 (Figure 2) with partially protected adenosine derivative 5 
was evaluated using various activators. Based on 31P-NMR spectroscopic analysis and the obtained yields, 
5-(ethylthio)-1H-tetrazole (ETT) and 1H-tetrazole performed equally well, while (dicyanoimidazole) DCI 
gave cleaner conversions and more reproducible results (Figure 2). As determined by 31P-NMR 
spectroscopy, subsequent oxidation of 6 by tert-butyl hydroperoxide provided me-ADP 7 (Figure 2, B » C). 
Although NMR analysis showed clean conversion of the DCI mediated coupling, the isolated yield of me-
ADP 7 was unsatisfactory, never exceeding 55%. Exclusion of product loss during column purification and 
washing steps led to the tentative conclusion that the methylene bisphosphonate moiety in 7 binds Mg2+ 
from magnesium sulfate (used during work-up). Indeed, switching to the use of sodium sulfate as a drying 
agent resulted in the isolation of 7 in significantly higher yields (76-85%). Subsequent removal of the tert-
butyl group in 7, to give 8, would permit the next condensation with the C5-OH from methyl 2,3-diacetyl-
ß-D-ribofuranoside (13, Scheme 3). Cleavage of the tert-butyl group using 10% TFA in DCM quantitatively 
provided phosphonic acid 8 as determined by 31P-NMR and 1H-NMR spectroscopy. Surprisingly, the 
following condensation of 2,3-di-O-acetyl-D-ribofuranoside and 8 under influence of the reagent 
combination, 2-mesitylenesulfonyl chloride (TMBSC) and 4-methoxypyridine-N-oxide (MNO) was 
unsuccesful.12 
 
Scheme 1: First attempted synthesis of Me-ADPR (36), while using TFA during tBu-deprotection. Reagents and conditions: [a] 
10% TFA in DCM, 0.5h. [b] TMBSC, MNO, pyridine/MeCN » methyl 2,3-diacetyl-ß-D-ribofuranoside, 3h. 
 
In order to investigate this unexpected outcome, various conditions were screened using methylene 
bisphosphonate tetraester 10 as a model compound. By monitoring the coupling reactions with 31P-NMR 
spectrometry, it became evident that the activator was quenched by the presence of one equivalent of 
TFA in each batch of methylphosphonic acid 11a (Scheme 2). It was found that the TFA used during tert-
 
Scheme 2: tert-Butyl deprotection of model substrate 10 using TFA (R = ·COCF3), showing the postulated caged structure 





butyl deprotection formed an inseparable (by co-evaporation) complex with the formed 
methylphosphonic acid. This was substantiated by 1H-NMR spectrometric analysis of the deprotected 
compounds, where in each instance the phosphonic acid proton formed a singlet that integrating for two 
protons. It was postulated that the formation of a putative acid-acid complex 11a could be attributed to 
favorable “caged” hydrogen bonding, as depicted in scheme 2 (11a). Applying activation conditions to the 
TFA-phosphonic complex showed the formation of a single new phosphonate species on 31P-NMR 
spectrometry, which was identified as an unproductive mixed anhydride of TFA and the bisphosphonate. 
Switching to 1.5 equivalents of HCl in hexafluoroisopropanol (HFIP) effectively cleaved the tert-butyl 
group, providing 8 in quantitative yield. Indeed, the subsequent key PV-coupling reaction of 8 with 13, 
under the agency of TMBSC and MNO, afforded a mixture of the fully protected target me-ADPR 9 and its 
 
Figure 3: Condensation of ribose 13 with me-ADP 8, monitored over 120 minutes by 31P NMR spectrometry (162 MHz). A 
NMR tube was charged with an aliquot of the reaction mixture and fitted with an acetone-d6 capillary (required for locking). 
The experiment shows the conversion of the phosphonic acid (II) into methylene bisphosphonate tetraester (III). During the 




mono-demethylated derivative, in a combined yield of 60% (Scheme 3). Previously Wada and co-workers 
have shown that phosphonium reagents are selective and effective agents to facilitate condensation of 
methylphosphonates with alcohols.13 Implementing 3-nitro-1,2,4-triazol-1-yl-tris(pyrrolidin-1-yl) 
phosphonium hexafluorophosphate (PyNTP) as the condensing agent further improved the yield of 
protected me-ADPR  9  to 84% yield. The monitoring of this condensation by 31P-NMR spectroscopy is 
shown in Figure 3. Two-step removal of all protecting groups in 9 was accomplished through 
demethylation by thiophenol in MeCN/TEA, followed by deacylation using aqueous ammonia. Purification 
of the crude product by gel filtration, provided the desired me-ADPR in 52% yield (14, Scheme 3). 
 
Scheme 3: Synthesis of Me-ADPR (14) and Me-FAD (17). Reagents and conditions: [a] i: DCI, MeCN, 15 min. ii: tBuOOH, 15 
min. [b]. HCl (1.5 eq, 0.2 M), HFIP [c] PyNTP, 13, 2,6-lutidine, MeCN, 1h or PyNTP, 15, 2,6-lutidine, MeCN, 1h. [d] i: 




The thus obtained optimal protocol for the installation of unsymmetric methylene bisphosphonates was 
implemented in the synthesis of 17, a known bioisostere for FAD.14 Riboflavin building block 15 was 
condensed with 8 under the agency of PyNTP to furnish protected me-FAD derivative 16 in 54% yield. 
Ensuing two-step deprotection, followed by purification with size-exclusion chromatography, gave me-
FAD 17 in 43% isolated yield. The synthesis towards me-FAD proved to be challenging as the poor solubility 
of the flavin moiety slowed the conversion rate and complicated the purification processes. Regardless, 




The phosphanylmethylphosphonate reagent 1, described in Chapter 2 was successfully adopted in the 
synthesis of unsymmetric methylene bisphosphonates me-ADPR 14 and me-FAD 17. Reagent 1 is fitted 
with a tert-butyl protective group that is orthogonal relative to the methyl esters. Reagent 1 reacts with 
an alcohol of choice using the phosphoramidite coupling-oxidation sequence to give the respective, fully 
protected, methylene bisphosphonate tetraester. These reactions could conveniently be monitored with  
31P NMR spectroscopy, which indicated fast and clean conversions. An investigation of the cleavage of the 
tert-butyl by TFA revealed that the produced phosphonic acid formed a complex with TFA, the presence 
of which was detrimental for the subsequent PV-condensation. An efficient alternative cleavage procedure 
for the tert-butyl group was found in HFIP·HCl. From here, the second alcohol could be introduced through 
condensation using PyNTP as an activator, yielding the protected unsymmetric methylene 
bisphosphonates. Global deprotection via a two-step-one-pot procedure, provided me-ADPR 14 and me-
FAD 17. The successful synthesis of me-ADPR 14 and me-FAD 17 indicates that a general procedure is 






General: All solvents used under anhydrous conditions were stored over 4Å molecular sieves except for 
methanol which was stored over 3Å molecular sieves. Solvents used for workup and column 
chromatography were of technical grade from Sigma Aldrich and used directly. Unless stated otherwise, 
solvents were removed by rotary evaporation under reduced pressure at 40 °C. Reactions were monitored 
by TLC‐analysis using Merck aluminum DC Silicagel 60 F254 with detection by spraying with 20% H2SO4 in 
EtOH, (NH4)6Mo7O24·4(H2O) (25 g/L) and (NH4)4Ce(SO4)4·2(H2O) (10 g/L) in 10% sulfuric acid or by spraying 
with a solution of ninhydrin (3 g/L) in EtOH / AcOH (20/1 v/v), followed by charring at approx. 250°C. 
Column chromatography was performed on Fluka silicagel (0.04 – 0.063 mm) or for methylene 
bis(phosphorus) compounds on high-purity grade silica (Sigma-Aldrich, Davisil Grade, 633). 
NMR: 1H‐, 13C‐ and 31P-NMR Experiments were carried out on a Brüker AV-400 (400 MHz) or a Brüker AV-
500 (500 MHz) and AVIII-Brüker DMX‐600 (600 MHz). Chemical shifts are given in ppm (δ) and directly 
referenced to TMS (0.00 ppm) in CDCl3 or D2O via the solvent residual signal. CDCl3 used in the 
characterization of phosphoramidite containing compounds was neutralized before use by filtering over 
aluminum oxide (Type WB-5: Basic). 31P Chemical shifts are indirectly referenced to H3PO4 (0.00 ppm) 
according to the IUPAC method. 31P NMR spectra measured to monitor reactions were made by charging 
a NMR tube with an aliquot of the reaction mixture and fitting the tube with an acetone-d6 capillary. 
LC-MS: Analysis were carried out on a JASCO HPLC system (detection simultaneously at 214 and 254 nm) 
coupled to a PE/SCIEX API 165 single quadruple mass spectrometer (Perkin-Elmer) using an analytical 
Gemini C18 column (Phenomex, 50 x 4.60 mm, 3 micron) in combination eluents A: H2O; B: MeCN and C: 
0.1 M aq. NH4OAc or a Thermo Finnigan LCQ Advantage MAX ion-trap mass spectrometer with an 
electrospray ion source coupled to Surveyor HPLC system (Thermo Finnegan) using an analytical Gemini 
C18 column (Phenomex, 50 x 4.60 mm, 3 micron) in combination with eluents A: H2O; B: MeCN and C: 1% 
aq. TFA as the solvent system. High resolution mass spectra were recorded by direct injection (2 μL of a 2 
μM solution in water/acetonitrile; 50/50; v/v and 0.1% formic acid) on a mass spectrometer (Thermo 
Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, 
sheath gas flow 10, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z 
= 150-2000) and dioctylpthalate (m/z = 391.2842) as a “lock mass”. 
Trace Metal Chelation: High purity grade silica should be used when purifying methylene mono-
phosphonic acids by silica gel column chromatography. Methylene mono-phosphonic acids (8) could be 
purified using silica gel column chromatography. However, it was found that after column purification 
the characteristic 31P NMR peaks showed extreme signal broadening, to such an extent that the signals 
became difficult to detect. This broadening effect could be reversed by passing the purified methylene 
mono-phosphonic acid over an EDTA functionalized resin (a resin used to capture metal ions). This 
indicates that signal broadening resulted from metal ions bound to the phosphate, which could only 





Fully Protected me-ADP 7: N6-Benzoyl-2,3-O-di-iso-butyryladenosine (1.60 g, 3.12 mmol, 1 eq) and 
phosphanyl methylphosphonate 1 (1.12 g, 3.43 mmol, 1.1 eq) were co-evaporated with MeCN (15 mL), 
redissolved in MeCN (13 mL) and put under argon atmosphere. The reaction mixture was stirred until all 
solids were dissolved, then DCI (0.737 g, 6.24 mmol, 2 eq) was added. 31P-NMR indicated full conversion 
within 15 minutes. Oxidation was initiated by the addition of tert-butyl hydroperoxide (1.134 ml, 6.24 
mmol, 2 eq) in decane (5.5M). The reaction mixture was stirred for an additional 15 minutes. The solution 
was poured into a separation funnel containing water and washed with aqueous sodium bicarbonate (to 
wash away DCI). The organic layer was dried over sodium sulfate and concentrated in vacuo. Purification 
by silica gel column chromatography (20% acetone in DCM » 30% acetone in DCM + 2% MeOH) yielded 7 
as a colorless oil (2.00 g, 2.65 mmol, 85%). 1H NMR: (500 MHz, CDCl3) δ 9.30 – 9.20 (m, 1H), 8.81 (s, 1H), 
8.59 – 8.47 (m, 1H), 8.07 – 7.98 (m, 2H), 7.63 – 7.57 (m, 1H), 7.52 (dd, J = 8.4, 7.0 Hz, 2H), 6.38 – 6.30 (m, 
1H), 5.95 – 5.84 (m, 1H), 5.72 (ddt, J = 31.8, 5.7, 3.5 Hz, 1H), 4.57 – 4.37 (m, 3H), 3.87 – 3.72 (m, 6H), 2.72 
– 2.39 (m, 4H), 1.58 – 1.44 (m, 9H), 1.23 (dd, J = 7.0, 1.2 Hz, 6H), 1.11 (ddt, J = 18.6, 7.0, 1.3 Hz, 6H). 13C 
NMR: (126 MHz, CDCl3) δ 175.59, 175.52, 175.48, 175.19, 175.16, 164.58, 152.78, 151.81, 151.76, 151.73, 
149.60, 133.54, 133.51, 132.65, 128.72, 127.79, 123.18, 123.15, 123.13, 99.89, 85.56, 85.49, 85.41, 84.53, 
84.52, 84.49, 84.46, 84.45, 84.42, 81.90, 81.88, 81.84, 81.83, 81.80, 81.77, 81.74, 81.71, 73.20, 73.17, 
73.13, 73.12, 70.55, 70.53, 70.39, 70.35, 65.25, 65.23, 65.21, 65.19, 65.05, 65.02, 64.97, 53.50, 53.45, 
53.30, 53.25, 53.20, 53.15, 53.06, 53.01, 52.97, 52.96, 52.92, 52.87, 33.67, 33.48, 30.18, 30.16, 30.13, 
27.28, 27.25, 27.21, 27.13, 26.19, 26.16, 26.14, 26.12, 26.09, 26.05, 26.02, 25.07, 25.05, 25.01, 24.93, 
18.81, 18.78, 18.71, 18.69, 18.64, 18.62, 18.54. 31P NMR: (202 MHz, CDCl3) δ 23.44 (d, J = 5.3 Hz), 23.37 
(d, J = 6.1 Hz), 22.93, 22.91, 22.89, 16.19, 16.18, 16.15, 16.12. HRMS: Calculated for C32H45N5O12P2 
754.26127 [M+H]+; found 754.26141. 
 
 
Protected me-ADP Triester 8: HCl (0.223 mL, 1.34 mmol, 1.5 eq) in dioxane : water (1:1 v:v, 6M) was 
added to a solution of me-Phos-62-2 (0.672 g, 0.892 mmol, 1 eq) in HFIP (6.6 mL). Reaction progress was 
monitored by 31P NMR; which showed complete conversion within 1h. The solution was co-evaporated 
with toluene, dioxane (2x) and chloroform (2x) to thoroughly remove all HFIP. This yielded the target 
compound as a white brittle foam (620 mg, 0.889, 100%). 1H NMR: (500 MHz, CDCl3) δ 9.38 (d, J = 65.2 
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Hz, 1H), 8.85 (d, J = 6.7 Hz, 1H), 8.17 – 8.08 (m, 2H), 7.60 (td, J = 7.4, 2.1 Hz, 1H), 7.51 (td, J = 7.8, 2.1 Hz, 
2H), 6.42 (d, J = 5.9 Hz, 1H), 5.90 (dt, J = 27.2, 5.8 Hz, 1H), 5.67 (ddd, J = 42.0, 5.7, 3.4 Hz, 1H), 4.53 – 4.36 
(m, 3H), 3.77 – 3.61 (m, 6H), 2.67 – 2.47 (m, 4H), 1.24 – 1.18 (m, 6H), 1.11 (ddd, J = 15.0, 7.0, 1.6 Hz, 6H). 
31P NMR: (202 MHz, CDCl3) δ 25.19, 25.15, 25.13, 17.22 (d, J = 6.1 Hz), 16.94 (d, J = 6.1 Hz). HRMS: 
Calculated for C28H38N5O12P2 698.19867 [M+H]+; found 698.19873 
 
 
Fully Protected me-ADPR 9: Protected me-ADP 8 (0.225 g, 0.323 mmol, 1 eq), TEA (0.045 ml, 0.323 mmol, 
1 eq), 2,6-lutidine (0.346 g, 3.23 mmol, 10 eq) and 1-methoxy-2,3-acetyl-D-Ribose (0.120 g, 0.484 mmol, 
1.5 eq) were put under argon atmosphere and dissolved in dry MeCN (1.6 mL).  PyNTP (0.483 g, 0.968 
mmol, 3 eq) was added and the reaction progression was monitored using 31P NMR, which indicated full 
conversion after 2 hours. The reaction mixture was quenched with NaOAc in MeOH (1 mL, 1 M). After an 
additional 10 minutes of stirring, the reaction mixture was poured into DCM and washed with 0.5M 
aqueous HCl. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. 
Purification by silica gel column chromatography (3% MeOH in DCM) afforded me-ADPR as a mixture of 
diastereoisomers (251 mg, 271 mmol, 84%). The product mixture was isolated as a white foam. No efforts 
were made to separate the diastereoisomers, as both phosphonates lose chirality during the next step of 
demethylation. NMR Data: The NMR spectra were obtained from the mixture of four diastereoisomers. 
As a result the NMR spectra contained numerous partially overlapping product peaks. 31P NMR: (162 MHz, 
CDCl3) δ 21.66, 21.62, 21.21, 21.19, 20.63, 20.60, 20.54, 20.51, 20.48, 20.45, 20.27, 20.23. HRMS: 
Calculated for C38H52N5O18P2 928.27771 [M+H]+; found 928.27875. 
 
 
me-ADPR (15): Protected me-ADPR 9 (150 mg, 0.162 mmol) was dissolved in MeCN:TEA:PhSH (3:3:2, 1.6 
mL) and stirred for 4 hours at 35 °C. Reaction progression was monitored by 31P NMR, which indicated 
complete demethylation after 4.5 hours. The solution was partially reduced in vacuo to remove MeCN 
and pyridine. The residue was dissolved in ammonia (30%, 5 mL) and stirred overnight. The excess 
ammonia was purged by stirring under vacuum. The resulting solution was diluted with water, acidified 
to pH 4 using acetic acid and poured into a separation funnel. The water layer was washed with DCM (3x) 
57 
 
to remove excess thiophenol. The water layer was lyophilized to acquire the crude product. Purification 
by size-exclusion chromatography (HW40-column, 0.15 M aqueous NH4OAc) followed by lyophilisation, 
yielded me-ADPR (48 mg, 0.084 mmol, 52%) as a colorless powder. 1H NMR: (600 MHz, Deuterium Oxide) 
δ 8.48 (s, 1H), 8.16 (s, 1H), 6.07 (d, J = 5.4 Hz, 1H), 4.82 (d, J = 1.3 Hz, 1H), 4.74 (t, J = 5.3 Hz, 1H), 4.51 (dd, 
J = 5.2, 4.1 Hz, 1H), 4.36 – 4.33 (m, 1H), 4.18 (dd, J = 6.6, 4.8 Hz, 1H), 4.17 – 4.13 (m, 2H), 4.06 (td, J = 6.2, 
4.2 Hz, 1H), 4.00 – 3.94 (m, 2H), 3.89 (dt, J = 11.0, 6.1 Hz, 1H), 3.31 (s, 3H), 2.18 (td, J = 20.0, 2.1 Hz, 2H). 
13C NMR: (151 MHz, D2O) δ 156.01, 153.15, 149.72, 140.90, 119.43, 108.79, 88.01, 84.85, 84.79, 82.45, 
82.40, 75.11, 74.97, 71.91, 71.10, 65.88, 65.84, 64.46, 64.43, 56.10, 27.93, 27.08, 26.24. 31P NMR: (162 




5-O-MMT-riboflavin (E2): MMT-Cl (2.71 g, 8.77 mmol, 1.1 eq) was added to a solution of riboflavin (3.00 
g, 7.97 mmol, 1 eq) in pyridine (100 mL), under argon atmosphere. Reaction was heated to 100 °C and 
stirred overnight. After cooling to room temperature, the reaction was quenched by the addition of MeOH 
(1 mL) and concentrated. The residue was redissolved in chloroform (160 mL) and filtered. The filtrate was 
washed with aqueous sodium bicarbonate. The organic layer was dried over magnesium sulfate and 
concentrated in vacuo. The residue was purified by silica gel column chromatography (2% TEA in DCM 
preflush, eluent: 1% » 3% » 5% MeOH in DCM) yielded 5-O-MMT-riboflavin (2.15 g, 3.48 mmol, 44%) as 
bright yellow flakes. NMR spectrometry showed strong rotameric effects – 1H NMR: (600 MHz, CDCl3) δ 
10.03 (s, 1H), 7.85 (s, 2H), 7.41 (d, J = 8.2 Hz, 4H), 7.28 (d, J = 14.4 Hz, 4H), 7.18 (t, J = 7.8 Hz, 4H), 7.09 (t, 
J = 7.6 Hz, 2H), 6.71 (d, J = 8.4 Hz, 2H), 5.20 (s, 1H), 4.83 (d, J = 33.7 Hz, 3H), 4.41 (s, 1H), 4.08 (d, J = 79.3 
Hz, 3H), 3.65 (s, 3H), 3.43 (d, J = 34.0 Hz, 2H), 2.33 (d, J = 28.5 Hz, 6H). 13C NMR: (151 MHz, CDCl3) δ 159.77, 
158.32, 156.15, 150.54, 148.49, 144.09, 137.34, 135.29, 135.15, 135.07, 131.90, 131.69, 130.27, 128.23, 
127.70, 126.74, 117.10, 113.41, 113.20, 112.97, 86.63, 74.22, 71.93, 71.48, 65.39, 55.03, 48.34, 21.33, 
19.35. HRMS: Calculated for C37H37N4O7 649.26568 [M+H]+; found 649.26636. 
 
 
5-O-MMT-2,3,4-tri-O-Benzoylriboflavin (E3): Benzoyl chloride (1.19 ml, 10.3 mmol, 3.1 eq) was added 
dropwise to a solution of 5-O-MMT-riboflavin (2.15 g, 3.31 mmol, 1 eq) in pyridine (70 mL) at 0 °C. The 
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reaction mixture was stirred for 1h, before being quenched with water (5 mL) and concentrated in vacuo. 
The residue was redissolved on DCM and washed saturated aqueous sodium bicarbonate. The organic 
layer was dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel 
column chromatography (0% » 10% acetone in DCM + 1% TEA) yielded hydroxyl protected 5-O-MMT-
2,3,4-tri-O-Benzoylriboflavin (1.5 g, 2.4 mmol, 73%) as a bright yellow powder. HRMS: Calculated for 
C58H48N4O10Na 983.32626 [M+Na]+; found mass 983.32638. 
 
 
2,3,4-tri-O-Benzoylriboflavin (15): 5-O-MMT-2,3,4-tri-O-Benzoylriboflavin (1.5 g, 1,561 mmol) was added 
to a cooled (0 °C) solution of and triisopropylsilane (0.96 ml, 4.7 mmol, 3 eq) in DCM:DCA (9:1 v:v, 15 mL). 
The reaction was stirred for 1 hour. Methanol was added and the reaction mixture was washed with 
aqueous sodium bicarbonate. The organic layer was dried over magnesium sulfate, filtered and 
concentrated in vacuo. The concentrate was purified by silica gel column chromatography, providing 
riboflavin 15 (0.923 g, 1.34 g, 86%) as a bright yellow powder. 1H NMR: (500 MHz, CDCl3) δ 9.46 (s, 1H), 
8.20 – 8.05 (m, 4H), 7.84 (s, 1H), 7.79 – 7.71 (m, 2H), 7.67 (s, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.54 – 7.42 (m, 
6H), 7.37 (t, J = 7.8 Hz, 2H), 7.30 (t, J = 7.7 Hz, 2H), 6.26 (dt, J = 8.3, 3.9 Hz, 1H), 6.10 (dd, J = 5.7, 3.1 Hz, 
1H), 5.81 (q, J = 4.4, 4.0 Hz, 1H), 4.23 (d, J = 11.5 Hz, 1H), 4.18 – 4.01 (m, 2H), 2.21 (d, J = 17.1 Hz, 6H). 13C 
NMR: (126 MHz, CDCl3) δ 165.65, 165.30, 159.49, 155.56, 150.51, 148.10, 136.72, 135.89, 134.56, 133.71, 
133.49, 133.31, 132.38, 131.16, 129.95, 129.58, 129.17, 128.88, 128.68, 128.42, 128.30, 115.84, 73.28, 
71.79, 70.62, 61.03, 20.96, 19.18. HRMS: Calculated for C37H37N4O7 689.22421 [M+H]+; found 689.22375. 
 
 
Protected me-FAD 16: me-ADP 8 (0.180 g, 0.258 mmol), TEA (36 µl, 0.258 mmol), 2,6-lutidine (301 µl, 2.58 
mmol, 10 eq) and 2,3,4-O-Bz-Riboflavin (267 mg, 0.387 mmol, 1.5 eq) were put under argon atmosphere 
and dissolved in dry MeCN (0.5 mL).  PyNTP (387 mg, 0.774 mmol, 3 eq) was added. Reaction proceeded 
within one hour, 31P-NMR and LCMS showed conversion of the starting material into protected me-FAD 
16. The reaction mixture was quenched with NaOAc in MeOH (1 mL, 1M). After an additional 10 minutes 
of stirring, the reaction mixture was poured into DCM and washed with 0.5M aqueous HCl. The organic 
layer was dried over sodium sulfate, filtered and concentrated in vacuo. Purification by silica gel column 
chromatography (30% » 100% acetone in DCM) yielded the product (191 mg, 0.140 mmol, 54%) as a bright 
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yellow solid. NMR Data: The NMR spectra were obtained from the mixture of four diastereoisomers and 
showed significant peak broadening as a result of rotameric effects. HRMS: Calculated for C66H68N9O20P2 
1368.40504 [M+H]+; found 1368.40515. 
 
   
me-FAD (17): Protected me-FAD 16 (153 mg, 0.112 mmol) was dissolved in MeCN:TEA:PhSH (3:3:2, 1.6 
mL) and stirred for 16 hours at 35 °C, after which 31P NMR spectroscopy indicated complete 
demethylation. The solution was partially reduced in vacuo to remove MeCN and pyridine. The residue 
was dissolved in ammonia (30%, 5 mL) and stirred overnight. The excess ammonia was purged by stirring 
under vacuum. The resulting solution was diluted with water, acidified to pH 4 using acetic acid and 
poured into a separation funnel. The water layer was washed with DCM (3x) to remove excess thiophenol. 
The water layer was concentrated in vacuo. Purification by size-exclusion chromatography (HW40-
column, 0.15 M aqueous NH4OAc) followed by lyophilisation, yielded me-FAD (38 mg, 0.048 mmol, 43% 
yield). 1H NMR: (600 MHz, D2O) δ 8.40 (s, 1H), 7.94 (s, 1H), 7.52 (s, 1H), 7.43 (s, 1H), 5.86 (d, J = 5.1 Hz, 
1H), 4.55 (t, J = 5.1 Hz, 1H), 4.48 (t, J = 4.7 Hz, 1H), 4.40 (d, J = 13.7 Hz, 1H), 4.33 (d, J = 3.9 Hz, 2H), 4.21 (d, 
J = 15.6 Hz, 2H), 4.05 (dt, J = 11.4, 5.8 Hz, 1H), 4.01 – 3.95 (m, 1H), 3.93 (dd, J = 7.9, 4.4 Hz, 1H), 2.39 – 2.14 
(m, 9H).  13C NMR: (151 MHz, D2O) δ = 161.74, 158.45, 153.66, 151.42, 150.70, 150.60, 148.82, 141.23, 
140.03, 135.15, 134.61, 132.24, 131.09, 118.58, 117.55. 31P NMR: (162 MHz, D2O) δ 18.60, 18.11. HRMS: 
Calculated for C28H36N9O14P2 784.18569 [M+H]+; found 784.18555. 
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Adenosine diphosphate ribosylation (ADP-ribosylation) is a post-translational modification in which, for a 
long period of time, glutamate and aspartate were considered to be the main acceptor amino-acids. 
Recently, the number of target amino acids in proteins for ADP-ribosylation is broadened with  lysine, 
arginine and serine.1–4 Besides, the reported data on the covalent poly-ADP-ribosylation of histone 
proteins at glutamate or aspartate residues seem to be conflicting. Furthermore, non-covalent complexes 
between poly-ADP and the histone have also been reported.5–7 To acquire more insight in the function of 
ADP-ribosylation of specific proteins and to indentify the involved amino acids, synthetically prepared, 
well-defined mono-ADP-ribosylated oligopeptides are important tools. In this respect the synthetic 
preparation and biochemical application of Asp and Glu ADP-ribosylated oligopeptides is restricted by the 
inherent susceptibility of anomeric esters to hydrolyze and/or migrate. For this reason attention was 
directed to the design and synthesis of analogues of mono-ADP-ribosylated oligopeptides, in which the 
glycosidic bond with Asp and Glu is stabilized.  
 
 
Figure 1: The structures of a native mono-ADP-ribosylated N-terminal H2B conjugate 
1 and its glutamine incorporated bioisostere 2. 
 
A relevant target is the human histone H2B peptide in which the Glu-2, corresponding to the N-terminal 
sequence, is one of the earliest discovered sites for ADP-ribosylation.8  Kistemaker et al. argued that the 
synthesis of the native mono-ADP-ribosylated H2B oligopeptide (Figure 1, 1) was deemed to be 
Synthesis of Carba-Ribose Incorporated Mono-ADP-
Ribosylated H2B Histone Peptide 
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unsuccessful due to the propensity of the anomeric glutamyl ester to migrate.9 To circumvent this side-
reaction attention was directed to the synthesis and evaluation glutamate bioisostere (2) having a more 
stable anomeric amide bond. Although interesting results were obtained with oligopeptide 2, the 
glycosidic bond in 2 is prone to acidic hydrolysis and anomerisation was also observed.10 The intrinsic 
lability of O- and N-glycosidic bonds  can be circumvened by the use of carba-ribose, an analogue where 
the ring-oxygen is substituted for a methylene. The resulting enhanced stability towards acidic conditions 
has the added benefit of significantly improving the compatibility with solid-phase peptide synthesis. This 
chapter describes  the synthesis of stabilized conjugate 3 (Figure 2). 
 
Results and Discussion 
Retrosynthetic Analysis. The general strategy towards conjugate 3 was analogous to that reported for 
glutamate bioisostere 2.9 Retrosynthetically phosphorylated building block 4, containing the pre-
constructed glutamyl functionalized carba-riboside, would be installed into the peptide as a whole via 
solid-phase synthesis (Figure 2). Subsequent selective deprotection of the di-tert-butyl phosphate, 
followed by on-resin phosphorylation with an adenosine phosphoramidite derivative, would construct the 
pyrophosphate bridge. Disconnecting building block 4 at the C1-glutamylamide and O5-phosphodiester 
residues, after suitable deprotection steps, reveals the core carba-riboside 5. The timely removal of the 
chemically robust isopropylidene acetal in 5 is required, as later stage constructs are incompatible with 
the deprotection conditions. Furthermore, it was anticipated that the unprotected C2- and C3-OH’s would 
not impair the later stage solid-phase synthesis. In 1996, Parry et al. had reported the synthesis for a 
similar carba-riboside as 5, containing an α-hydroxyl at the C1-position.11 They were able to install the C5-
CH2OH through the photochemical addition of methanol onto the β-position of cyclopentenone 6. 
Subsequent reduction of the ketone provided the desired α-hydroxyl. In both cases the reactions 
proceeded stereoselectively, owing to the envelope conformation induced by the isopropylidene. It was 
envisioned that a reductive amination would provide the α-C1-amine in a similar fashion. The route 
described by Perry et al. for the conversion of D-ribonolactone to cyclopentenone 6, however, entailed 
several low yielding steps with an overall yield of 10% after four steps. Therefore an alternative route, 
described by Borcherdinger and co-workers, for the synthesis of a cyclohexylidene protected analogue of 
6 was considered more efficient.12 Unfortunately, attempts to reproduce or improve upon their results 
were unsuccessful. Additional perusing of literature revealed that the exact same complications were 
experienced by Mariën et al., and their thorough reinvestigation yielded results conflicting with those 
 
Figure 2: Retrosynthetic analysis of the proposed stabilized mono-ADP-ribosylated H2B conjugate 3. 
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reported by Borcherdinger.13 At this point it was concluded that no satisfactory route for the synthesis of 
cyclopentenone 6 was available in literature, and thus a new route was designed. 
 
 
Scheme 1: The newly developed route towards enone 6. Reagents and conditions: [a] i: AcCl, MeOH, 1.5h. ii: 2,2-
dimethoxypropane, CSA, acetone 0.5h. [b] I2, PPh3, 1H-imidazole, toluene/MeCN, 100 ˚C, 45 min. [c] i: n-BuLi, THF, -78 ˚C, 2h. ii: 
vinylmagnesium bromide, THF, -78 ˚C, 30 min. [d] Grubbs-I, DCM, 16h. [e] MnO2, DCM, 16h. 
 
Synthesis of cyclopentenone 6. The new route towards cyclopentenone 6 commenced with the 
methanolic Fischer glycosylation of D-ribose. After neutralization and concentration, the crude α/β-
methoxy-D-ribose was directly subjected to isopropylidene protection of the C2-C3-diol. Treatment with 
2,2-dimethoxypropane and a catalytic amount of camphorsulfonic acid provided riboside 8 in 69% yield 
over 2 steps. Subsequent iodination of the primary alcohol with iodine and triphenylphosphine, under the 
agency of 1H-imidazole at 100 °C in toluene/MeCN, produced iodo-riboside 9 in 94%. It was envisioned 
that a lithium-halogen exchange induced fragmentation under controlled temperatures would cleanly 
convert 9 into aldehyde 10. This would allow for a combined one-pot procedure with the subsequent vinyl 
Grignard. Hence, fragmentation of 9 into intermediate 10 with n-butyllithium in THF at -78 °C, was directly 
followed by addition of vinylmagnesium bromide, to produce R/S-diallyl 11 in 90% yield over two steps. 
No efforts were undertaken to separate the diastereoisomers of 11, as the chiral center is lost during later 
stage oxidation. Ring-closing metathesis of diallyl 11 using 1st generation Grubbs catalyst in DCM provided 
R/S-cyclopentenoid 12 in 82% yield. During reaction refinement it was found that after thoroughly purging 
the solvent (DCM) of oxygen, the 1st generation Grubbs catalyst performed as well as the more expensive 
2nd generation variant. In addition, the catalyst loading could be reduced to 0.6 mol% on a 100 mmol scale. 
Final oxidation of R/S-cyclopentenoid 12 with excess manganese dioxide afforded target cyclopentenone 
6 in 79% yield. The new route for the conversion of D-ribose into enone 6 entailed seven steps, carried 
out in five reaction vessels, with an overall yield of 38%. 
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Synthesis of glutamine carba-riboside 4. Next, efforts were directed to the synthesis of glutamine 
carba-riboside 4 (Scheme 2). The photochemical addition of methanol onto the β-position of 
cyclopentenone 6 provided carba-riboside 13 in 61% yield.11 On larger scale, the dilute photochemical 
conditions made it increasingly difficult to adequately remove solvated oxygen from the copious amounts 
of methanol, and resulted in lower isolated yields. At this stage, it was envisioned that the photochemistry 
protocol could potentially be adapted to directly add trimethyl phosphate onto the β-position of 
cyclopentenone 6, which would reduce the overall length of the synthesis. Unfortunately, the envisioned 
phosphorylated product could no be prepared in this manner. Protection of the alcohol in 13 with TBSCl 
gave silylated product 14 in 86% yield. The quantitative condensation of ketone 14 with methoxylamine 
delivered imine 15 as a mixture of cis/trans-isomers. Stereoselective reduction of the imine proved 
difficult and various conditions (BH3, LiAlH4, NaBH3CN, Zn/H+) were explored, of which LiAlH4 in refluxing 
THF proved to be the most effective, providing carba-ribosamine 16 in 30% yield. It was later found that 
the low yields were due to either inertness of the starting material to the reagents, or degradation of the 
TBS group. During preliminary optimization experiments it was found that a significant higher yield (81%) 
was obtained when the C5OH was protected with a trityl instead of the TBS. PyBOB-mediated 
condensation of amine 16 with commercial Fmoc-Glu(OBn)-OH gave carba-ribosylated glutamine 17 in 
quantitative yield. Simultaneous deprotection of the TBS and isopropylidene using aqueous acetic acid at 
60 °C gave 18 in 42% yield. Phosphorylation of primary alcohol with di-tert-butyl-N,N-diisopropyl-
phosphoramidite and 1H-tetrazole, followed by in situ oxidation, afforded phosphate 19 in 50% yield. 
Hydrogenolysis of the benzyl ester provided SPS-building block 4 in 72% yield. 
 
 
With carba-riboside building block 4 in hand, the solid-phase peptide synthesis (SPPS) of stabilized mono-
ADP-ribosylated H2B conjugate 3 was undertaken (Scheme 3). The core peptide was constructed from a 
Tentagel resin functionalized with Fmoc-glycine through a 4-hydroxymethylbenzoic acid (HMBA) linker, 
using standard Fmoc-based SPPS methodology. Base-labile protecting groups were selected for the 
adenosine moiety and the nucleophilic amino acid side-chains, to later enable simultaneous global 
 
Scheme 2: Synthesis of glutamine carba-riboside 4. Reagents and conditions: [a] Benzophenone, MeOH, hv, 16h. [b] TBSCl, 
1H-imidazole, DCM, 16 h. [c] Methoxylamine, DCM, 3h. [d] LiAlH4, THF, 75 °C, 2h. [e] PyBOB, Fmoc-Glu(OBn)-OH, DMF, 16h. 
[f] AcOH, H2O, 60 °C, 16h. [g] i: 1-methylimidazole, 1-methylimidazole·HCl, di-tert-butyl-N,N-diisopropylphosphoramidite, 
DMF, 30 min. ii: tBuOOH, 10 min. [h] Pd/C, H2, MeOH, 16h. 
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deprotection and release from solid support. Instalment of artificial amino acid 4 into resin-bound 
conjugate 20 proceeded uneventfully, as was determined by LC-MS analysis of a resin-released and 
deprotected aliquot of the peptide. Deprotection of the tert-butyl groups in 20 with 10% TFA in DCM 
proceeded cleanly, as monitored by on-resin 31P NMR spectroscopy. From here the stage was set for 
construction of the ADP-pyrophosphate bridge. On-resin phosphorylation of 21 with adenosine 
phosphoramidite 22, under the agency of 5-ethylthiotetrazole (ETT), followed by CSO-mediated oxidation 
of the phosphate-phosphite intermediate, produced the protected resin-bound carba-ribosylated 
peptide. Final deprotection consisted of DBU-assisted elimination of the 2-cyanoethanol group, and 
subsequent global deacylation and concomitant release from solid-support through ammonolysis. The 
crude carba-ribosylated peptide was precipitated and HPLC purified, to provided mono-ADP-carba-
ribosylated H2B conjugate 3 in 9% (8.2 mg, 0.6 µmol) overall yield. 
 
Scheme 3: The solid-phase peptide synthesis of Carba-ribose incorporated mono-ADP-ribosylated H2B conjugate 3. Assembly of 
core peptide 20: [a] Piperidine, DMF, 20 min. [b] Corresponding amino acid building block*, DIPEA, PyBOP, NMP, 1h. [c] Ac2O, 
DIPEA, DMAP, NMP, 20 min. [*] After installment of the 8-Ser-Trt, the Trt was exchanged for Ac | Construction of the 
pyrophosphate: [d] 10% TFA, DCM, 1h. [e] i: Adenosine 22, ETT, MeCN, 30 min. ii (1S)-(+)-(10-camphorsulfonyl) oxaziridine (CSO), 
MeCN, 10 min. [f] DBU, THF, 10 min. | Global acyl deprotection and release from solid-support: [g] Ammonia, TFE, 16h. 
 
Conclusion 
This chapter describes the synthesis of a mono-ADP-ribosylated N-terminal H2B conjugate bioisostere, 
wherein a carba-riboside was incorporated as a stabilized replacement of the naturally occurring riboside. 
A new synthesis for the key intermediate cyclopentenone was developed. D-Ribose was converted into a 
protected 5-iodo-riboside and subjected to a tandem fragmentation-vinylation reaction. The diallylic 
product was ring-closed and oxidized, providing cyclopentenone 6 in 38% overall yield. Subsequent 
instalment of the C5-CH2OH through the photochemical addition of methanol, efficiently produced the 
Carba-ribose core structure (13). The ketone was converted into a methoxyimine and stereoselectively 
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reduced to obtain the pseudo-anomeric α-amine. Coupling of the amine with a glutamic acid derivative, 
followed by deprotection and phosphorylation of the primary alcohol afforded final carba-ribosylated 
glutamine building block 4. The building block was successfully installed into the H2B sequence through 
solid-phase peptide synthesis. On-resin phosphorylation of the carba-ribosyl phosphate was used to 
construct the ADP-pyrophosphate. Successive global deprotection and release from resin provided the 






General: Reactions were executed at ambient temperatures unless stated otherwise. All solvents used 
under anhydrous conditions were stored over 4Å molecular sieves, except for methanol which was stored 
over 3Å molecular sieves. Reactions were monitored by TLC‐analysis using Merck aluminum DC Silicagel 
60 F254 with detection by spraying with 20% H2SO4 in EtOH, (NH4)6Mo7O24·4(H2O) (25 g/L) and 
(NH4)4Ce(SO4)4·2(H2O) (10 g/L) in 10% sulfuric acid or by spraying with a solution of ninhydrin (3 g/L) in 
EtOH / AcOH (20/1 v/v), followed by charring at approximately 250°C. Column chromatography was 
performed on Fluka silicagel (0.04 – 0.063 mm). Unless otherwise stated, solvents were evaporated under 
reduced pressure at 40 °C. Analysis by NMR and HRMS were performed as described in the experimental 
section of chapter 2. The reported peptide was synthesized using an automated peptide synthesizer (ABI-
433A, Applied Biosystems, Perkin-Elmer). 
 
 
D-ribose (15.31 g, 101.98 mmol, 1 eq) was dissolved in MeOH (100 ml) and acetic chloride (2 ml, 30 mmol, 
0.3 eq.) was added. After 1.5h, the reaction mixture was quenched by the addition of Et3N (10 ml) and 
concentrated in vacuo. The resulting clear oil was dissolved in 2,2-dimethoxypropane (100 ml) and 
camphorsulfonic acid (4.7 g, 20.2 mmol, 0.2 eq.) was added. The reaction mixture was stirred for 30 
minutes, before it was neutralized with saturated aqueous sodium bicarbonate and extracted EtOAc. The 
organic layers were combined, dried with magnesium sulfate filtered and the filtrate was evaporated 
under reduced pressure. The resulting oil was purified using silica gel column chromatography (5% » 10% 
» 20% EtOAc in PE) to yield the title compound as a colorless oil (14.41 g, 70.56 mmol, 69%). 1H NMR: (300 
MHz, CDCl3) δ 4.88 (d, J = 3.4 Hz, 1H), 4.72 (d, J = 5.7 Hz, 1H), 4.49 (d, J = 5.7 Hz, 1H), 4.32 (s, 1H), 3.56 (s, 
2H), 3.33 (s, 3H), 3.23 (s, 1H), 1.39 (s, 3H), 1.23 (s, 3H). 13C NMR: (75 MHz, CDCl3) δ 112.03, 109.81, 88.16, 
85.67, 81.45, 63.86, 55.33, 26.30, 24.66.  
 
 
Riboside 8 (13.0 g, 63.8 mmol, 1 eq) was co-evaporated with dioxane and dissolved in dry toluene : 
acetonitrile (3:1 v:v, 400 mL). Imidazole (6.52 g, 95.8 mmol, 1.5 eq.), triphenylphosphine (20.1 g, 76.7 
mmol, 1.2 eq.) and iodine (19.4 g, 76.4 mmol, 1.2 eq.) were added in succession and the reaction was left 
to stir overnight. The solvents were carefully evaporated under reduced pressure and the resulting was 
re-dissolved in Et2O (200 ml). The organic layer was washed with a saturated aqueous sodium bicarbonate 
(2 x 100 mL), dried with magnesium sulfate, filtered and concentrated in vacuo. The resulting yellow oil 
was purified using silica gel column chromatography (5% Et2O in PE) to yield the title compound as a 
colorless oil (18.9 g, 60.2 mmol, 94%). 1H NMR: (300 MHz, CDCl3) δ 4.98 (s, 1H), 4.69 (dd, J = 5.9, 1.0 Hz, 
1H), 4.56 (d, J = 5.9 Hz, 1H), 4.37 (dd, J = 10.0, 6.1 Hz, 1H), 3.30 (s, 3H), 3.22 (dd, J = 9.9, 6.1 Hz, 1H), 3.09 
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(t, J = 10.0 Hz, 1H), 1.40 (s, 3H), 1.25 (s, 3H). 13C NMR: (75 MHz, CDCl3) δ 112.51, 109.59, 87.35, 85.29, 
82.97, 55.18, 26.43, 25.02, 6.80.  
 
 
Iodo-riboside 9 (28.6 g, 91.2 mmol, 1 eq) was co-evaporated with dioxane, dissolved in dry THF (500 ml) 
and put under argon atmosphere. The solution was cooled to -78 ˚C and a 2.5 M solution of n-BuLi in THF 
(40 ml, 100 mmol, 1.1 eq.) was added drop-wise. After 4 hours, TLC analysis indicated full conversion of 
the starting material into the lower running aldehyde intermediate 10. A 1 M solution of vinylmagnesium 
bromide in THF (110 ml, 110 mmol, 1.2 eq.) was slowly added and the reaction was left to stir overnight 
at -78 ˚C. The reaction mixture was allowed to warm to RT, after which the solvent was evaporated in 
vacuo. The resulting oil was dissolved in EtOAc (200 ml) and washed with water (100 ml). The aqueous 
layer was acidified using 1 M aqueous HCl to dissolve the white precipitate and was extracted with EtOAc 
(3 x 100 ml). The organic layers were combined, dried with magnesium sulfate, filtered and concentrated 
in vacuo. The residual yellow oil was purified using silica gel column chromatography (10% EtOAc in PE) 
to yield R/S-diallyl 11 as a pale-yellow oil (15.2 g, 82.2 mmol, 90%).  
 
 
A solution of R/S-diallyl 11 (11.7 g, 63.4 mmol. 1 eq) in dry MeOH (250 ml) was purged of oxygen by ultra 
sonification while bubbling through argon (±10 min). Grubbs 1st generation catalyst (306 mg, 0.37 mmol, 
0.6 mol%) was added and the reaction mixture was left to stir overnight. TLC analysis indicated full 
conversion of the starting materials into R/S-cyclopentenoid products. The reaction mixture was 
concentrated in vacuo, and the residue was purified using silica gel column chromatography (15% EtOAc 
in PE) to yield R/S-cyclopentenoid 12 as a colorless oil (8.09 g, 51.78 mmol, 82%). 1H NMR: (400 MHz, 
CDCl3) δ 5.95 (d, J = 5.8 Hz, 1H), 5.83 (d, J = 6.7 Hz, 1H), 5.22 (d, J = 5.7 Hz, 1H), 4.68 (s, 1H), 4.43 (d, J = 5.7 
Hz, 1H), 3.47 (s, 1H), 1.34 (s, 3H), 1.28 (s, 3H). 13C NMR: (101 MHz, CDCl3) δ 135.19, 134.80, 111.73, 85.92, 
84.31, 80.70, 27.30, 25.72. 
 
 
MnO2 (107.3 g, 1.23 mol, 15 eq) was added to a solution of R/S-cyclopentenoid 12 (12.8 g, 82.2 mmol) in 
DCM (450 mL). After 16h, the reaction mixture was filtered through celite and concentrated in vacuo. The 
resulting oil was purified using silica gel column chromatography (20% EtOAc in PE), providing 
cyclopentenone 6 as a colorless crystalline material (10.1 g, 65.2 mmol, 79%). 1H NMR: (400 MHz, CDCl3) 
δ 7.51 (dd, J = 5.9, 2.3 Hz, 1H), 6.08 (d, J = 5.9 Hz, 1H), 5.17 (dd, J = 5.5, 2.3 Hz, 1H), 4.34 (d, J = 5.5 Hz, 1H), 
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A solution of cyclopentenone 6 (4.97 g, 32.2 mmol, 1 eq) and benzophenone (891 mg, 4.89 mmol, 0.15 
eq) in MeOH (2 L) was purged of oxygen by ultra sonification while bubbling through argon (± 1h). The 
solution was irradiated with a 360 nm UVA lamp for 16 hours. The residual yellow oil was purified using 
silica gel column chromatography (20% » 40% EtOAc) to yield the carba-riboside 13 as a colorless oil (3.635 
g, 19.52 mmol, 61%). 1H NMR: (400 MHz, CDCl3) δ 7.51 (dd, J = 5.9, 2.3 Hz, 1H), 6.08 (d, J = 5.9 Hz, 1H), 
5.17 (dd, J = 5.5, 2.3 Hz, 1H), 4.34 (d, J = 5.5 Hz, 1H), 1.28 (s, 3H), 1.27 (s, 3H). 13C NMR: (101 MHz, CDCl3) 
δ 202.88, 159.68, 134.04, 115.20, 78.45, 76.32, 27.23, 25.96. HRMS: Calculated for C9H15O4 [M+H]+; 
187.0965, found 187.0966. 
 
 
carba-riboside 13 and imidazole (1.31 g, 19.2 mmol, 1.5 eq) were co-evaporated with dioxane, put under 
argon atmosphere and dissolved in dry DCM (100 mL).  TBSCl (2.31 g, 15.3 mmol, 1.2 eq) was added to 
the solution and the reaction mixture was stirred for 16 h. The reaction was quenched by the addition of 
MeOH (5 mL) and washed twice with water (100 mL). The organic layer was dried over magnesium sulfate, 
filtered and concentrated in vacuo. The residual yellow oil was purified using silica gel column 
chromatography (20% EtOAc in PE) to yield the title compound as a yellow oil (3.28 g, 10.9 mmol, 86%). 
1H NMR: (400 MHz, Chloroform-d) δ 4.61 (d, J = 5.4 Hz, 1H), 4.19 (d, J = 5.4 Hz, 1H), 3.79 (dd, J = 9.8, 2.3 
Hz, 1H), 3.60 (dd, J = 9.8, 2.7 Hz, 1H), 2.69 (dd, J = 18.1, 9.0 Hz, 1H), 2.48 (d, J = 8.9 Hz, 1H), 2.05 (d, J = 18.1 
Hz, 1H), 1.39 (s, 3H), 1.31 (s, 3H), 0.81 (s, 9H), -0.00 (s, 3H), -0.02 (s, 3H). 13C NMR: (101 MHz, CDCl3) δ 
212.88, 111.03, 82.01, 79.08, 65.32, 39.07, 37.27, 26.84, 25.87, 24.65, 18.26, -5.67, -5.75. HRMS: 
Calculated for C15H29O4Si 301.1830 [M+H]+; found 301.1833.  
 
 
Sodium acetate (3.58 g, 43.6 mmol, 4.0 eq) and methoxylamine · HCl (1.83 g, 21.91 mmol, 2.0 eq) were 
added to a solution of compound 14 (3.28 g, 10.9 mmol, 1 eq) in dry MeOH (100 ml). After 3 hours, TLC 
analysis indicated full conversion of the starting material into the cis/trans-imine. The reaction mixture 
was concentrated in vacuo and taken-up into EtOAc (100 ml). The solution was washed with water (100 
ml), dried with magnesium sulfate, filtered and concentrated in vacuo. The resulting yellow oil was 
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purified using silica gel column chromatography (10% Et2O in pentane) to provide the cis/trans-imine 15 
mixture as a yellow oil (3.45 g, 10.5 mmol, 96%). Trans-isomer 1H NMR: (300 MHz, CDCl3) δ 4.81 (d, J = 5.4 
Hz, 1H), 4.54 (d, J = 5.5 Hz, 1H), 3.86 (s, 3H), 3.61 (dd, J = 10.0, 3.8 Hz, 1H), 3.47 (dd, J = 10.0, 4.1 Hz, 1H), 
2.63 (dd, J = 18.1, 8.6 Hz, 1H), 2.49 (d, J = 16.4 Hz, 1H), 2.40 (s, 1H), 1.42 (s, 3H), 1.32 (s, 3H), 0.84 (s, 9H), 
0.00 (s, 3H), -0.01 (s, 3H). 13C NMR: (75 MHz, CDCl3) δ 162.18, 110.96, 82.67, 79.75, 65.08, 61.89, 43.09, 
27.86, 27.13, 25.88, 24.90, 18.29, -3.71, -5.60. Cis-isomer 1H NMR: (300 MHz, CDCl3) δ 5.04 (d, J = 5.5 Hz, 
1H), 4.55 (d, J = 5.5 Hz, 1H), 3.85 (s, 3H), 3.65 (dd, J = 10.0, 3.7 Hz, 1H), 3.53 (dd, J = 10.0, 3.8 Hz, 1H), 2.87 
(ddd, J = 16.7, 8.4, 1.3 Hz, 1H), 2.37 (dt, J = 7.6, 3.5 Hz, 1H), 2.25 (dd, J = 16.7, 1.0 Hz, 1H), 1.44 (s, 3H), 1.34 
(s, 3H), 0.85 (s, 9H), 0.01 (s, 3H), 0.00 (s, 3H). 13C NMR: (75 MHz, CDCl3) δ 162.19, 110.84, 83.37, 74.96, 
65.11, 62.02, 42.08, 30.93, 26.93, 25.86, 24.61, 18.23, -5.63, -5.65. HRMS: Calculated for C16H32NO4Si 
330.2095 [M+H]+; found 330.2093.  
 
 
cis/trans-imine 15 (0.968 g, 2.94 mmol, 1 eq) was co-evaporated with dioxane and dissolved in dry THF 
(30 ml). A 2.4 M solutions of LiAlH4 (11.76 mmol 4.9 ml, 4 eq) was added and the reaction mixture was 
refluxed for 2 hours. After cooling to RT, the reaction was quenched with water (1 mL). The reaction 
mixture was poured into a separation funnel containing water (30 ml) and extracted with Et2O (3 x 50 ml). 
The organic layers were combined, dried with magnesium sulfate, filtered and concentrated in vacuo. The 
resulting yellow oil was purified using silica gel column chromatography (2% MeOH in DCM) to yield carba-
ribosamine 16 as a yellow oil (0.681 g, 2.26 mmol, 30%). 1H NMR: (400 MHz, Chloroform-d) δ 4.45 (d, J = 
5.6 Hz, 1H), 4.33 (t, J = 5.4 Hz, 1H), 3.53 (dd, J = 10.1, 5.7 Hz, 1H), 3.46 (dd, J = 10.1, 5.9 Hz, 1H), 3.34 (ddd, 
J = 12.5, 7.0, 5.4 Hz, 1H), 2.08 (q, J = 6.2 Hz, 1H), 1.73 (s, 1H), 1.71 (s, 1H), 1.67 (s, 2H), 1.45 (s, 3H), 1.31 (s, 
3H), 0.86 (s, 9H), 0.02 (s, 6H). 13C NMR: (101 MHz, CDCl3) δ 109.98, 83.37, 81.25, 64.79, 54.48, 45.21, 




carba-ribosamine 16 (0.143 g, 0.48 mmol, 1 eq) and Fmoc-Glu(OBn)-OH (0.252 g, 0.55 mmol, 1.15 eq) 
were co-evaporated with dioxane and dissolved in dry THF (5 ml). DIPEA (0.12 ml, 0.72 mmol, 1.5 eq), 
PyBOP (0.273 g, 0.525 mmol, 1.1 eq) and 1-methylimidazole (4 µl, 0.05 mmol, 0.1 eq) were added and the 
reaction mixture was stirred overnight. The reaction mixture was poured into a separation funnel 
containing water (15 mL) and extracted with Et2O (2 x 15 mL). The organic layers were combined, dried 
with magnesium sulfate, filtered and concentrated in vacuo. The resulting oil was purified using silica gel 
column chromatography (20% » 40% EtOAc in PE + 1% TEA) to provide carba-ribosylated glutamine 17 as 
a yellow oil (0.351 g, 0.47, 98%). 1H NMR: (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 6.6 Hz, 
2H), 7.40 (t, J = 7.5 Hz, 2H), 7.37 – 7.28 (m, 7H), 5.98 (d, J = 7.5 Hz, 1H), 5.78 (d, J = 8.0 Hz, 1H), 5.18 (d, J = 
2.7 Hz, 2H), 4.49 (d, J = 4.7 Hz, 1H), 4.47 – 4.37 (m, 4H), 4.34 (dd, J = 10.5, 7.4 Hz, 1H), 4.21 (t, J = 7.0 Hz, 
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1H), 3.57 (dd, J = 10.2, 5.4 Hz, 1H), 3.47 (dd, J = 10.2, 6.3 Hz, 1H), 2.22 (d, J = 9.0 Hz, 2H), 2.15 (q, J = 6.1 
Hz, 1H), 2.04 – 1.98 (m, 1H), 1.88 (dd, J = 12.6, 6.8 Hz, 1H), 1.78 – 1.69 (m, 1H), 1.66 (s, 2H), 1.47 (s, 3H), 
1.29 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H). 13C NMR: (101 MHz, CDCl3) δ 189.19, 172.03, 171.26, 
156.31, 144.09, 141.43, 128.77, 128.64, 128.49, 127.85, 127.21, 125.32, 125.27, 120.10, 110.24, 100.10, 
82.88, 79.53, 67.46, 67.18, 64.46, 53.80, 51.21, 47.29, 45.16, 32.51, 28.27, 26.37, 26.05, 24.07, 18.37, -




A suspension of compound 17 (0.409 g; 0.55 mmol) in water : AcOH (15 mL, 2:1 v.v) was heated 60 ᵒC and 
stirred overnight. The solvents were evaporated in vacuo. The white residue was purified using silica gel 
column chromatography (5% » 10% » 20% EtOH in EtOAc) to yield the title compound as white crystals 
(0.138 g, 0.23 mmol, 42%). 1H NMR: (300 MHz, D2O) δ 7.74 (t, J = 8.3 Hz, 2H), 7.64 – 7.55 (m, 2H), 7.36 – 
7.21 (m, 9H), 5.15 – 5.06 (m, 2H), 4.40 – 4.22 (m, 2H), 4.21 – 4.15 (m, 1H), 4.10 (dd, J = 13.1, 5.3 Hz, 1H), 
4.04 (dd, J = 8.1, 4.5 Hz, 1H), 3.87 (t, J = 3.9 Hz, 1H), 3.76 (dd, J = 7.7, 3.9 Hz, 1H), 3.59 (dd, J = 10.7, 4.8 Hz, 
1H), 3.53 – 3.42 (m, 1H), 3.27 (dt, J = 3.3, 1.6 Hz, 1H), 2.26 (d, J = 6.6 Hz, 2H), 2.21 – 2.06 (m, 3H), 1.97 – 
1.84 (m, 1H), 1.83 – 1.73 (m, 2H). 13C NMR: (75 MHz, D2O) δ 129.54, 129.27, 129.20, 128.79, 128.18, 
128.15, 126.30, 126.21, 120.91, 103.11, 77.12, 75.57, 74.68, 68.05, 67.95, 64.57, 55.16, 51.73, 51.16, 
48.35, 45.88, 44.65, 33.18, 31.79(CH2), 28.43(CH2), 25.17(CH2). HRMS: Calculated for C33H37N2O8 
589.2544 [M+H]+; found 589.2544. 
 
 
Compound 18 (0.206 g, 0.343 mmol, 1 eq), 1-methylimidazolium chloride (0.122 g, 1.03 mmol, 3 eq), 1-
methylimidazole (54 µl, 0.69 mmol, 2 eq) and several molecular sieves were co-evaporated together with 
dioxane, dissolved in dry DMF (3.33 ml) and put under argon atmosphere. di-tert-butyl-N,N-
diisopropylphosphoramidite (0.12 ml, 0.38 mmol, 1.1 eq.) was added. 31P-NMR indicated full conversion 
within 30 minutes. Oxidation was initiated by the addition of tert-butyl hydroperoxide (0.3 ml, 1.65 mmol, 
5 eq) in decane (5.5 M). The reaction mixture was stirred for an additional 15 minutes, before being 
filtered and concentrated in vacuo. The resulting yellow oil was purified using silica gel column 
chromatography (2% » 5% MeOH in EtOAc) to produce phosphate 19 as a colorless oil (0.134 g, 0.168 
mmol, 50%). 1H NMR: (300 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 6.8 Hz, 2H), 7.45 – 7.27 (m, 
9H), 6.34 (d, J = 7.4 Hz, 1H), 5.86 (d, J = 8.1 Hz, 1H), 5.17 (s, 2H), 4.54 – 4.30 (m, 3H), 4.30 – 4.09 (m, 3H), 
4.09 – 3.79 (m, 4H), 2.51 – 2.36 (m, 1H), 2.35 – 2.09 (m, 3H), 2.08 – 1.98 (m, 1H), 1.90 – 1.76 (m, 3H), 1.48 
(s, 18H). 13C NMR: (101 MHz, CDCl3) δ 172.11, 171.83, 156.35, 144.02, 143.79, 141.36, 141.34, 135.30, 
128.72, 128.58, 128.41, 127.80, 127.18, 125.31, 125.26, 120.05, 75.02, 73.76, 68.65, 67.40, 67.19, 53.81, 
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53.56, 50.02, 47.22, 43.45, 32.37, 31.52, 29.94, 28.01. 31P NMR: (121 MHz, CDCl3) δ -10.16. HRMS: 




A solution of phosphate 19 (0.10 g, 0.128 mmol, 1 eq) in MeOH (2 ml), Pd/C (2 mg, 0.019 mmol, 0.15 eq) 
was degassed by ultra sonification. Hydrogen gas (±5 L) was bubbled through and the solution was stirred 
overnight under hydrogen atmosphere. The reaction mixture was filtered through celite and concentrated 
in vacuo. The resulting yellow oil was purified using silica gel column chromatography (5% » 10% MeOH 
in DCM + 1% AcOH) to yield compound 20 as a white foam (64 mg, 93 µmol, 72%). 1H NMR: (400 MHz, 
Methanol-d4) δ 7.79 (d, J = 7.3 Hz, 2H), 7.67 (t, J = 7.3 Hz, 2H), 7.38 (t, J = 7.3 Hz, 2H), 7.31 (t, J = 7.2 Hz, 
2H), 4.35 (dq, J = 17.4, 10.3, 9.9 Hz, 2H), 4.25 – 4.15 (m, 2H), 4.13 (dt, J = 8.5, 4.3 Hz, 1H), 4.05 (dt, J = 9.1, 
4.4 Hz, 1H), 4.00 – 3.95 (m, 1H), 3.94 (d, J = 3.8 Hz, 1H), 3.83 (dd, J = 8.1, 3.7 Hz, 1H), 2.34 (t, J = 7.2 Hz, 
3H), 2.19 (dd, J = 12.6, 5.1 Hz, 1H), 2.03 – 1.91 (m, 1H), 1.88 (t, J = 8.6 Hz, 2H), 1.48 (s, 18H). 13C NMR: (101 
MHz, MeOD) δ 175.41, 174.51, 158.61, 145.31, 145.15, 142.54, 128.77, 128.16, 126.30, 126.25, 120.90, 
84.32, 84.24, 74.93, 74.51, 69.48, 67.99, 54.86, 51.39, 44.14, 33.31, 31.61, 30.20, 30.16, 28.75. HRMS: 
Calculated for C34H48N2O11P 691.2990 [M+H]+; found 691.2994. 
 
 
The intermediate peptide Fmoc-Pro-Ala-Lys-Ser-Ala-Pro-Ala-Pro-Lys-Lys-Gly-HMBA was synthesized on an 
automated peptide synthesizer using standard SPPS sequences: Starting from pre-loaded Fmoc-Gly-HMBA 
Tentagel S resin (0.238, 52 µmol), 5 equivalents of Fmoc-Lys(TFA)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH and 
Fmoc-Ser(Trt)-OH were applied respectively. Activation was effectuated by treatment with 5 equivalents 
of HCTU in NMP (0.5 M) and 12.5 equivalents of DIPEA in NMP (1.25 M) for 1 hour. After each coupling, 
the Fmoc groups were cleaved using 20% piperidine in DMF. Next, the side-chain trityl group attached to 
Serine was cleaved by sequential treatment with 5% TFA in DCM, until no yellow discoloration of the 
solution occurred. The resin was washed with DCM and NMP, followed by the addition of Ac2O (0.24 mL, 
50 eq), DIPEA (0.44 mL, 50 eq), DMAP (cat.) and NMP (2 mL). The reaction vessel was shaken for 15 
minutes, before being rinsed with NMP and DCM. From here the carba-ribosylated glutamine 20 was 
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introduced manually. After elimination of the terminal Fmoc-protective group, compound 20 (31 mg, 75 
µmol, 1.5 eq), HCTU (31 mg, 1.5 eq), DIPEA (26 µL, 3 eq) in NMP (2 mL) were added and the resin was 
shaken for 16 h. The final Fmoc-Pro-OH was installed using the standard SPPS sequence. An aliquot of 
resin was treated with saturated aqueous ammonia (30%) and analyzed with LCMS, which revealed 
formation of the target peptide. 
Next, the instalment of the pyrophosphate bridge was initiated by cleavage of the tert-butyl groups. 
The deprotection cycle of treatment with 10% TFA in DCM (2 ml) and shaking for 30 minutes was repeated 
twice. The resin was washed with dry MeCN and flushed with argon, before being taken-up in a 0.25 M 
solution of ETT in MeCN (1 ml, 0.25 mmol, 5.0 eq). A dry solution of adenosine-amidite 22 (80 mg, 2.5 eq) 
in MeCN (1 mL) was added. The was shaken for 30 minutes, filtered and rinsed with MeCN. A 0.5 M 
solution of CSO in MeCN (0.25 mmol, 5.0 eq) was added and the mixture was shaken for an additional 10 
minutes. The resin was filtered, washed with MeCN and treated with a 0.5 M solution of DBU in DMF (1 
mL) for 10 minutes. The resin was filtered and rinsed with DMF and DCM. 31P-NMR of the resin indicated 
full conversion of the di-tert-butylphosphate into a pyrophosphate. The peptide was released from resin 
by treatment with 30% saturated aqueous ammonia in trifluorethanol (3 mL) for 16 h. The solvents were 
evaporated under reduced pressure and the resulting yellow foam was re-dissolved in MeOH : AcOH (1.5 
mL, 15:1 v.v). The peptide was precipitated by injection of the solution in ice-cooled Et2O. The resulting 
suspension was centrifuged and decanted to provide crude target peptide. Further purification by RP-
HPLC, followed by lyophilization, gave mono-ADP-carba-ribosylated H2B conjugate 3 as a white powder 
(8.2 mg, 4.4 µmol, 9% based on initial loading). 1H NMR: (400 MHz, D2O) δ 8.52 (s, 1H), 8.24 (s, 1H), 6.13 
(d, J = 6.0 Hz, 1H), 4.59 (dt, J = 12.9, 6.9 Hz, 4H), 4.53 – 4.49 (m, 1H), 4.45 – 4.35 (m, 7H), 4.34 – 4.24 (m, 
5H), 4.24 – 4.19 (m, 2H), 4.01 – 3.88 (m, 7H), 3.86 – 3.80 (m, 3H), 3.76 (dd, J = 13.4, 6.7 Hz, 3H), 3.69 – 
3.57 (m, 5H), 3.57 – 3.44 (m, 1H), 3.02 – 2.92 (m, 6H), 2.37 (t, J = 7.5 Hz, 3H), 2.26 (dd, J = 11.8, 8.0 Hz, 5H), 
2.10 (s, 3H), 2.06 – 1.93 (m, 11H), 1.85 (dd, J = 13.4, 7.2 Hz, 5H), 1.82 – 1.73 (m, 7H), 1.73 – 1.59 (m, 8H), 
1.56 – 1.41 (m, 6H), 1.39 (d, J = 7.2 Hz, 4H), 1.35 (d, J = 7.0 Hz, 7H). 31P NMR: (162 MHz, D2O) δ -10.29 (d, 
J = 21.0 Hz), -10.83 (d, J = 21.1 Hz). HRMS: Calculated for C75H126N23O28P2 1858.8601 [M+3H]3+, 
compensated for triple charge 619.6200;  found 619.6208. 
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Bioorthogonal chemistry strives to chemoselectively modify biomolecules, such as proteins, 
carbohydrates and lipids, within the complex environments of cell-lysates, living cells and, ultimately, in 
living animals. Bioorthogonal chemistry has pushed forward various fields of research, such as activity-
based protein profiling, in vitro and in vivo imaging and modified metabolite labeling.1 Ideally, in a 
bioorthogonal process a reactive group incorporated into the biomolecule of interest reacts selectively 
with a complementary reactive group modified with a reporter moiety, such as a fluorescent label to 
enable visualization of the target or an affinity probe for post-labeling purification.2 To enable this, a 
bioorthogonal tag should be inert to the broad spectrum of functional groups that reside in a biological 
system, while exerting fast enough reaction kinetics for conjugation to occur at nanomolar 
concentrations. Additives to facilitate the reaction between the tag and the reactive functionality of the 
reporter group are best avoided. Finally, the tag should be sterically compact to minimize unfavorable 
steric interactions with the biological system being studied and be synthetically accessible. 
In the last decade, several bioorthogonal ligation strategies have been developed. Among these, 
prominent transformations are the Staudinger-Bertozzi ligation3, the copper-catalysed4 and the strain-
promoted azide-alkyne [2+3] cycloaddition.5 An important recent development is the inverse-electron-
demand Diels-Alder reaction (IEDDA), which exhibits the fastest reaction kinetics among all commonly 
used bioorthogonal transformations, while being chemo-selective, efficient and additive-free.6–8 In the 
most typical setup, IEDDA uses a strained alkene tag, while its reaction partner is a reporter-group 
functionalized tetrazine derivative. Well-established strained alkene handles are norbornene (Figure 1, A) 
and trans-cyclooctene (Figure 1, B). Although these alkenes react exceptionally fast, their steric bulk and 
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lipophilicity may induce a biological response, bringing a paradoxical problem, known as the observer 
effect, into chemical biology. Hence, there is room for the development of more compact dienophiles for 
tetrazine mediated bioorthogonal cycloadditions. Recently, Devaraj and co-workers introduced the 
methylcyclopropene core (Figure 1, C), as dienophile for IEDDA that combines small size with fast reaction 
kinetics.9 
Currently, all contemporary dienophiles – norbornene, trans-cylcooctene and cyclopropene – used in 
IEDDA-based bioorthogonal chemistry rely on ring strain to attain the desired reactivity towards 
tetrazines. These were first described in the seminal 1990 report by Sauer and co-workers on the reactivity 
of cyclic dienophiles in IEDDA processes.10 In the same paper, it was shown that alkenes activated by a 
single electron-donating heteroatom adjacent to the double bond, would exhibit a higher reactivity 
towards tetrazine relative to their non-conjugated analogues. Introduction of a heteroatom into the 
cyclobutene scaffold should therefore lead to a viable dienophile for IEDDA-based bioorthogonal 
chemistry. Following this reasoning, a 2-azetine would be the smallest viable core that could utilize this 
effect in addition to ring-strain, with the ring-nitrogen amenable for functionalization to yield a new and 
compact bioorthogonal tag. Although N-alkylazetines are theoretically the more electron-rich species, N-
acylazetines (Figure 1, D) were considered more suitable candidates because of their reported stability.11 
This chapter describes the development and optimization of a synthetic route towards a bioorthogonal 
tag based on N-acylazetine moiety and a study towards its applicability in IEDDA-based bioorthogonal 
chemistry. 
 
Synthesis Results and Discussion 
The synthesis of linkable N-alkyl-azetines 6 and 7, equipped with an activated ester for further 
modification, (Scheme 1) commenced with the preparation of the azetidine core.12,13 Epichlorohydrin was 
reacted with benzhydrylamine in a two-step one-pot procedure to afford protected azetidine 2. The 
hydroxy group of 2 was mesylated, affording methanesulfonate 3. Deprotection of the benzhydryl with 
chloroethyl chloroformate provided the acyl-intermediate, which was degraded by refluxing in methanol 
to give 3-mesylazetidine hydrochloride 4. The route from 1 to 4 was optimized in such a way that each 
intermediate could be purified through crystallization and washing steps (in 48% yield over three steps). 
With free amine 4 in hand, the ring-opening of glutaric anhydride could commence. Initially this was 
carried out under the agency of triethylamine. However, during the reaction, the methane sulfonate was 
substituted by chloride originating from 3-mesylazetidine hydrochloride. Furthermore, the use of 
triethylamine complicated the column purification of the formed carboxylic acid. These problems were 
addressed by switching to potassium carbonate as the base, and premixing 4 with silver 
methanesulfonate, to precipitate the chloride as AgCl. After successful conversion, the free acid was 
regenerated from the potassium salt by treating with Amberlite-H+, providing 5 in 79% yield. The following 
elimination-esterification sequence was carried out in a one-pot procedure. First, methanesulfonic acid 
was eliminated with KOtBu to afford the N-acylazetine moiety. Next, the carboxylate was converted to 
either pentafluorophenol (PFP, 6) or p-nitrophenol (PNP, 7) esters via EDC mediated condensation with 
the appropriate alcohol. Both esters were readily obtained, however PFP-ester 6 proved to be unstable 
and could not be stored for extended periods of time. Another disadvantage was its gel-like consistency 
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at room temperature, making it difficult to handle. On the other hand, PNP-ester 7 was isolated as a 
crystalline solid that is stable at room temperature for at least three months. 
 
 
Scheme 1: Synthesis of active ester functionalized N-acylazetine 6 and 7. Reagents and conditions: [a] i: Epichlorohydrin, iPrOH, 
30 ˚C, 16h. ii: NaHCO3, MeCN, reflux, 30h, 83%. [b] MsCl, TEA, DCM, -40 ˚C, 0.5h, 80%. [c] i: Chloroethyl chloroformate, DCE, 
reflux, 1.5h. ii: MeOH, reflux, 2h, 66%. [d] i: MsOAg, MeCN, 15 min. ii: K2CO3, glutaric anhydride, reflux, 2h, 79%. [e] i: KOtBu, 
DMF, 50 ˚C, 2h. ii: EDC·HCl, PFP/PNP, 1.5h, 6: 63% 7: 85%. 
 
Besides the required physical properties, the applicability of a ligation handle is also dependent on its 
synthetic accessibility. The above described synthesis to acylazetine 7 consists of six reactions of which 
the ring-opening of glutaric anhydride by 3-mesylazetidine and the sequential one-pot elimination–
esterification sequence are  the key steps. Despite various attempts  of optimization, these steps constrain 
the overall efficiency and scalability. Therefore another synthetic route towards 7 was explored (Scheme 
2). Commercially available 3-hydroxyazetidine 8 was used as starting compound and the mesyl group was 
replaced by the tosyl group that is UV-detectable and  a slightly better leaving group.  The synthesis started 
with the sequential Boc-protection and tosylation of 3-hydroxyazetidine (8), providing protected azetidine 
9 in 72% over two steps. To prevent potential tosyl displacement the Boc-group was cleaved using p-
toluenesulfonic acid. Purification by crystallization from MeOH yielded 10 in 80%. Ring-opening of succinic 
and glutaric anhydride with 10 was carried out under the agency of potassium carbonate in refluxing 
acetonitrile, yielding the four- (11) and five-carbon spacer (12), respectively. Next, the key elimination was 
initiated by the addition of a KOtBu solution in THF. The use of the tosyl improved solubility while the 
reaction now proceeded readily at room temperature. The respective N-acylazetine intermediates were 
treated in situ with bis(p-nitrophenyl)carbonate, to provide linkable handles 7 (80%) and 13 (69%) in good 
yields over two steps. Initially, the p-nitrophenol was introduced using DIC or EDC as coupling reagents. 





Scheme 2: Improved synthesis of activated N-acylazetine handle 7 and the four-carbon variant 13. Reagents 
and conditions: [a] i: Boc2O, TEA, MeOH, 0 ˚C, 2h, used crude. [b] TsCl, TEA, DCM, 2h, 86% over 2 steps. [c] 
pTsOH, DCE, reflux, 16h, 79% [d] Succinic- (11) or glutaric  (12) anhydride, K2CO3, MeCN, reflux, 6h, 50% 11, 
70% 12. [e] KOtBu, DMF, 2h. ii: bis(p-nitrophenol)carbonate, 16h, 13: 80% 7: 69%. 
 
Reaction Kinetics 
To investigate the rate of the IEDDA reaction of N-acylazetine with tetrazine, 7 was coupled with 
morpholine to make water soluble N-acylazetine 14 (Figure 2). A ten-fold excess of model compound 14 
was reacted with tetrazine 15.14 The rate was determined by monitoring the absorbance of the tetrazine 
at 517 nm (Figure 2). The pseudo-first order rate constant k1 was established to be 4.5·10-3 ± 1.6·10-3 s-1 
at 20 °C in a solution of 12% DMSO in water. In a separate experiment, the second-order rate constant k2 




Figure 2: The graph consists of a data plot following the tetrazine absorption band over time in a reaction between N-acylazetine 
14 (6 mM) and tetrazine 15 (0.6 mM) in 12% DMSO/water. The kinetics experiment was performed four times. Compound 16 is 
formed as a mixture of regioisomers and potentially as  tautomers. 
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The mass-spectroscopic data of the reaction product, formed as a mixture of isomers, were fully 
consistent with putative structure 16. However, characterization of 16 by NMR was complicated by the 
two tertiary amide bonds, which appeared to exist as rotamers on the NMR time scale. In order to obtain 
more conclusive spectroscopic data of the product, while simultaneously studying the course of the N-
acylazetine cycloaddition in more detail, compound 17 was reacted with symmetrical tetrazine 18 
(Scheme 2). During this experiment it was found that immediate IEDDA adduct 19 rapidly ring-opens to 
form compound 20 as the sole product. This process is likely thermodynamically driven by the restoration 
of aromaticity and relief of ring-strain, of which former is more favorable in higher conjugated systems. 
Trace amounts of product resulting from the same rearrangement were observed after the reaction of 14 
with 15, as evidenced by the resonance of the tertiary carbon of pyridazine at 123 ppm in the 13C NMR 
spectrum of 16.  
 
 
Scheme 2: Model cycloaddition between N-acylazetine 17 and tetrazine 18, shows that direct adduct 19 completely 
rearranges to open-ring isomer 20. 
 
Labeling Evaluation 
In order to evaluate the applicability of the novel N-acylazetine ligation handle for biological labeling 
strategies, the tag was incorporated into an activity-based proteasome probe to enable two-step 
activity-based protein profiling through ligation with a fluorescently labeled tetrazine (23, Figure 3). As 
a model target enzyme the constitutive proteasome was selected. The proteasome is a multi-subunit 
protein complex containing three different catalytically active subunits (β1, β2 and β5). These β-
subunits each have a different substrate preference and can be targeted by various subunit-selective15 
or broad-spectrum16 activity based probes (ABPs). The designed ABP 21 is based on the broad-spectrum 
irreversible proteasome inhibitor epoxomicin, functionalized at the N-terminus with the acylazetine 
moiety.17–19 Compound 21 (Figure 3) was readily prepared from protected peptide epoxyketone.  
The ability of the N-acylazetine-functionalized ABP 21 to target the catalytically active proteasome β-
subunits was confirmed by performing competition experiments against the fluorescent broad-spectrum 
proteasome ABP MV151 in human embryonic kidney (HEK) cell extracts. These experiments revealed that 
3 µM of ABP 21 was required to completely block the fluorescent labeling by MV151. Therefore, for all 
ensuing two-step labeling experiments a probe concentration of 5 µM was used. The utility of the N-
acylazetine tag for two-step labeling of proteasome activity in cell extracts was established by exposure 
of HEK cell extracts to ABP 21, followed by ligation with varying concentrations of tetrazine 23. As a 
control, the same procedure was performed using the previously reported norbornene-functionalized 
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ABP 22.20 Analysis of the labeled proteins on gel with fluorescent readout (Figure 3, A) revealed that 
tetrazine ligation of cell extracts treated with N-acylazetine-functionalized ABP 21 resulted in the specific 
fluorescent labeling of three bands, which correspond to the proteasome β-subunits labeled by 
fluorescent ABP MV151. The labeling is dependent on the concentration of tetrazine in a similar manner 
as for norbornene-functionalized ABP 22. With both ABPs a comparable increase in fluorescent labeling 
was observed when the ligation step was performed at prolonged reaction times (Figure 3, B). 
These results demonstrate that, in this experimental setup, the N-acylazetine moiety reacts with equal 
efficiency as the norbornene ligation handle in IEDDA reaction with tetrazine 23. The absence of labeling 
in samples in which the proteasome activity was inhibited by an excess of epoxomicin, confirms that ABP 
21 labels the catalytically active proteasome β-subunits. In order to determine whether N-acylazetine may 




Figure 3: Structures of N-acylazetine- (20) and norbornene (21)-functionalized proteasome ABPs and 
tetrazine-BODIPY reporter reagent (17). [A] Labeling of proteasome activity in HEK cell extracts by exposure 
to 5 μM of ABP 21 or ABP 22 for 1 h followed by reaction with 0.3−100 μM of Bodipy-tetrazine 23 for 1 h. [B]: 
Labeling of proteasome activity in HEK cell extracts by exposure to 5 μM of ABP 21 or ABP 22 for 1 h followed 
by reaction with 10 μM of Bodipy-tetrazine 23 for 5−240 min. “ep”: 100 μM epoxomicin added to incubation 




performed in HEK cell extracts using alkyne-, azide- and phosphine-functionalized reagents instead of 
tetrazine for the ligation step. No proteasome labeling was detected when using Bodipy-alkyne20, Bodipy-
azide21, biotin-phosphine22 and biotinylated dibenzocyclooctene23 reagents, demonstrating that these do 
not react with the N-acylazetine-tagged probe. Together these results demonstrate the utility of the new 
compact N-acylazetine ligation handle for bioorthogonal labeling of proteins or other biomolecules via 
tetrazine ligation.  
 
Conclusion 
In conclusion, two N-acylazetine handles (7 and 13) for the tetrazine ligation strategy were designed and 
synthesized. After optimization, these handles have become accessible through an efficient four-step 
synthesis. Determination of the reaction kinetics between the N-acylazetine and tetrazine showed a 
reaction rate constant in line with that of the methylcyclopropene mini-tag. The applicability of the N-
acylazetine was demonstrated in an ABPP experiment, where epoxomicin – a broad-spectrum 






General: Reactions were executed at ambient temperatures unless stated otherwise. All solvents used 
under anhydrous conditions were stored over 4Å molecular sieves, except for methanol which was stored 
over 3Å molecular sieves. Reactions were monitored by TLC‐analysis using Merck aluminum DC Silicagel 
60 F254, using varying stains for visualization; an aqueous solution of cerium molybdate 
((NH4)6Mo7O24·4H2O 25 g/L), an aqueous solution of potassium permanganate (5 g KMnO4, 25 g K2CO3 per 
L) or an ethanolic solution bromocresol (0.4 g in 1 L, addition of 0.1M NaOH(aq) until the solution turns 
blue). Column chromatography was performed on silica gel (40-63 µm). Analysis by NMR and HRMS were 
performed as described in the experimental section of chapter 2. 
 
 
1-Benzhydrylazetidin-3-ol: Epichlorohydrin (10.75 ml, 138 mmol, 1.1 eq) was added to a solution of 
benzhydrylamine (21.55 ml, 125 mmol) in isopropanol (125 mL) and the reaction mixture was stirred 
overnight at 30 °C. LC/MS analysis showed full conversion into the open-chain intermediate. The reaction 
mixture was concentrated in vacuo and redissolved in MeCN (200 mL). Sodium bicarbonate (11.44 g, 188 
mmol, 1.5 eq) was added and the reaction mixture was refluxed for 30 h. The reaction mixture was filtered 
and reduced in vacuo, providing a pale-yellow solid. The solid cake was thoroughly pulverized, suspended 
in an Et2O/Pentane/EtOAc mixture (9:9:2, 50 mL) and sonicated for 15 minutes. The white residue was 
collected by filtration and dried under reduced pressure, yielding 1-benzhydrylazetidin-3-ol as a white 
solid (24.85 g, 104 mmol, 83%), which was used in the next step without further purification. Rf = 0.49 (1:1 
; EtOAc:PE). 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.12 (m, 10H), 4.42 (p, J = 5.8 Hz, 1H), 4.34 (s, 1H), 3.55 – 
3.47 (m, 2H), 3.17 (s, 1H), 2.96 – 2.83 (m, 2H). 13C NMR: (101 MHz, CDCl3) δ 141.80, 128.42, 127.38, 127.14, 
78.43, 63.30, 61.89. 
 
 
1-Benzhydrylazetidin-3-O-Mesyl: 1-benzhydrylazetidin-3-ol (24.65 g, 103 mmol) and triethylamine (21.53 
ml, 155 mmol, 1.5 eq) were dissolved in DCM (80 mL) under argon atmosphere and cooled to -40 °C. 
Methanesulfonyl chloride (9.63 ml, 124 mmol, 1.2 eq) in DCM (20 mL) was slowly added dropwise, while 
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maintaining the temperature at -40 °C. The reaction mixture was stirred for 30 minutes, after which it was 
diluted with DCM (50 mL) and washed with water (2 x 100 mL). The organic phase was dried over 
magnesium sulfate, filtered and concentrated in vacuo (if the concentrate did not solidify, the oil was 
diluted with EtOAc and re-concentrated). The residual yellow solid was pulverized and thoroughly rinsed 
with cold Et2O. The solid was suspended in a mixture of acetone/water (1:1, 50 mL) and sonicated for 15 
minutes, filtered and vacuum dried, yielding product 3 as an off-white solid (26.3 g, 83 mmol, 80%). TLC 
Rf = 0.33 (1:3 ; EtOAc:PE). 1H NMR: (400 MHz, CDCl3) δ = 7.53 – 7.25 (m, 10H), 5.16 (p, J=5.8, 1H), 4.50 (s, 
1H), 3.73 – 3.66 (m, 2H), 3.31 – 3.23 (m, 2H), 2.93 (s, 3H). 13C NMR: (101 MHz, CDCl3) δ 141.29, 128.46, 
127.29, 127.19, 77.99, 67.86, 60.04, 37.91. 
 
 
Azetidin-3-O-mesyl hydrochloride (4): A solution of 1-benzhydrylazetidin-3-yl methanesulfonate (26.3 g, 
83 mmol) in DCE (150 mL) was charged with 1-Chloroethyl chloroformate (9.96 ml, 91 mmol, 1.1 eq) and 
heated to reflux. After 1.5 hour, TLC (Rf = 0.38 - 2:3 ; EtOAc:PE) indicated conversion of the starting 
material in a lower running product. The solution was concentrated in vacuo, redissolved in MeOH (150 
mL) and refluxed for an additional 2 h. The reaction mixture was concentrated in vacuo. The residual 
yellow cake was suspended in a mixture of Et2O:EtOH (2:1, 50 mL) and sonicated for 15 minutes. The 
remaining white solid was isolated by filtration, washed with Et2O and dried in vacuo, yielding mesyl 
azetidine 4 (10.2 g, 54.4 mmol, 65.5 % yield) as a white solid. 1H NMR: (400 MHz, Methanol-d4) δ 5.44 
(ddd, J = 6.8, 4.8, 1.9 Hz, 1H), 4.52 (dt, J = 12.5, 4.4 Hz, 2H), 4.30 (dd, J = 12.6, 4.8 Hz, 2H), 3.23 (s, 3H).  13C 
NMR: (101 MHz, Methanol-d4) δ 70.08, 54.51, 37.92. 
 
 
Glutaric Acylazetidine 5: A suspension of mesyl azetidine 4 (3.52 g, 18.8 mmol, 1.05 eq) and silver 
methanesulfonate (3.88 g, 19.1 mmol, 1.07 eq) in dry MeCN (25 mL) was prepared under argon 
atmosphere, and stirred vigorously at 40 °C for 15 minutes. Dry potassium carbonate (2.14, 35.7 mmol, 2 
eq) and glutaric anhydride (2.04 g, 17.9 mmol, 1 eq) were added and the reaction was refluxed for 2 h. 
TLC indicated completion (10% EtOH in DCM), using bromocresol as a visualization agent. The reaction 
mixture was filtered over celite and carefully rinsed with water three times to remove product from the 
cake. The filtrate was diluted with 25% water in MeCN and acidified with Amberlite (IR120, H-form) to a 
pH below 3. After filtration, the solution was concentrated and purified by column chromatography (7% 
» 10% EtOH in DCM), yielding the title compound as a thick white solid (3.75 g, 14.1 mmol, 79%). 1H NMR 
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(400 MHz, CDCl3) δ = 5.28 (tt, J=6.7, 4.1, 1H), 4.52 (ddd, J=10.1, 6.6, 1.5, 1H), 4.41 (ddd, J=11.5, 6.6, 1.4, 
1H), 4.36 – 4.29 (m, 1H), 4.20 – 4.14 (m, 1H), 3.12 (s, 3H), 2.45 (t, J=7.0, 2H), 2.23 (t, J=7.3, 2H), 1.97 (p, 
J=7.1, 2H). 13C NMR (101 MHz, CDCl3) δ 177.36, 172.75, 66.53, 57.47, 55.14, 38.37, 32.87, 30.29, 19.60. 
HRMS: Calculated for C14H10F5NO3 266.06928 [M+H]+; found 266.06919 
 
 
Pentafluorphenol Acylazetine 6: Potassium tert-butoxide in THF (20.5 mL, 1.6 M, 32.9 mmol, 2.3 eq) was 
added to a solution of mesylazetidine pentanoic acid spacer 5 in DMF (150 mL), under argon atmosphere. 
The reaction mixture was stirred at 50 °C for 2 h. After cooling to room temperature, EDC·HCl (8.23 g, 42.9 
mmol, 3 eq.) and pentafluorophenol (4.58 mL, 42.9 mmol, 3 eq.) were added, and the reaction mixture 
was stirred for an additional 1.5 h. The mixture was poured into H2O (150 mL) and extracted with DCM 
(150 mL). The organic layer was washed with brine (30 mL), dried over magnesium sulfate, filtrated and 
concentrated in vacuo. The crude product was purified by column chromatography (10% » 30% EtOAc in 
PE) to yield 6 as a colorless oil which solidified upon standing at -20°C (3 g, 9 mmol, 63%). 1H NMR (400 
MHz, CDCl3) δ = 6.93 – 6.69 (d, J=95.6, 1H), 5.75 (d, J=9.6, 1H), 4.52 (d, J=37.4, 2H), 2.90 – 2.76 (m, 2H), 
2.42 (dt, J=36.0, 7.2, 2H), 2.15 (p, J=7.1, 2H). 13C NMR (101 MHz, CDCl3) δ 177.36, 172.75, 66.53, 57.47, 
55.14, 38.37, 32.87, 30.29, 19.60. HRMS: Calculated for C14H10F5NO3 336.06536 [M+H]+; found 336.06512. 
 
 
p-Nitrophenol Gluctaric Acylazetine 7: A solution of mesylazetidine pentanoic acid spacer 5 (0.58 g, 2.186 
mmol) in DMF (25 mL) was prepared and put under argon atmosphere. Next, potassium tert-butoxide 
(3.01 ml, 4.81 mmol) was slowly added and the reaction mixture was warmed to 50 °C and stirred 
vigorously for 2 hours. The reaction was allowed to cool to room temperature, after which p-nitrophenol 
(0.912 g, 6.56 mmol) was added. The reaction mixture was stirred until a clear yellow solution had formed. 
Then EDCˑHCl (1.257 g, 6.56 mmol) was added and the reaction was stirred for additional 2 hours. The 
reaction mixture was poured into ether/EtOAc (2:1) and washed with water and brine. The organic layer 
was dried over magnesium sulfate, filtrated and concentrated in vacuo. The crude product was purified 
by column chromatography (30% » 80% EtOAc in PE) to yield 7 as a white crystalline substance (0.54 g, 
1.86 mmol, 85%). 1H NMR (400 MHz, CDCl3) δ = 8.27 (d, J=9.1, 2H), 7.29 (d, J=9.1, 2H), 6.80 (dd, J=100.2, 
1.7, 1H), 5.73 (d, J=6.9, 1H), 4.51 (d, J=35.3, 2H), 2.74 (t, J=7.2, 2H), 2.46 (t, J=7.1, 1H), 2.37 (t, J=7.1, 1H), 
2.13 (p, J=7.2, 2H). 13C NMR (101 MHz, CDCl3) δ = 170.72, 155.28, 145.20, 137.40, 136.68, 125.13, 122.37, 






N-Boc-azetidin-3-O-mesyl (9): A solution of commercially available 3-hydroxyazetidine hydrochloride 
(115 mmol, 10.55 g, 1 eq) and Et3N (161 mmol, 22.5 mL, 1.4 eq) in MeOH (115 mL) was prepared at 0 ˚C. 
Boc2O (126.5 mmol, 27.6 g, 1.1 eq) was added and the ice-bath was removed. After 5 hours of stirring, the 
reaction mixture was concentrated in vacuo, redissolved in DCM and washed twice with water. The water 
layers were combined and extracted twice with DCM. The organic layers were combined, dried with 
magnesium sulfate, filtered and concentrated in vacuo. The intermediate Boc-hydroxyazetidine was used 
without further purification. An ice-cooled solution of the crude 8 and Et3N (172.5 mmol, 24 mL, 1.5 eq) 
in dry DCM (100 mL) was prepared under argon atmosphere. p-Toluenesulfonyl chloride (138 mmol, 26.3 
g, 1.2 eq) was added in eight portions over 2 hours and the reaction mixture was stirred overnight. The 
reaction mixture was washed with water twice and the combined aqueous layers were extracted thrice 
with DCM. The organic layers were combined, dried over magnesium sulfate, filtered and concentrated in 
vacuo. The crude product was purified by column chromatography (5% » 10% EtOAc in pentane), yielding 
tosylate 9 as a yellow oil. (82.6 mmol, 27.7 g, 72% over two steps). 1H NMR: (300 MHz, CDCl3) δ 7.75 (d, J 
= 8.1 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 4.97 (ddd, J = 10.8, 6.6, 4.3 Hz, 1H), 4.14 – 4.01 (m, 2H), 3.97 – 3.82 
(m, 2H), 2.43 (s, 3H), 1.38 (s, 9H). 13C NMR: (75 MHz, CDCl3) δ 155.86, 145.61, 132.91, 130.17, 127.92, 
80.23, 67.84, 56.28, 28.30, 21.74. HRMS: Calculated for 327.11404 [M+H]+; found 328.12132. 
 
 
Azetidin-3-O-tosyl tosylate (10): A solution of compound 9 (82.6 mmol, 27.1g, 1 eq) in DCE (165 mL) was 
charged with p-toluenesulfonic acid (90.9 mmol, 17.3g, 1.1 eq) and refluxed for 20 hours. The reaction 
mixture was concentrated in vacuo. The crude product was crystalized from MeOH, yielding compound 
20 as a white crystalline substance (65 mmol, 25.9 g, 79%). 1H NMR (400 MHz, CDCl3) δ 9.00 (d, 2H), 7.70 
(d, J = 8.2 Hz, 4H), 7.29 (d, J = 8.1 Hz, 2H), 7.19 (d, J = 7.8 Hz. 13C NMR (101 MHz, CDCl3) δ 146.07, 141.26, 
132.03, 130.38, 129.39, 128.17, 125.92, 67.85, 53.37, 21.86, 21.55. 
 
 
Succinic Acylazetidine 11: Compound 10 (20.0 mmol, 5.58 g, 1.1 eq) was co-evaporated with dioxane, 
redissolved in MeCN (200 mL), and put under argon atmosphere. Succinic anhydride (18.2 mmol, 1.82 g, 
1 eq) was added to the reaction mixture, followed by potassium carbonate (45.5 mmol, 6.3 g, 2.5 eq) and 
the reaction mixture was refluxed for 6 hours. Reaction progress was monitored by TLC, using a 
bromocresol stain to visualize the produced carboxylic acid. The reaction mixture was diluted with water 
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(200 mL) and Amberlite-H+ (IR120, ±70 g) was added until the pH fell below 3. The solution was filtered 
and the residual MeCN was removed in vacuo. The water layer was extracted twice with EtOAc. The 
organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography (5% » 10% EtOH in DCM), yielding compound 11 
as a white crystalline substance (9.1 mmol, 3.09 g, 50%). 1H NMR: (400 MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 
2H), 7.39 (d, J = 8.2 Hz, 2H), 5.08 (ddd, J = 11.1, 6.9, 4.3 Hz, 1H), 4.42 (dd, J = 9.4, 7.5 Hz, 1H), 4.30 – 4.08 
(m, 2H), 3.94 (dd, J = 11.5, 4.0 Hz, 1H), 2.71 – 2.61 (m, 2H), 2.48 (s, 3H), 2.35 (t, J = 6.8 Hz, 2H). 13C NMR: 
(101 MHz, CDCl3) δ 171.99, 145.99, 130.37, 128.07, 76.84, 67.22, 57.38, 55.23, 28.81, 26.20. 
 
 
p-Nitrophenol Succinic Acylazetidine 13: Compound 11 (9.1 mmol, 3.09 g, 1 eq) was co-evaporated with 
dioxane, redissolved in dry DMF (45.5 mL) and put under argon atmosphere. Next, a 1 M solution of 
potassium tert-butoxide in THF (20 mL, 2.1 eq) was added to the reaction mixture and the reaction was 
stirred for 1 hour. Subsequently the reaction mixture was charged with bis(para-nitrophenyl)carbonate 
(10 mmol, 3.01 g, 1.1 eq) and left stirring for an additional 3 hours. The reaction mixture was diluted with 
EtOAc and washed twice with 10% aqueous sodium bicarbonate, twice with water and once with brine. 
The combined organic layers were dried with MgSO4, filtered and concentrated in vacuo. The crude 
product was purified with column chromatography (50% » 100% EtOAc in pentane), yielding compound 
13 as a yellow crystalline substance (7.3 mmol, 2.0 g, 80%). 1H NMR: (400 MHz, CDCl3) δ 8.26 (d, J = 9.2 
Hz, 2H), 7.31 (d, J = 9.1 Hz, 2H), 6.91 (s, 0.5H), 6.71 (s, 0.5H), 5.75 (d, J = 5.3 Hz, 1H), 4.61 (s, 1H), 4.48 (s, 
1H), 2.97 (t, J = 6.6 Hz, 2H), 2.75 (t, J = 6.5 Hz, 1H), 2.66 (t, J = 6.5 Hz, 1H). 13C NMR: (101 MHz, CDCl3) δ 
170.76, 165.26, 164.88, 155.48, 145.32, 137.43, 136.64, 125.22, 122.55, 114.19, 113.93, 77.16, 58.67, 
56.91, 29.13, 29.03, 26.74, 25.76. 
 
 
Succinic Acylazetidine 12: Compound 10 (14.0 mmol, 5.58g, 1.1 eq) was co-evaporated with dioxane, 
redissolved in MeCN (140 mL) and put under argon atmosphere. Glutaric anhydride (12.7 mmol, 1.45 g, 1 
eq) was added to the reaction mixture, followed by potassium carbonate (31.8 mmol, 4.48 g, 2.5 eq) and 
the reaction mixture was refluxed for 6 hours. Reaction progression was monitored by TLC, using a 
bromocresol stain to visualize the produced carboxylic acid. The reaction mixture was diluted with water 
(200 mL) and Amberlite-H+ (IR120, ±50 g) was added until the pH fell below 3. The solution was filtered 
and the residual MeCN was removed in vacuo. The water layer was extracted twice with EtOAc. The 
organic layers were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography (3% » 5% EtOH in DCM), yielding compound 12 as 
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a white crystalline substance (8.9 mmol, 3.06 g, 70%). 1H NMR: (400 MHz, CDCl3) δ 7.81 (d, J = 8.3 Hz, 2H), 
7.40 (d, J = 8.1 Hz, 2H), 5.08 (tt, J = 6.8, 4.2 Hz, 1H), 4.45 – 4.33 (m, 1H), 4.26 – 4.13 (m, 2H), 3.93 (dd, J = 
11.5, 4.3 Hz, 1H), 2.49 (s, 3H), 2.42 (t, J = 7.0 Hz, 2H), 2.17 (t, J = 7.3 Hz, 2H), 1.92 (p, J = 7.2 Hz, 2H). 13C 
NMR: (101 MHz, CDCl3) δ 177.76, 172.54, 145.84, 132.58, 130.24, 127.93, 67.11, 57.23, 54.93, 32.93, 
30.29, 21.78, 19.57. 
 
 
p-Nitrophenol Glutaric Acylazetine 7: Compound 10 (8.9 mmol, 3.04 g, 1 eq) was co-evaporated with 
dioxane, redissolved in dry DMF (44.5 mL), and put under argon atmosphere. Next, a 1 M solution of 
potassium tert-butoxide in THF (18.7 mL, 2.1 eq) was added to the reaction mixture and left stirring for 1 
hour. Subsequently the reaction mixture was charged with bis(para-nitrophenol)carbonate (9.8 mmol, 
2.95 g, 1.1 eq) and left stirring for another 3 hours. The reaction mixture was diluted with EtOAc and 
washed twice with 10% aqueous sodium bicarbonate, twice with water and once with Brine. The 
combined organic layer were dried with magnesium sulfate, filtered and concentrated in vacuo. The crude 
product was purified with column chromatography (50% » 100% EtOAc in pentane), yielding compound 7 
as a yellow crystalline substance (6.1 mmol, 1.78 g, 69%). 1H NMR: (400 MHz, CDCl3) δ 8.26 (d, J = 9.2 Hz, 
2H), 7.31 (d, J = 9.1 Hz, 2H), 6.91 (s, 0.5H), 6.71 (s, 0.5H), 5.75 (d, J = 5.3 Hz, 1H), 4.61 (s, 1H), 4.48 (s, 1H), 
2.97 (t, J = 6.6 Hz, 2H), 2.75 (t, J = 6.5 Hz, 1H), 2.66 (t, J = 6.5 Hz, 1H). 13C NMR: (101 MHz, CDCl3) δ 170.76, 
165.26, 164.88, 155.48, 145.32, 137.43, 136.64, 125.22, 122.55, 114.19, 113.93, 77.16, 58.67, 56.91, 
29.13, 29.03, 26.74, 25.76. 
 
 
Morpholine Glutaric Acylazetine 14: Morpholine (0.099 ml, 1.137 mmol) was added to a solution of 4-
nitrophenyl 5-(azet-1(2H)-yl)-5-oxopentanoate 7 (0.11 g, 0.379 mmol) in DCM (1 mL). After 1 hour, the 
reaction mixture was directly purified by column chromatography (DCM » DCM:Acetone:EtOH 80:20:1 » 
50:45:5) to give 14 (88 mg, 0.369 mmol, 97%). 1H NMR: (400 MHz, CDCl3) δ = 8.27 (d, J=9.1, 2H), 7.29 (d, 
J=9.1, 2H), 6.80 (dd, J=100.2, 1.7, 1H), 5.73 (d, J=6.9, 1H), 4.51 (d, J=35.3, 2H), 2.74 (t, J=7.2, 2H), 2.46 (t, 
J=7.1, 1H), 2.37 (t, J=7.1, 1H), 2.13 (p, J=7.2, 2H). 13C NMR: (101 MHz, CDCl3) δ = 170.72, 155.28, 145.20, 
137.40, 136.68, 125.13, 122.37, 113.71, 113.41, 58.53, 56.56, 33.23, 30.60, 29.56, 19.96, 19.78. HRMS 
[M+H]+ m/z calc. for [C14H14N2O5] = 291.09755, found 291.09744. HRMS: Calculated for C12H18N2O3 




Synthesis of Model Compounds 
 
IEDDA Adduct 16: Tetrazine 14 was added to a solution of acylazetidine 15 in a H2O:THF mixture (1:1, 1 
mL). The reaction was stirred for 0.5 hour, diluted with water and washed with EtOAc. The water layer 
was separated and reduced in volume and co-evaporated with dioxane. The residue was redissolved in 
DMSO (1 mL). Diethyl ether (10 mL) was added and the mixture was sonicated for 0.5 hour. The ether was 
decanted and the remaining off-yellow powder was dried in vacuo to give adduct 16.  
 
 
Model Acylazetidine 24: 3-Phenylpropionyl chloride (2.228 ml, 15.00 mmol) was added to a cooled 
solution (-78 °C) of azetidin-3-yl methanesulfonate hydrochloride (2.81 g, 15 mmol) and TEA (4,60 ml, 33,0 
mmol) in DCM (60 mL), under argon atmosphere. The reaction mixture was stirred for 30 minutes, before 
being quenched with water. The aqueous layer was extracted twice with DCM (30 mL). The organic layer 
was isolated and dried over magnesium sulfate, filtered and concentrated in vacuo. The residual oil was 
purified by flash column chromatography (70% » 100% EtOAc in pentane), yielding 24 (3.04 g, 10.73 mmol, 
72%) as a white crystalline substance. 1H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 8.1, 6.7 Hz, 2H), 7.24 – 7.16 
(m, 3H), 5.12 (tt, J = 6.7, 4.1 Hz, 1H), 4.36 – 4.25 (m, 1H), 4.18 (ddd, J = 10.1, 6.6, 1.5 Hz, 1H), 4.11 – 3.97 
(m, 2H), 3.03 (s, 3H), 2.93 (t, J = 7.6 Hz, 2H), 2.43 – 2.32 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 172.36, 
140.81, 128.60, 128.41, 126.42, 66.61, 57.17, 54.89, 38.35, 33.77, 31.04. 
 
 
Model Acylazetine 17: Potassium tert-butoxide (1,459 g, 13.00 mmol) was added to a solution of 24 (2.83 
g, 10 mmol) in tBuOH (30 mL), under argon atmosphere. The reaction mixture was stirred for 4h at 50 °C. 
The reaction mixture was poured into a diluted ammonium chloride solution and extracted with DCM. 
The organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by 
silica gel column chromatography (40% » 50% EtOAc in pentane) yielded 17 (1.09 g, 5.84 mmol, 58%) as a 
colorless oil that solidified upon standing. 1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 7.1, 1.7 Hz, 2H), 7.62 
(s, 1H), 7.53 (t, J = 6.0 Hz, 1H), 7.45 – 7.38 (m, 1H), 7.38 – 7.23 (m, 7H), 7.14 – 7.01 (m, 6H), 4.27 (d, J = 5.9 
Hz, 2H), 2.88 (t, J = 7.6 Hz, 2H), 2.51 (t, J = 7.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 172.92, 159.03, 157.98, 
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140.49, 137.75, 135.72, 129.90, 129.07, 128.85, 128.72, 128.41, 128.27, 128.07, 126.92, 126.03, 122.63, 
39.77, 37.48, 31.28. 
 
 
IEDDA Adduct 20: 3,6-diphenyl-1,2,4,5-tetrazine (62.6 mg, 0.267 mmol) was added to a solution of 1-
(azet-1(2H)-yl)-3-phenylpropan-1-one (50 mg, 0.267 mmol) in H2O:THF (1:4, 0.5 mL). The reaction mixture 
was stirred overnight. TLC (20% EtOAc in DCM) showed conversion into a single product. The solution was 
concentrated in vacuo and purified by column chromatography, yielding adduct 20 as a pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.80 (d, J = 7.1, 1.7 Hz, 2H), 7.62 (s, 1H), 7.53 (t, J = 6.0 Hz, 1H), 7.45 – 7.38 (m, 
1H), 7.38 – 7.23 (m, 7H), 7.14 – 7.01 (m, 5H), 4.27 (d, J = 5.9 Hz, 2H), 2.88 (t, J = 7.6 Hz, 2H), 2.51 (t, J = 7.7 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 172.92, 159.03, 157.98, 140.49, 137.75, 135.72, 129.90, 129.07, 
128.85, 128.72, 128.41, 128.27, 128.07, 126.92, 126.03, 122.63, 39.77, 37.48, 31.28. 
 
Acylazetine Epoxomicin 21: Epoxomicin-Thr(tBu)-Boc (0.05 g, 0.076 mmol) was dissolved in 0.5 ml TFA 
and stirred for 15 minutes. The reaction mixture was diluted with toluene and concentrated in vacuo. The 
residue was co-evaporated with toluene and redissolved in DMF (0.5 mL). DIPEA (0.053 ml, 0.305 mmol) 
was added, followed by perfluorophenyl 5-(azet-1(2H)-yl)-5-oxopentanoate (6) (0.026 g, 0.076 mmol). The 
reaction progress was followed by TLC-MS analysis. Upon completion, the reaction mixture was purified 
by HPLC to give 21 (15 mg, 0.023 mmol, 30%). 1H NMR (600 MHz, DMSO-d6) δ = 7.96 – 7.74 (m, 4H), 6.95 
(d, J=20.1, 1H), 5.81 (d, J=48.3, 1H), 4.84 – 4.71 (m, 1H), 4.54 (d, J=4.9, 1H), 4.42 – 4.35 (m, 1H), 4.31 (s, 
1H), 4.27 – 4.15 (m, 3H), 3.87 (h, J=5.7, 1H), 3.18 (d, J=5.3, 1H), 3.00 (d, J=5.3, 1H), 2.27 – 2.08 (m, 3H), 
1.81 – 1.58 (m, 3H), 1.39 (s, 3H), 1.36 – 1.24 (m, 2H), 1.12 – 1.02 (m, 2H), 0.99 (d, J=6.3, 3H), 0.89 (d, J=6.7, 
3H), 0.85 – 0.73 (m, 15H). 13C NMR (151 MHz, DMSO-d6) δ = 208.00, 171.63, 171.17, 170.85, 170.06, 
138.49, 137.20, 113.98, 112.74, 66.43, 58.79, 58.36, 57.86, 56.86, 56.03, 51.55, 49.23, 43.30, 38.69, 36.44, 








Determination of the pseudo-first order reaction rate constant 
A 1.2 mM stock solution of tetrazine 15 in 12% DMSO:Water (v:v) and a 12 mM stock solution of 
acylazetine 14 in 12% DMSO:Water were prepared. 1 mL of the 1.2 mM tetrazine 15 stock solution was 
brought into a quarts cuvette (10 mm width, 2 mL volume), which was placed in the measurement 
chamber of a Cary 300 UV-Vis spectrophotometer (Agilant Technologies). Then, 1 mL of the 12 mM 
acylazetine 14 stock solution was added to the cuvette and the measurement was immediately started. 
Upon addition of the second solution, the concentration became 0.6 mM for 15 and 6 mM for 14. The 
absorption decay was followed at 517 nm, measuring at 13 second intervals over 30 minutes. The 
experiments were conducted at uncontrolled room temperature (±20 ˚C). 
The reaction rate was derived from four data sets using every measurement interval up to 600 seconds 
(absorption range from 100% to >10%). This gave 4 data points per value of time (x). This array was 
subjected to the LINEST function (Microsoft Excel 2013) to determine the slope and the standard 
deviation. The slope represents the pseudo first-order rate constant. 
   
 
   
  Slope Intercept 
Parameter 0.004488 -0.06637 
Std. Dev. 8.15E-05 2.88E-02 
R² 0.942175 0.200321 






























Determination of the second order rate constant 
The second order rate was derived from the observed pseudo-first order reaction rates at three different 
(excess) concentrations of 14. These experiments were conducted at uncontrolled room temperature 































Preparation of cell extracts 
Human Embryonic Kidney (HEK) cell extracts were prepared from cultured HEK-293T cells by harvesting, 
washing with PBS (2x) and cell lysis in digitonin lysis buffer (50 mM Tris pH 7.5, 250 mM sucrose, 5 mM 
MgCl2, 1 mM DTT, 2 mM ATP, 0.025% digitonin) for 30 min on ice followed by sonication on ice for 3x 10 
s. After centrifugation of the cells at 16,100 g for 15 min at 4 C, the supernatants were collected and the 
protein concentration was determined by Bradford assay.  
 
 
Competition assay versus MV151 
HEK cell lysates (20 µg total protein per experiment) in lysis buffer (9 µL) were exposed to the indicated 
concentrations of 21 (1 μL 10x solution in DMSO) for 1 hr at 37 C, after which the lysates were incubated 
with 1 μM MV151 (1.1 µL 10 µM in DMSO) for 1 hr at 37 C. The reaction mixtures were then boiled at 
100 C for 5 minutes with 4 µL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved 
on 12.5% SDS-PAGE. In-gel visualization of the fluorescent labeling was performed in the wet gel slabs 
directly using a Typhoon Variable Mode Imager (Amersham Biosciences) with Cy3/TAMRA settings 
(excitation wavelength 532 nm, emission wavelength 580 nm). As a loading control gels were stained with 
Coomassie Brilliant Blue. As a protein standard the PageRuler Plus Prestained Protein Ladder (Thermo 
Scientific) was used. 
 
 
Figure E1. Competition experiment in HEK cell extracts. Cell extract were first exposed to 0 - 10 µM of azetidine-functionalized 
ABP 21 for 1 hr and then to fluorescent proteasome ABP MV151 for 1 hr. 12.5% SDS-PAGE with fluorescent readout followed by 






Tetrazine ligation in cell extracts 
HEK cell lysates (20 µg total protein per experiment) in lysis buffer (19 µL) were exposed to 5 µM of 12 or 
11 (1 μL 100 µM in DMSO) for 1 hr at 37 C. As a control, lysates were incubated with 11 in the presence 
of 100 μM epoxomicin (1 μL 2 mM in DMSO) or labeled with 1 µM MV151 (1 µL 20 µM in DMSO) for 1 hr 
at 37 C. The cell extracts were then exposed to the indicated concentrations of 13 (1.1 µL 20x solution in 
DMSO) for the indicated time at 37 C. After quenching by chloroform/methanol precipitation,24 the 
proteins were taken up in 10 µL Laemmli’s sample buffer containing 2-mercaptoethanol, boiled at 100 C 
for 5 minutes and resolved on 12.5% SDS-PAGE. In-gel visualization of the fluorescent labeling was 
performed in the wet gel slabs directly using a Typhoon Variable Mode Imager (Amersham Biosciences) 
with Cy3/TAMRA settings (excitation wavelength 532 nm, emission wavelength 580 nm). As a loading 
control gels were stained with Coomassie Brilliant Blue. As a protein standard the PageRuler Plus 











Test of cross-reactivity in cell extracts 
HEK cell lysates (20 µg total protein per experiment) in lysis buffer (19 µL) were exposed to 5 µM of 21 (1 
μL 100 µM in DMSO) for 1 hr at 37 C. The cell extracts were then exposed to 100 µM biotin-phosphine, 
100 µM biotin-dibenzocyclooctyn, 50 µM azido-Bodipy, 50 µM Bodipy-alkyne or 50 µM tetrazine-Bodipy 
(each 1 µL 20x in DMSO) for 1 hr at 37 C. After quenching by chloroform/methanol precipitation,16 the 
proteins were taken up in 10 µL Laemmli’s sample buffer containing 2-mercaptoethanol, boiled at 100 C 
for 5 minutes and resolved on 12.5% SDS-PAGE. In-gel visualization of the fluorescent labeling was 
performed in the wet gel slabs directly using a Typhoon Variable Mode Imager (Amersham Biosciences) 
with Cy2/Blue Fam settings (excitation wavelength 488 nm, emission wavelength 520 nm). Next, the 
proteins were transferred onto a PVDF membrane for detection of biotinylated proteins. The membrane 
was blocked with 1% BSA in TBS-t(+) (0.1% Tween 20) for 1 hr at room temperature, hybridized with 
Streptavidin-HRP for 45 min at room temperature (1:10,000 in blocking buffer) (Molecular Probes, Life 
Technologies), washed with TBS-t(+) and TBS and then visualized using an ECL+ Western Blotting detection 
kit (Amersham Biosciences). As a loading control the membrane was stained with Coomassie Brilliant Blue.  
 
Figure E4. Test of cross-reactivity in HEK cell extracts. Cell extract were first exposed to 5 µM of azetidine-functionalized ABP 21 
for 1 hr and then to Bodipy-azide (50 µM), Bodipy-alkyne (50 µM), tetrazine-BodipyFl (50 µM), biotin-phosphine (‘BioP’, 100 µM) 
or biotin-dibenzocyclooctyne (‘DIBO’, 100 µM) for 1 hr. 12.5% SDS-PAGE with fluorescent readout for detection of Bodipy-labeled 
proteins followed by streptavidin Western blotting to detect biotinylated proteins. Coomassie brilliant blue staining is shown as 
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The inverse-electron-demand Diels-Alder (IEDDA) reaction between (cyclic) alkenes and tetrazines has 
been well-studied for several decades.1–8 Scientific interest spiked in 2008, due to the breakthrough of 
tetrazine ligation in the field of bioorthogonal chemistry.9,10 Bioorthogonal ligation handles require an 
intricate balance between several physical properties. Preferably the handle should be sterically small in 
size and be stabile under physiological and preparative conditions, while maintaining high reactivity 
towards tetrazines. An additional beneficial property is the moderate- to high hydrophilicity, to assist the 
water solubility of the functionalized chemical probe. By now, a strong positive correlation had been 
established between the ring-strain within cyclic alkenes and enhanced reactivity towards tetrazines.5 
Although surprising, considering the nature of the reaction, significantly less effort has been directed 
towards studying the effects of alkene electron density on reactivity. Chapter 5 describes a new compact 
ligation handle featuring an N-acylazetine as the reactive partner, which was designed to utilize both ring-
strain and electron donating properties to enhance reactivity towards tetrazines.8 A reactive N-acylazetine 
tag was synthesized and successfully applied in an activity-based protein profiling experiment. These 
advancements warranted further investigation into the structure-reactivity relationship of the N-alkene 
structure. This chapter describes the synthesis of various N-vinyl derivatives (Figure 1, 3-7) and the 
empirical assessment of their stability and reactivity towards tetrazines. By comparing the reaction-rate 
constants with those of model N-acylazetines 1 and 2, fundamental insight could be gained in the 
contribution of both ring-strain and electron donating effects on the tetrazinophilicity. Ultimately this 
knowledge may lead to improved handles for the tetrazine ligation strategy. 
 
 
 Figure 1: The N-acylazetine and five model N-vinyl derivatives. 
Reaction Rates of Various Acylenamines in the 




As entries for the reaction-rate comparative study the N-vinylamide (3), N-vinylcarbamates (4 and 5) and 
N-vinylurea (6 and 7) were considered. As a result of the tautomerization equilibrium between the amine 
and imine form, these N-vinyl groups are simultaneously electrophilic at the α-carbon and nucleophilic at 
β-carbon.11 This ambivalent nature makes them susceptible to hydrolysis, or polymerization in either acid 
catalyzed or radical mediated processes.12,13 Alkylation at the nitrogen of the N-vinyl derivatives stabilizes 
the groups by preventing tautomerization. In addition, an analysis of the N-acylazetine core reveals that 
a disconnection between the N-CH2 and the N-vinyl-β-CH1 leads to the N-methyl-N-vinylamide (3) 
structure. With these considerations in mind,  one can view methylation at the vinyl nitrogen of the earlier 
suggested N-vinyl derivatives as a logical modification that more thoroughly isolates the effects of the 
ring-strain during the comparative IEDDA reaction-rate study, while at the same time stabilizing the N-
vinyl group. Morpholine based nucleophiles were chosen in the preparation of the N-vinylcarbamate and 
-urea analogue to ensure the required water solubility for the kinetic experiments. 
 
Results and Discussion 
Commercially available N-methyl-N-vinylamide (3) was considered a convenient model substrate to study 
the influence of ring-strain and was directly used in IEDDA kinetic experiments. Literature provides several 
methods for the preparation of N-vinylcarbamates.14–18 The most prevalent strategy makes use of the 
Curtius rearrangement of acryl azide (9), in situ generated from acryloyl chloride (8) and sodium azide 
(Scheme 1). Through heating the acryl azide rearranges to vinyl isocyanate (10), which can react with an 
alcohol of choice to provide an N-vinylcarbamate. A small amount of base and radical scavenger, such as 
hydroquinone or phenothiazine, is added to suppress dimerization and radical polymerization. Following 
this strategy, a solution of acryl azide in toluene was prepared and slowly added to a reaction mixture 
containing 2-morpholinoethanol, pyridine and hydroquinone in toluene at 100 ˚C, providing N-
vinylcarbamate 4 in 29% isolated yield. The vinyl nitrogen was methylated with sodium hydride and 
methyl iodide in THF at 0 ˚C, to give N-methyl-N-vinylcarbamate 5. 
 
 
Scheme 1: Overview of research conducted for the synthesize N-vinyl derivatives 5 and 6 via  Curtius rearrangement. 
Reagents and Conditions: [a] NaN3, H2O/Toluene (1:1), 6h. [b] Pyridine, hydroquinone, 100 ˚C, 1.5h. [c] 2-
morpholinoethanol, toluene, 1h. [d] i: NaH, THF, MeI, 0 ˚C, 1.5h, 75%. [e] Morpholine, toluene, 1h.   
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In this transformation, substituting 2-morpholinoethanol for morpholine should theoretically result in N-
vinylurea 6. However, considering the discussed ambivalent reactivity and the lack of literature reports 
supporting the N-vinylurea structure, this class of compounds is likely too unstable to be isolated under 
preparative conditions. Indeed, no product could be isolated when morpholine was reacted with in situ 
generated vinyl isocyanate (10). Alternatively, carboxylic acids can be converted into isocyanates using 
the milder Lossen rearrangement (Scheme 2).19 Using this method, acrylic acid (11) was converted into 
acryl hydroxamide (12) via a carbonyldiimidazole-assisted (CDI) condensation. In situ activation of the 
hydroxamide 12 with CDI generated dioxazalone intermediate 13, which was expected to decarboxylate 
into vinyl isocyanate upon heating to 80 ˚C in acetonitrile. Again, attempts to capture the vinyl isocyanate 
with morpholine were unsuccessful. In a final attempt to synthesize a vinyl urea derivative, efforts were 
made to directly prepare the more stable N-methylated derivative 7 (Figure 1). Derived from the 
optimized synthesis for the N-acylazetines (Chapter 5), it was considered that the N-vinyl urea could be 
accessed through tosylate elimination. In a one-pot procedure, phosgene was unsymmetrically 
functionalized with morpholine and N-methylethanolamine, to provide urea 15. However, tosylation of 
the primary alcohol lead to degradation into various side-products. With these final results, the synthesis 
of the urea derivatives (6 and 7, Figure 1) was abandoned. 
 
 
Scheme 2: Alternative methods explored for the synthesis of N-vinylurea 6. Reagents and Conditions: [a] i: CDI, 
MeCN, 1.5h. ii: NH2OH·HCl, 2h, used crude. [b] CDI, 0.5h. [c] Morpholine, 60 ˚C, 1h. [d] Morpholine, Et3N, DCM, 
0 ˚C » Phosgene in toluene, 1h. 51% [e] TsCl, Et3N, DCM, 0 ˚C, 16h. 
 
Considering the discussed reactivity of N-vinyl compounds, the influence of potential degradation of these 
substrates during both the kinetic experiments and biorthogonal tagging reactions had to be excluded. 
The aqueous stability of N-acylazetine 2 and N-vinylcarbamates 4 and 5 was evaluated by dissolving the 
respective compounds in deuterated water and monitoring the solution over a 13 hour period at 37 ˚C 
through 1H-NMR spectroscopy. After the full duration, secondary N-vinylcarbamate 4 showed 4% 
hydrolysis of the vinyl group, as determined by integration of the formyl hydrogen (δ = 9.74) resulting 
from the formed acetaldehyde. Fortunately, this rate of decomposition proved to be insignificant within 
the thirty minute timeframe required for the kinetic experiments (Table 1). N-acylazetine 2 and N-
vinylcarbamate 5 proved to be stable during the experiment. In addition, the N-acylazetine group stability 
was evaluated in the presence of 100 mM of ethanethiol and 2-aminoethanol, to mimic the physiological 




With the N-acylazetines 1, 2 and N-vinyl derivatives 3, 4, 5 in hand, the stage was set for determining the 
rate of their reaction with tetrazine 17 (Chapter 5). For comparative purposes the same conditions were 
used as reported by Devaraj et al in their work featuring the 1-methylcyclopropene ligation handle.20 The 
pseudo-first-order and second-order reaction-rates were assessed by reacting a ten-fold excess of the 
respective dienophile with tetrazine 17 in 12% aqueous DMSO. The rate of tetrazine consumption was 
measured by monitoring the characteristic tetrazine absorption at 517 nm. Each experiment was 
conducted thrice at both room temperature (RT = 20 ˚C) and cell temperature (CT = 37 ˚C). The results are 
summarized in Table 1. 
 
Table 1: Reaction-rates for addition of various dienophiles to tetrazine 17. The first-order reaction rates were calculated from 
three data sets each using all measurement intervals up until t1/2. The errors ranges are the standard deviations derived from the 
generated first-order rate data. Half-life values are calculated from first-order rate constant: t1/2 = ln(2) / k. 
 
 
# Dienophile T (˚C) 1st Order (s-1) 2nd Order (M-1·s-1) Half-life (s) 
1 
 
20 4.10 · 10-3 ± 3.71 · 10-4 6.88 · 10-1 ± 6.23 · 10-2 169 
37 7.11 · 10-3 ± 8.95 · 10-5 1.21 ± 1.42 · 10-2 97 
2 
 
20 4.40 · 10-3 ± 1.57 · 10-4 7.50 · 10-1 ± 2.62 · 10-2 157 
37 7.78 · 10-3 ± 4.25 · 10-5 1.32 ± 7.40 · 10-3 89 
3 
 
20 3.12 · 10-4 ± 2.16 · 10-6 5.27 · 10-2 ± 3.67 · 10-4 2223 
37 5.05 · 10-4 ± 1.68 · 10-6 8.54 · 10-2 ± 2.88 · 10-4 1372 
4 
 
20 1.27 · 10-3 ± 2.04 · 10-5 2.16 · 10-1 ± 3.48 · 10-3 544 
37 1.97 · 10-3 ± 9.34 · 10-5 3.34 · 10-1 ± 1.59 · 10-2 351 
5 
 
20 7.53 · 10-4 ± 8.54 · 10-6 1.27 · 10-1 ± 1.44 · 10-3 920 
37 1.63 · 10-3 ± 4.65 · 10-5 2.76 · 10-1 ± 7.90 · 10-3 424 
 
Chapter 5 describes the synthesis and reaction kinetics at RT of model N-acylazetine 2. To further establish 
the N-acylazetine reaction-rate data, the experiments were repeated and supplemented with the four-
carbon variant 1 and include CT rates. The data shows that shortening the spacer length by one carbon 
results in minor decrease in reaction-rate, which can be explained by the increased proximity of the 
electron withdrawing carbonyl group relative to the azetine moiety. When comparing the reaction rates 
for  N-acylazetine 2 and N-vinylamide 3, the influence of ring-strain can be assessed. Evidently, ring strain 
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contributes significantly to the reaction rate, as the acyclic N-vinylamine results (both at RT and CT) in a 
15-fold increase in half-life time. A similar comparison between 3 and 5 reflects the increase in electron 
density by progressing from an N-vinylamide to an N-vinylcarbamate. Here the results show that an 
approximate 2.8-fold decrease in half-life time, considerably less impactful than the effects induced by 
ring-strain. Methylation at the nitrogen of 5 into secondary N-vinylamide 4 only induces a minor (1.5-fold) 
increase in half-life time.  
 
Conclusion 
This chapter describes an investigation into the contribution of ring-strain and electron donating effects 
upon the IEDDA reactivity of acylenamines towards tetrazines. To this end, efforts were made to prepare 
N-vinyl derivatives 4-7 to allow a comparison with the N-acylazetine 1 and 2. N-vinylcarbamate 4 and 5 
could accessed through the Curtius rearrangement of acryl azide. The synthesis of N-vinylureas 6 and 7 
was unsuccessful via a similar approach. Alternative attempts, involving the Lossen rearrangement and 
elimination of tosylate, were also unfruitful. The IEDDA rate constants were determined for N-acylazetine 
1 and 2 and N-vinyl compounds 3-5 at 20 ˚C and 37 ˚C. Comparison between the reaction rates of N-
acylazetine 2 and N-vinylamide 3 shows a 15-fold higher reaction rate for the four-membered ring. The 
influence of the differences in electron donation between a N-vinylamide and a N-vinylcarbamate (5) was 






General: All solvents and reagents were obtained commercially and used as received. Reactions were 
executed at ambient temperatures unless stated otherwise. Reactions were monitored by TLC‐analysis 
using Merck aluminum DC Silicagel 60 F254 with detection by spraying with various sprays; an aqueous 
solution of cerium molybdate ((NH4)6Mo7O24·4H2O 25 g/L) or an aqueous solution of potassium 
permanganate (5 g KMnO4, 25 g K2CO3 per L). Column chromatography was performed on Fluka silicagel 
(0.04 – 0.063 mm). 1H and 13C-APT spectra were recorded on a Bruker AV-400 (400 MHz), Bruker DMX-
600 (600 MHz) or Bruker BioSpin (850 MHz). All present 13C-APT spectra are proton decoupled. The high 
resolution mass spectrometry were recorded by direct injection (2 µL of a 2µM solution in 
water/acetonitrile; 50/50; v/v and 0.1% formic acid) on a mass spectrometer (Thermo Finnigan LTQ 
Orbitrap) equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas 
flow 10, capillary temperature 250 ˚C) with resolution R = 600000 at m/z 400 (mass range m/z = 120-400). 
 
 
Acryloyl Azide (9): Acryloyl chloride (10 mmol, 0.81 mL, 1 eq) in toluene (1.3 mL) was added to an ice-
cooled solution of NaN3 (683 mg, 10.5 mmol, 1.05 eq) in water (2.5 mL). The ice-bath was removed and 
the two-layered reaction mixture was stirring vigorously for 4 hours. Toluene was added (1.3 mL) and the 
mixture was poured into a separation funnel and washed twice with saturated aqueous sodium hydrogen 
carbonate, twice with water and once with brine. The organic layer was dried over magnesium sulfate, 




2-Morpholinoethyl vinylcarbamate (4): A solution of hydroquinone (55 mg, 0.5 mmol, 0.05 eq), pyridine 
(36 μL, 0.5 mmol, 0.5 eq), N-ethoxymorpholine (20 mmol, 2.4 mL, 2 eq) in toluene (2 mL) was put under 
argon atmosphere and heated to 100 ˚C. The prepared solution of acryloyl azide in toluene was added 
dropwise over one hour. After complete addition, the reaction mixture was stirred for an additional 30 
minutes at 100 ̊ C, before being allowed to cool to RT. The mixture was filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (0% » 5% EtOH/DCM), yielding vinylcarbamate 
4 as a yellow oil. (2.85 mmol, 570 mg, 29% over two steps). 1H NMR: (400 MHz, CDCl3) δ 7.19 (s, 1H), 6.62 
(dt, J = 15.8, 10.0 Hz, 1H), 4.41 (d, J = 15.8 Hz, 1H), 4.21 (d, J = 8.9 Hz, 1H), 4.20 – 4.13 (m, 2H), 3.71 – 3.61 
(m, 4H), 2.60 – 2.52 (m, 2H), 2.44 (s, 4H). 13C NMR: (101 MHz, CDCl3) δ 153.68, 129.99, 93.23, 66.69, 61.80, 





2-Morpholinoethyl methyl(vinyl)carbamate (5): Sodium hydride (60% in mineral oil, 2.4 mmol, 96 mg, 1 
eq) was added potion-wise to a solution of vinylcarbamate 4 (2.4 mmol, 480 mg, 1 eq) in dry THF (8 mL), 
under argon atmosphere. The reaction mixture was sonicated until hydrogen evolution ceased. The 
reaction mixture was cooled to 0 ˚C and methyl iodide (2.52 mmol, 0.16 mL, 1.05 eq) was added. The 
reaction mixture was stirred for 1.5 hours, quenched with Et3N·HCl and concentrated in vacuo. The crude 
product was purified by column chromatography (2% » 5% EtOH in DCM), yielding N-methyl-
vinylcarbamate 5 as a yellow liquid. (1.81 mmol, 387 mg, 75%). 1H NMR: (400 MHz, CDCl3) δ 7.24 – 7.01 
(m, 1H), 4.37 – 4.15 (m, 4H), 3.76 – 3.59 (m, 4H), 3.01 (s, 2H), 2.65 (t, J = 5.8 Hz, 2H), 2.54 – 2.38 (m, 4H). 
13C NMR: (101 MHz, CDCl3) δ 134.20, 133.51, 91.95, 66.86, 63.42, 57.25, 53.80, 30.23. HRMS: Calculated 
for C7H18N2O3 215.13957 [M+H]+; found 215.13911. 
 
 
N-(2-hydroxyethyl)-N-methylmorpholine-4-carboxamide (15): A solution of morpholine (5 mmol, 0.43 
mL, 1 eq) and Et3N (10 mmol, 1.4 mL, 2 eq) in dry DCM (37.6 mL) was prepared under argon atmosphere. 
Phosgene (1.9M solution in toluene, 2.9 mL, 1.1 eq) was added dropwise over 1 hour. The reaction mixture 
was allowed to warm to RT and stirred for additional 15 minutes. The reaction was quenched by the 
addition of MeOH and concentrated in vacuo. The residue was redissolved in MeCN (25 mL) and 2-
(methylamino)ethanol (5.5 mmol, 0.44 mL, 1.1 eq), DIPEA (5 mmol, 0.87 mL, 1 eq) and DMAP (5.5 mmol, 
672 mg, 1.1 eq) were added. The reaction mixture was heated to 45 ˚C and left stirring for 2 hours. The 
reaction mixture was concentrated in vacuo and the crude product was purified by column 
chromatography (49% Acetone in DCM + 1% MeOH » 46% Acetone in DCM + 4% MeOH), yielding 
compound 15 as a yellow oil (2.55 mmol, 480 mg, 51%). 1H NMR: (300 MHz, CDCl3) δ 4.42 (s, 1H), 3.77 – 
3.71 (m, 2H), 3.69 – 3.63 (m, 4H), 3.37 – 3.30 (m, 2H), 3.28 – 3.20 (m, 4H), 2.89 (s, 3H). 13C NMR: (75 MHz, 
CDCl3) δ 165.66, 66.68, 60.26, 52.09, 49.83, 47.26, 37.03.  
 
 
Kinetic Data Plots 
A 0.6 mM stock solution of tetrazine 17 in 12% DMSO:H2O (v:v) was prepared and 1mL was transfered 
into a quarts cuvette (10 mm width, 3 mL volume) equipped with a small magnetic stirrer. The cuvette 
was placed in the measurement chamber of a Cary 300 UV-Vis spectrophotometer (Agilent Technologies). 
A 12 mM solution of the corresponding probe (1-5) was prepared in 12% DMSO:H2O (v:v), of which 1 mL 
was transfered to the cuvette. The measurement was immediately started upon closing the chamber. The 
absorption decay was followed at 517 nm. The experiments were conducted at climate controlled room 
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temperature (20 ˚C) and at cell temperature (37 ˚C). For experiments conducted at cell temperature, the 
probe solutions were pre-heated in a stove, while the tetrazine solution was warmed by a Cary 
Temperature Controller (Agilent Technologies).   
The reaction rate was derived from three data sets using every measurement interval from the start 
until the second of the three runs reached 50% of the starting absorption. The datasets following from 
the experiments were subjected to the LINEST function (Microsoft Excel 2013) to determine the slope and 
the standard deviation for both pseudo first- and second order rate constant. The slope represents 
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Phosphate esters are ubiquitous functionalities in a wide variety of fundamental biochemical processes, 
from interlinking the nucleotides in our DNA, to protein regulation and cellular respiration. Therefore, it 
is not surprising that all four major biomolecules are directly, or indirectly, subjected to various types of 
phosphorylation reactions. A specific example of a post-translation modification that involves phosphate 
esters is adenosine diphosphate ribosylation (ADP-ribosylation). This post-translation modification (PTM) 
is regulated by ADP-ribose transferases that utilize NAD+ as a glycosyl donor and transfer one (mono) or 
more (poly) ADP-ribose residues onto a nucleophilic heteroatom of an acceptor biomolecule. In humans, 
both mono(ADP)ribosylation and poly(ADP)ribosylation are modifications primarily introduced by 
enzymes of the PARP family. Particularly the PARylation processes of PARP-1, PARP-2 and PARP-3 have 
become subject of scientific interest due to their roles in DNA damage repair, inflammation, telomere 
maintenance and regulation of apoptosis. During PARylation, ADP-ribose oligomer grows on a nucleophilic 
amino acid residue, either in the auto-modification domain of PARP itself or that of another target protein, 
to form linear or branched chains of poly-ADP-ribose, consisting of up to 200 monomeric units. The 
produced dendritic ADPR-polymer triggers a conformational change that is essential to the respective 
biological event, such as the recruitment of DNA repair enzymes. Synthetic organic chemistry has already 
provided access to structurally well-defined ADP-ribosylated oligopeptides and poly-ADPr fragments, and 
thereby helped advance our understanding of this important PTM. However, these native constructs 
contain labile functionalities, such as the pyrophosphate moiety and glycosidic bond, which can constrain 
both synthesis and biological application due to their susceptible to hydrolytic or enzymatic degradation. 
An organic chemical approach to address such limitations is to introduce chemical modifications that 
stabilize specific labile bonds, while retaining similar overall physical and chemical properties. The 
research described in this Thesis focuses on the development of new molecular tools aimed to facilitate 
the study of the adenosine diphosphate ribosylation PTM, with an emphasis on stabilizing the 
aforementioned labile functionalities. In this context new reagents and methodology have been 
developed for the synthesis of stabilized pyrophosphorylated bioisosteres.  
 




Figure 1: The two primary reagents designed to introduce methylene 
bisphosphonates in biomolecules described in Chapter 2 and 3.  
 
Chapter 2 discusses a new class of orthogonally protected phosphanylmethylphosphonate reagents 
that have been developed for the controlled synthesis of methylene bisphosphonate monoesters. 
Methylene bisphosphonates are stabilized analogues of pyrophosphates in which the oxygen atom, 
conjoining the two phosphates in the original pyrophosphate, is replaced by a methylene to provide 
resistance to cleavage. After refinement of reactions conditions, the phosphanylmethylphosphonate 
reagents became readily accessible through a one-pot procedure by reacting a lithiated 
methylphosphonate diester with a chlorophosphoramidite. Condensation of the presented reagents with 
an alcohol of choice through azole‐mediated phosphoramidite chemistry, followed by in situ oxidation, 
efficiently provides orthogonally protected methylene bisphosphonate tetraesters. Global deprotection 
of the acquired tetraester yields the respective terminal methylene bisphosphonate. Using these 
reagents, several methylene bisphosphonate analogues of biologically relevant nucleoside di- and 
triphosphates where synthesized. In addition, the method has proven to be compatible with solid-phase 
chemistry.  
The research described in Chapter 3 expands on that of Chapter 2, by adopting the concept to the 
synthesis of unsymmetrical methylene bisphosphonates. This uses a second generation of the reagent, 
which is protected with two methyl groups and a single tert-butyl protective group at the PV. After 
installment of the first alcohol, using the phosphoramidite coupling-oxidation sequence, the terminal tert-
butyl in the methylene bisphosphate tetraester is selectively cleaved. This allows for introduction of a 
second alcohol, through PyNTP-mediated condensation, yielding the protected methylene bisphosphate 
with two different alkyl substituents at its termini. Subsequent global deprotection via a two-step-one-
pot procedure provides the respective unsymmetrical methylene bisphosphate. The power of this 
methodology was demonstrated in the synthesis of the methylene bisphosphonate analogues of ADPR 
and flavin adenine dinucleotide (FAD). 
The lithiation conditions used during the assembly of the phosphanylmethylphosphonate reagent 
prevent the direct installment of base labile protecting groups at the phosphonate end of the molecule. 
This restriction in orthogonality limits the scope to acid stable substrates, as exemplified by the 
degradation of the methylene bisphosphonate analogues of farnesyl pyrophosphate and isopentenyl 
pyrophosphate during tert-butyl cleavage (Chapter 2; Scheme 6). A strategy to circumvent this limitation 
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can be envisioned in the implementation of 2-hydroxyethyl methyl sulfide as a “masked” base-labile 
protecting group. In order to synthesize prenoids the phosphonate could be fitted with two 2-
hydroxyethyl methyl sulfide moieties (1), then lithiated and reacted with bis(diisopropylamino) 
chlorophosphoramidite to provide  2, which in turn would be converted to reagent 3 (Scheme 1). During 
the phosphanyl coupling-oxidation sequence, an additional oxidation step would be added to fully oxidize 
the thioether. This could be achieved selectively by treatment with hydrogen peroxide in the presence of 
cyanuric chloride.1 The resulting sulfonyl (4) is now susceptible to base mediated β-elimination, similarly 
to the cyanoethyl. 
 
 
Scheme 1: Proposed variant of the phosphanylmethylphosphonate reagent, which makes use of a “masked” base-labile 
protecting group 2-hydroxyethyl methyl sulfide. The group becomes base cleavable after oxidation to the corresponding sulfone. 
 
Chapter 4 describes the synthesis of a stabilized analogue of a mono-ADP-ribosylated N-terminal 
peptide of histon H2B, which is a relevant fragment involved in the ADP-ribosylation process triggered by 
single-strand DNA damage. The Glu-2, corresponding to the native H2B conjugate, is a well-studied site of 
ADP-ribosylation. Previous attempts at synthesizing the native conjugate were unsuccessful due to the 
propensity of the anomeric glutamyl ester to migrate. The migration can be circumvented by instalment 
of glutamine as a glutamate bioisostere, effectively substituting the more stable amide bond for the ester. 
However, this form of stabilization does not fully exclude epimerization or (acidic) hydrolysis. The intrinsic 
lability of the glycosidic bond primarily stems from the oxocarbenium resonance enabled by the adjacent 
ring-oxygen. Therefore, a carba-riboside was incorporated as a stabilized replacement of the naturally 
occurring riboside. A new synthesis towards the α-carba-ribosylamine was developed. D-Ribose was 
converted into a protected 5-iodoriboside and subjected to a tandem fragmentation-vinylation reaction. 
The diallylic product was ring-closed and oxidized, providing cyclopentenone precursor 6. Ensuing 
photochemical addition of methanol, to install the C5-CH2OH, efficiently produced the carba-
ribonolactone core structure. The ketone was converted into a methoxyimine and stereoselectively 
reduced to obtain the pseudo-anomeric α-configured amine (7). Coupling of the amine with a glutamic 
acid derivative, followed by deprotection and phosphorylation of the C5-OH afforded final carba-
ribosylated glutamine building block 8. Incorporation of the building block into the H2B conjugate 
fragment was achieved through solid-phase peptide synthesis. On-resin phosphorylation of the carba-
ribosyl phosphate was used to construct the ADP-pyrophosphate. Successive global deprotection and 
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release from resin provided the target mono-ADP-carba-ribosylated H2B conjugate 9 in multi-milligram 
amounts. 
 
Scheme 2: Summarized synthesis of the mono-ADP-carba-ribosylated H2B conjugate described in Chapter 4. 
 
Given the established usefulness of synthetic MARylated oligopeptides as tools for studying the ADP-
ribosylation PTM2, it is not unreasonable to think that improving accessibility to such constructs would 
benefit the field of biochemistry. In this context shelf-stable pre-ADP-ribosylated amino acids, that are 
compatible with standard solid phase peptide chemistry, could be envisioned as powerful tools to provide 
convenient access to a wide variety of MARylated oligopeptides. However, both the anomeric linkage and 
pyrophosphate bridge presented in native construct would pose incompatibility with SPPS. Chapter 4 
presents a solution for the former, while the chemistry described in Chapter 2 and 3 could be adopted to 
incorporate a methylene bisphosphonate to address the latter. This would require an iteration of the 
phosphanylmethylphosphonate reagent fitted with protecting groups that are orthogonal with Fmoc-
based SPPS (Figure 2). The use of two p-methoxybenzyl groups in combination with the masked base-
labile protecting group strategy described above is expected to present the desired orthogonality. The 
resulting reagent 10 is then first to be coupled to an adenosine protected with acid-cleavable groups (11). 
This order of installment would be mandatory due to incompatibility of base-labile MSE group with the 
integrity of the Fmoc-protection. After basic removal of the MSE, the protected me-ADP can be condensed 
with the appropriate carba-ribosylated asparagine or glutamine (12), which itself is easily accessible from 
7 (Scheme 2). Final selective removal of the allyl, by Pd(PPh3)4, would yield the respective pre-ADP-
ribosylated amino acid (13). Building blocks of this design are expected to be compatible with the standard 
Fmoc-based SPPS. After incorporation into an oligopeptide of choice, the Boc, PMBs and isopropylidene 






Figure 2: Retrosynthetic analysis of the proposed pre-ADP-ribosylated building block designed for SPPS. 
 
In the same context of facilitating PARylation related research, Kistemaker et al developed a synthetic 
route for the synthesis of structurally well-defined native ADP-ribose oligomers.3 The methodology 
employs a pre-phosphorylated disaccharide building block to construct the PAR-polymer via on-resin 
phosphorylation reactions, similar to that described for compound 9. An interesting point of continuation 
would be to combine this disaccharide approach with the methylene bisphosphonate chemistry described 
in Chapter 2 and Chapter 3. The envisioned building block 14 (Figure 3) could be polymerized onto a resin 
bound peptide via block synthesis, to result in a methylene bisphosphonate enriched PARylated peptide. 
First, the disaccharide would have to be functionalized with a methylene bisphosphonate, which is 
proposed to be done via the phosphanylmethylphosphonate-based methodology. Difficulty arises from 
finding the correct orthogonality, since the glycosidic bond in 2’-O-ribosyladenosine is incompatible with 
strong acidic conditions. A benzyl at the PV-position and two masked MSE groups are envisaged as suitable 
protecting groups for the phosphanylmethylphosphonate reagent (similar to 10 in Figure 2). After 
installment of the reagent onto the adenosine 5’-OH, the benzyl would be cleaved reductively. While 
adhering to the published route, the 5’-OH of the 2’-O-ribosyl residue would at this stage be protected 
with a TIPS-group, which is to be exchanged for a DMT. It is however uncertain if the DMT-group can 
selectively be installed on the 5’-OH in the presence of  the methylene phosphoric acid triester. Although 
it is considered unlikely that the PV-OH would form a stabile bond with the DMT-moiety at all, the 
difference in stability between a PVO-DMT bond and a 5’-O-DMT is expected to be significant, and thus 
distinguishable. Alternatively, the reagent could be fitted with an allyl instead of the benzyl, which could 
be removed selectively over the DMT by applying a palladium catalyst. PAR assembly at the C5-OH of an 
immobilized carba-ribosylated peptide is envisioned to be possible by repetitive coupling cycles with 
building block 14; each cycle would consist of Pv-coupling, capping and DMT deprotection (Figure 3). In 
this instance phosphortriester-based chemistry has to be used for the solid-phase phosphorylative 
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elongations, over the more established phosphoramidite approach.4 Nevertheless, the viability of the 
phosphortriester approach has thoroughly been demonstrated by the solid-phase synthesis of DNA.5,6 
 
 
Figure 3: Proposed solid-phase synthesis of a methylene bisphosphonate enriched PARylated peptide. Building block 
14 is coupled to the terminal hydroxyl, following DMT deprotection to provide the hydroxyl for the succeeding cycle. 
 
Chapter 5 and Chapter 6 describe the development of new biorthogonal reagents. Bioorthogonal 
reactions are defined as selective reactions between two artificial moieties that are inert to the diverse 
spectrum of functional groups that reside in a biological system. These have significantly advanced the 
field of molecular biology providing tools to study biochemistry in living cells or even complete organisms, 
enabling the conjugation of functional moieties to proteins or the in vivo assembly of molecular tags used 
for imaging. In the same way, bioorthogonal chemistry has also proven to be a key component in the 
molecular toolbox used to unravel ADP-ribosylation processes. Various NAD+ analogues functionalized 
with a bioorthogonal handles have been developed and employed in the mapping of ADP-ribosylation 
activity. The inverse-electron-demand Diels–Alder (IEDDA) reaction is the most recent addition to 
bioorthogonal reactions. It involves a Diels–Alder reaction between an electron deficient tetrazine (diene) 
and strained alkene or alkyne. The main advantage of the IEDDA reaction is that it exhibits the fastest 
reaction kinetics among bioorthogonal reactions, while the main disadvantages are that both the tetrazine 
and most reactive dienophiles are relative lipophilic and sterically encumbered. These properties may 
have a negative effect on both water solubility and the biological response of the functionalized 
molecules. The contemporary IEDDA dienophiles – norbornene, trans-cylcooctene and cyclopropene – 
use ring strain to acquire the desired reactivity towards tetrazines.  
Chapter 5 describes a new compact bioorthogonal ligation handle suitable for IEDDA ligation strategy, 
based on the N-acylazetine core. This moiety was envisioned as the smallest viable structure that could 
utilize ring-strain in conjunction with the electron-donating properties to increase the dienophilicity. The 
initial five-step synthesis started by reacting benzhydrylamine with epichlorohydrin, to afford the 
protected azetidine core. Mesylation of the alcohol, followed by benzhydryl cleavage, yielded 3-
mesylazetidine hydrochloride. Application of the former in the ring-opening of glutaric anhydride 
provided a linker that is sutable to attach the N-acylazetine to a biomolecule via an amide bond. In a one-
pot procedure, the mesyl-moiety was eliminated by KOtBu, to install the double bond, and the carboxylate 
was converted into either the pentafluorophenol or p-nitrophenol activated ester (PNP). The PNP-tag was 
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used to create a model compound to determine the reaction kinetics with tetrazine. The N-acylazetine 
showed a second-order rate constant of 0.39 ± 0.1 s−1 M−1; a value comparable to that of the 
methylcyclopropene mini-tag. Secondly, the handle was used to functionalize epoxomicin (a broad-
spectrum proteasome inhibitor), which in turn was used to successfully label the proteasome through 
tetrazine ligation. Because the practicality of a ligation handle is highly dependent on its synthetic 
accessibility, efforts were redirected at optimizing the synthesis. However, several key steps in the original 
synthesis proved to be constraining to the overall efficiency and scalability. Therefore it was opted to 
develop a new synthetic route, in which 3-hydroxyazetidine was first N-Boc-protected and then tosylated. 
The tosyl group was selected for it is UV-detectable, has a lower polarity and a better leaving-group 
capacity. After deprotection of the nitrogen, the resulting azetidine was used to ring-open succinic and 
glutaric anhydride, yielding the respective four- and five-carbon spacers. Elimination proceeded smoothly 
at room temperature due to the improved solubility of the tosylated hydroxyazetidine. The thus obtained 
N-acylazetine carboxylate intermediates were converted in situ into the corresponding PNP-esters by 
addition of bis(p-nitrophenyl)-carbonate. With this the N-azetine tags have become accessible through an 
efficient four-step synthesis.   
Chapter 6 is an extension of the work described in Chapter 5. The research described here delves 
further into the reaction kinetics, separating the effects of electron induction and ring-strain on the 
reactivity of the N-acylenamines to tetrazines. To this end efforts were made to prepare model N-
acylazetines, N-vinylcarbamates, N-vinylureas and a N-vinylamide. The N-acylazetines were obtained by 
reacting the four- and five-carbon spacer PNP-esters with morpholine. The N-vinylcarbamates were 
accessed through the Curtius rearrangement of acryl azide. The various attempted synthesis of N-
vinylureas were unsuccessful due to their instability. Through a comparative study between N-
acylazetines, N-vinylcarbamates and an N-vinylamide it was shown that ring-strain has a more significant 
effect on the rate of the IEDDA cycloaddition of N-acylenamines to tetrazines than electron donation.  
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Fosfaatesters zijn functionele groepen die aanwezig zijn in tal van biologisch actieve moleculen die op hun 
beurt deelnemen aan een breed scala van fundamentele processen in organismen en in de daarbij 
behorende cellen. Het meest bekend zijn de fosfaatdiesters in DNA en RNA die de bouwstenen van 
nucleïnezuren of de nucleosiden onderling verbinden. Daarnaast komen verschillende klassen van 
fosfaatesters voor in moleculen die behoren bij de overige hoofdgroepen van biomoleculen, de eiwitten, 
koolhydraten en vetten. Fosforyleringen zijn reacties waarbij een fosfaatgroep op een specifieke positie 
in een biomolecuul wordt geïntroduceerd. Fosforylering van eiwitten in cellen bijvoorbeeld is een post-
translationele modificatie (PTM), waarbij het gefosforyleerde eiwit door deze reactie functioneel of juist 
inactief wordt.   Een belangrijke PTM, waar op het ogenblik veel onderzoek naar wordt verricht is 
adenosine difosfaat ribosylering (ADP-ribosylering). Gedurende dit cellulaire proces wordt met behulp van 
nicotinamide adenine dinucleotide (NAD+) één of meerdere adenosine difosfaat ribose eenheden 
enzymatisch covalent gebonden aan de nucleofiele zijketen van een specifieke aminozuur in een 
doeleiwit. In mensen worden zowel mono- als poly-ADP-ribosylering (PARylerings) hoofdzakelijk 
gekatalyseerd door enzymen behorend tot de PARP-familie. Vooral vanwege hun betrokkenheid bij DNA-
schadeherstel, ontstekingsreacties, genoom onderhoud en het reguleren van geprogrammeerde celdood 
is uitgebreid onderzoek gedaan naar PARP-1, PARP-2 en PARP-3 enzymen. Een PARylerings proces 
voorziet een doeleiwit van een polymeer die een lengte tot 200 ADP-ribose eenheden kan hebben. Het 
ADPR-polymeer brengt vervolgens de fysiologische verandering teweeg die benodigd is voor het 
betreffende biologische proces, bijvoorbeeld het rekruteren van een DNA-reparatie enzym. Een belangrijk 
onderzoeksdoel is het vergroten van het inzicht in mono- en poly-ADP-ribosylering processen. Eén van de 
benaderingen is de organische synthese van goed gedefinieerde ADP-geribosyleerde oligopeptiden en de 
toepassing daarvan om de hierboven genoemde cellulaire processen op moleculair niveau te bestuderen. 
Echter een eigenschap van natuurlijk voorkomende mono- en poly-ADP geribosyleerde eiwitten en 
fragmenten daarvan is dat deze chemisch instabiel zijn, waardoor zowel de synthese als de biologische 
toepasbaarheid worden beperkt. Een organisch chemische aanpak van dit probleem is het stabiliseren 
van de labiele chemische bindingen zonder dat biologische eigenschappen van het oorspronkelijke 
molecuul sterk worden aangetast. Het onderzoek beschreven in dit proefschrift richt zich op het 
ontwikkelen van gestabiliseerde ADP-geribosyleerde fragmenten, om het biochemische onderzoek naar 
ADP-ribosylering te faciliteren. In deze context zijn onder andere nieuwe reagentia ontwikkeld voor het 
synthetiseren van gestabiliseerde pyrofosfaatesters.  
In Hoofdstuk 1 worden een aantal biochemische aspecten van het PARP gekatalyseerde ADP-
ribosyleringsproces toegelicht. Om het ADP-ribosyleringsproces op moleculair niveau te bestuderen zijn 
synthetische fragmenten van natuurlijk voorkomende ADP-geribosyleerde eiwitten niet altijd geschikt. De 
oorzaak hiervan is de instabiliteit van de volgende structuurelementen in deze moleculen; de 
pyrofosfaatbrug, de glycosidische band tussen de adenosine en de riboside, en de binding die het 
anomere centrum van ribose met de zijketen van het aminozuur verbindt. Dit inleidend hoofdstuk geeft 
een overzicht van verschillende gestabiliseerde analoga die hebben bijgedragen aan het ophelderen van 
het ADP-ribosyleringsproces. Ook wordt de synthese en modus operandi van een aantal gestabiliseerde 
analoga behandeld. Vervolgens worden methyleenbisfosfonaten geïntroduceerd als gestabiliseerde 
analoga voor pyrofosfaten. In methyleenbisfosfonaten is het zuurstofatoom, dat de twee fosfor atomen 
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in pyrofosfaten verbindt, vervangen door een methyleengroep waardoor breukresistentie wordt 
verkregen. Een aantal gebruikelijke synthese strategieën en hun beperkingen worden besproken. Met 
deze uiteenzetting wordt duidelijk gemaakt waarom het ontwikkelen van nieuwe chemische methoden 
voor de synthese van gestabiliseerde ADPr-gerelateerde fragmenten wenselijk is. Tot slot wordt het 
belang van de bio-orthogonale chemie, die voor veel biologische vraagstukken breed wordt toegepast 
toegelicht voor het ADP-ribosyleringsonderzoek. Bio-orthogonale reacties maken het mogelijk om 
artificiële moleculen binnen het complexe milieu van levende cellen selectief met elkaar te verbinden. De 
meeste recente ontwikkeling is de IEDDA-reactie die de grootste reactiesnelheidsconstante heeft. Hierbij 
reageert een alkeen onder ringspanning met een tetrazine, waarbij de twee covalent verbonden worden. 
Meestal zijn de hiervoor geschikte alkenen omvangrijk. Deze eigenschap is nadelig voor de 
wateroplosbaarheid en biologische beschikbaarheid van het gefunctionaliseerde molecuul. Hieruit kan 
worden opgemaakt dat het ontwikkelen van kleine, polaire alkenen waardevol kunnen zijn. 
Hoofdstuk 2 beschrijft orthogonaal beschermde fosfanylmethylfosfonaten als reagentia voor de 
gecontroleerde synthese van methylbisfosfonaat monoesters. Na optimalisatie van de reactiecondities 
zijn de fosfanylmethylfosfonaat reagentia toegankelijk geworden via een één-kolf procedure; reactie van 
een gelithieerd methylfosfonaatdiester met een chlorofosforamidiet. Onder invloed van een azole kan 
het zo gevormde reagens gekoppeld worden aan een alcohol naar keuze, waarna het product direct 
geoxideerd wordt om zo de volledig beschermde methylfosfonaattetraester op efficiënte wijze te 
verkrijgen. Ontscherming van de fosfonaat-groepen leidt tot de gewenste eindstandige 
methylbisfosfonaat monoester. De praktische toepasbaarheid van de reagentia werd gedemonstreerd 
door de synthese van de methylbisfosfonaat analoga van verscheidene biologisch relevante di- en 
trifosfaten. Bovendien bleek de methodologie ook geschikt voor vaste-drager synthese. 
Het onderzoek beschreven in Hoofdstuk 3 bouwt voort op datgene wat beschreven wordt in hoofdstuk 
2. Hier wordt een tweede generatie van het reagens gebruikt om complexere niet-symmetrische 
methylfosfonaatdiesters te synthetiseren. Het ontwikkelde reagens maakt gebruik van een aangepast 
patroon van beschermgroepen, bestaand uit twee methyl groepen en een tert-butyl groep aan de PV. Na 
koppeling aan een eerste alcohol, door middel van de in hoofdstuk 2 beschreven koppeling-oxidatie 
sequentie, wordt de eindstandige tert-butylgroep selectief afgesplitst. Hierna kan een tweede alcohol 
worden geïnstalleerd via een PyNTP-gedreven condensatiereactie. Afsplitsing van alle beschermgroepen 
leidt tot de respectievelijke niet-symmetrische methylfosfonaatdiester. De potentie van deze 
methodologie werd gedemonstreerd door de synthese van methylbisfosfonaat analoga van ADPR en 
flavine adenine dinucleotide. 
In Hoofdstuk 4 wordt de synthese van een gestabiliseerd mono-ADP-geribosyleerd H2B oligopeptide 
beschreven. Het H2B eiwit is betrokken in het ADP-ribosyleringsproces dat optreedt als gevolg van DNA-
schade. Eerdere pogingen om het natuurlijk voorkomende conjugaat te synthetiseren zijn niet geslaagd, 
doordat de anomere binding tussen de ribose en het aminozuur migreerde, hydrolyseerde of 
anomeriseerde. Deze nevenreacties zijn een gevolg van de labiliteit van anomere esters. Door de 
ringzuurstof in de ribose te vervangen door een methyleengroep wordt een aanzienlijk stabieler molecuul 
verkregen. Een dergelijk analoog wordt ook wel een carba-riboside genoemd. Een nieuwe syntheseroute 
naar de α-carba-ribosylamine werd ontwikkeld. D-Ribose werd omgezet naar een beschermde 5-iodo-
riboside en vervolgens onderworpen aan een fragmentatie-vinyladditie sequentie. Het diallylische 
product werd ring-gesloten en geoxideerd tot een cyclopentenon bouwsteen. Onder fotochemische 
condities werd methanol geaddeerd op de dubbele band, om zo op elegante wijze carba-ribonolacton, 
een voorloper van carba-riboside  te verkrijgen. Het keton werd geconverteerd naar het methoxyimine 
120 
 
en stereoselectief gereduceerd. Het verkregen α-amine werd gekoppeld aan een beschermd 
glutaminezuur derivaat. Na ontscherming werd op de 5-OH een di-tert-butyl fosfaattriester geïnstalleerd, 
waarmee de carba-geribosyleerde glutaminezuur bouwsteen werd verkregen. Deze werd ingebouwd in 
het H2B conjugaat via vaste drager peptide synthese. De pyrofosfaat werd vervolgens geconstrueerd door 
fosforylering van het geïmmobiliseerde carba-ribosylfosfaat met een beschermd adenosine 
fosforamidiet. Globale ontscherming, met gelijktijdige afsplitsing van de vaste drager, gaf het gewenste 
mono-ADP-carba-geribosylated H2B conjugaat in milligram hoeveelheden. 
Hoofdstuk 5 beschrijft de ontwikkeling van een nieuwe compacte ligatiegroep ter verbetering van de 
bio-orthogonale IEDDA ligatiestrategie. De N-acylazetine ligatiegroep kan worden beschouwd als de 
kleinst mogelijke structuur die in staat is om ringspanning te combineren met elektronen donerende 
eigenschappen, om zo de reactiviteit naar tetrazines te verhogen. Ook werd onderzoek verricht om deze 
ligatiegroep zo efficiënt mogelijk op een doelmolecuul aan te brengen. De N-acylazetinegroep werd 
daarom voorzien van een verbindingsmolecuul van vier of vijf koolstofatomen lang, die eindstandig een 
geactiveerde para-nitrofenyl ester bevat; een zogenaamde ligatiehandle. Hiermee kan het geheel 
eenvoudig aan aminegroepen van een doelmolecuul gekoppeld worden. Na optimalisatie werd de 
ligatiehandle toegankelijk via een vier-stapsynthese. Het onderzoek naar de reactiekinetiek tussen de N-
acylazetine groep en tetrazine leverde een tweede-orde shelheidsconstante van 0.39 ± 0.1 s−1 M−1 op wat 
gelijkwaardig is aan de vergelijkbare cyclopropeen ligatiehandles. De ligatiehandle werd vervolgens 
gebruikt om epoximicin, een bekende proteasoomremmer, te voorzien van de N-acylazetinegroep. De 
resulterende moleculaire sonde was in staat het proteasoom te labelen in een twee-staps 
labelingsexperiment. Hiermee werd de toepasbaarheid van de N-acylazetinegroep als bio-orthogonale 
handle bewezen. 
Het werk besproken in Hoofdstuk 6 bouwt voort op dat uit hoofdstuk 5.  De invloed van de structuur 
op de kinetiek van de reactie tussen de N-acylaminekern en tetrazines werd onderzocht. Hiervoor werd 
een aantal model N-acylazetines, N-vinylcarbamaten, N-vinylurea’s en een N-vinylamide gesynthetiseerd. 
Door de tweede-orde reactiesnelhedsconstanten van deze verbindingen met een tetrazine te bepalen en 
onderling te vergelijken, kon er worden opgemaakt dat ringspanning significanter bijdraagt aan 
reactiesnelheidsconstante van deze reacties dan elektronendonatie. Het afsluitende Hoofdstuk 7 geeft 
een samenvatting van de behaalde onderzoeksresultaten en doet op grond daarvan aanbevelingen voor 
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